Psychotic-like symptomatology and reward responsivity in chronic ketamine and cannabis users by Joye, AM
  
 
 
 
 
Psychotic-like symptomatology and reward responsivity in 
chronic ketamine and cannabis users 
 
 
 
 
 
 
 
Alyssa Joye 
 
 
 
 
D.Clin.Psy. thesis (Volume 1), 2015 
University College London 
  
2 
  
 
 
UCL Doctorate in Clinical Psychology 
 
Thesis declaration form 
 
 
 
 
I confirm that the work presented in this thesis is my own. Where information 
has been derived from other sources, I confirm that this has been indicated in the 
thesis. 
 
 
 
Signature: 
 
 
 
Name:   Alyssa Joye 
 
 
 
Date:  9th July 2015 
 
 
3 
  
 
 
Overview 
 
This thesis assesses psychotic-like symptomatology and reward responsivity in 
chronic users of two illicit drugs, cannabis and ketamine.  As use of these drugs is 
steadily increasing, with cannabis being the most widely used drug worldwide 
(following alcohol, caffeine and tobacco) and the recent proliferation of ketamine 
misuse in parts of Asia, Europe and the United States, it is important to examine the 
effects of their habitual use.  While research has linked cannabis use to sub-clinical 
psychotic-like symptoms, longitudinal studies examining the association between 
cannabis use, psychotic-like symptoms and transition to psychosis have revealed 
mixed findings.  Additionally, although acute ketamine administration has been 
shown to produce psychotic-like symptoms in drug-naïve volunteers, there has been 
less research on the effects of chronic ketamine use. 
 
Part 1 of the thesis is a literature review investigating the assessment of cannabis use 
in studies of individuals meeting clinical ‘high risk’ criteria for transition to 
psychosis.  It examines measures of cannabis use, as well as findings regarding the 
association between cannabis and subsequent conversion to psychosis.  It also 
examines whether such studies measured further significant outcome variables, such 
as social and role functioning.  Finally, the literature review considers the limitations 
in how cannabis use has been assessed and the implications of this for future research 
on the extent to which cannabis influences the development of psychotic-like 
symptomatology and risk of conversion to frank psychosis. 
 
Part 2 of the thesis comprises an investigation of symptoms of prodromal psychosis 
and reward responsiveness in three groups – chronic users of cannabis, ketamine, and 
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healthy controls.  This investigation formed part of a joint project conducted with one 
other trainee clinical psychologist examining the chronic effects of cannabis and 
ketamine use on psychosis proneness and cognitive functioning. 
 
The empirical paper reports a between subjects study, comparing 20 cannabis users, 
20 ketamine users and 20 healthy controls on a number of self-report measures 
indexing depression (BDI-II), psychosis-like symptoms and schizotypy (PQ-B and O-
LIFE), and trait anhedonia (TEPS), and on two laboratory-based tasks assessing 
reward sensitivity (the ‘Probabilistic Reward Task’) and effort-based decision making 
(the ‘Effort-Expenditure for Rewards Task’).  Both drug using groups were found to 
have higher levels of schizotypy (O-LIFE) and positive psychosis symptomatology 
(PQ-B) than controls, while group differences were found on the probabilistic reward 
task, with controls demonstrating greater response bias than cannabis users and 
greater discriminability than ketamine users.  No group differences were found on the 
effort-based decision-making task. 
 
A critical appraisal of the research forms Part 3 of the thesis.  It describes the process 
of working collaboratively on the project rationale and design, reflections on 
recruiting and working with drug using participants, and thoughts on clinical 
implications of the project. 
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Abstract 
 
Background: Cannabis use has been associated with the development of psychotic-
like symptoms that characterise prodromal psychosis, the period marked by changes 
in functioning and sub-threshold psychotic-like symptoms that is thought to precede 
onset of frank psychosis.  While studies have suggested an association between 
cannabis and the development of psychosis, the nature of the relationship remains 
unclear. 
 
Aims: The aim of the current review was to examine how cannabis use is assessed in 
studies of ‘clinical high risk’ individuals at risk of transition to psychosis, and to 
ascertain the reported relationship between cannabis use and subsequent transition in 
these samples.  It also reported on whether other significant outcome variables (e.g. 
functioning) were linked with cannabis use.  
 
Method: A computerized literature search of PsycINFO and PUBMED databases was 
peformed with the following keywords: cannabis, psychosis, positive symptoms and 
negative symptoms, prodrome, mania, bipolar disorder, schizoaffective disorder, 
schizophrenia, basic symptoms, and ultra-high risk.  Studies were selected from those 
published between 2005 and June 2015, and the main exclusion criterion was non-
human studies. 
 
Results: There were few recent studies of individuals at high risk of transition to 
psychosis which assessed cannabis use and these were found to vary widely in 
measurements of cannabis exposure, making valid between-study comparisons 
difficult.  The majority of studies did not find a relationship between cannabis use and 
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transition to psychosis.  Most studies also did not include longitudinal assessment of 
other major outcome variables in their analyses. 
 
Conclusion: Currently, the literature examining cannabis use in clinical high risk 
individuals is minimal and is hindered by a lack of detailed and consistent methods of 
assessing cannabis use.  Many of these studies report no association between cannabis 
use and risk of conversion to psychosis, which may be a result of sample 
characteristics.  Yet while the association may be weak, research among first-episode 
patients continues to suggest vulnerability for psychosis among cannabis-using 
individuals.  Studies that undertake more comprehensive assessments of cannabis use 
and which map distinctive patterns of use are necessary.  Such studies would benefit 
from incorporating objective, biological measures of cannabis use, controls for 
confounding variables such as use of other drugs and medications, and longitudinal 
assessments, including changes in use and functioning and other clinical outcomes 
over time.  
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How has cannabis exposure been measured in studies investigating its role in 
risk of transition to psychosis? 
 
1. Introduction 
1.1 Overview 
 
 Comorbid drug misuse and mental illness is common worldwide and presents 
serious obstacles for effective treatment, leading to poorer outcomes in the treatment 
of both primary psychiatric disorders and drug dependence (Carey et al, 1991; Hunt, 
Bergen & Bashir, 2002; Weaver et al, 2003).  Individuals with psychotic illnesses 
have particularly high rates of comorbid substance misuse, with prevalence estimates 
suggesting that up to half of schizophrenic patients may also have substance use 
disorders, including higher rates of alcohol, tobacco, cannabis dependence, as well as 
use of other illicit drugs, and that the risk of substance use in schizophrenics is 4.6 
times that of the general population (Dixon, 1999; Mueser et al, 1990; Regier et al, 
1990; Volkow, 2001).  Research suggests that the prevalence of comorbid substance 
use disorder in psychotic populations is moderated by clinical, demographic and 
socio-cultural variables (Lambert et al, 2005). 
 While prevalence studies suggest that drug use has decreased among children and 
adolescents in recent decades, alcohol and illicit drugs are widely available to these 
age groups and are viewed as a veritable rite of passage among adolescents, with the 
available opportunity to use illicit drugs reported by over 80% of US adolescents in 
the early 2000s (Currie, Small & Currie, 2005; NHS Information Centre, Lifestyle 
Statistics, 2011; Swendsen et al, 2012; Watson, Benson & Joy, 2000).  Numerous 
studies have suggested that adolescence is a crucial developmental period implicated 
in the onset of mental illness and in risk of transition to psychosis (Kessler et al, 2007; 
McGorry, Purcell, Goldstone & Amminger, 2011). 
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 Cannabis is the most widely used illicit drug worldwide, with psychosis patients 
frequently reporting using cannabis more than any other drug (Addington et al, 2013; 
Burns, 2013).  Apart from its ability to induce transient psychotic-like symptoms from 
acute intoxication, long term use of cannabis has been linked to psychosis (D’Souza 
et al, 2004).  Research suggests that earlier cannabis use among young people is 
associated with increased risk of conversion to frank psychosis and earlier onset of 
psychosis, although the mechanisms of these associations are as yet unclear 
(Arsenault et al, 2002; Casadio, Fernandes, Murray & di Forti, 2011; di Forti et al, 
2014; Stefanis et al, 2013).   Cannabis use has also been linked with earlier onset of 
sub-clinical psychosis-like symptoms, with studies suggesting that cannabis use prior 
to psychiatric symptoms may be linked to earlier age of onset and higher reported 
levels of prodromal symptoms in both first-episode psychosis patients and non-
clinical populations (Compton et al, 2009; Fergusson, Horwood & Ridder, 2005). 
 Research on prodromal psychosis is important as it can improve knowledge of risk 
factors implicated in subsequent transition to psychosis and therefore inform 
treatment strategies for those at greater risk of transition.  The prodromal period has 
been conceptualised as a period before the onset of frank psychosis, characterised by 
changes in functioning and sub-threshold, frequently self-experienced, symptoms, 
including changes in drive, motivation, cognition and emotion (Yung et al, 2005).  As 
much research on the psychosis prodrome has been done retrospectively (i.e. in first-
episode psychosis patients), it is difficult to reliably predict the duration and severity 
of symptoms that characterise this period (Yung et al, 1998; Yung et al, 2005).  
Nonetheless, researchers have developed the construct of the clinical ‘high risk’ state 
for psychosis, which encompasses the trajectory of symptomatology commonly 
present before psychosis; this ‘high risk’ state has also been referred to as the ‘at-risk 
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mental state’ (or ‘ARMS’), the ‘prodromal’ period, and the ‘ultra-high risk’ (or 
‘UHR’) state (Fusar-Poli et al, 2013; Schultze-Lutter, Schimmelmann & Ruhrmann, 
2011; Yung, Phillips and McGorry, 1998). 
 This prodromal period or trajectory begins with an early pre-morbid phase during 
which initial changes may only be detectable to the individual himself, followed by 
what is considered to be the early prodromal phase, marked by ‘basic symptoms’ – 
subtle self-experienced deficits (e.g. in affect, such as increased anhedonia and 
depression) that may continue to be present throughout the course of the prodromal 
period (Yung et al, 2005).  ‘Attenuated positive symptoms’ mark the late prodromal 
period, which include the presence of subthreshold overt or positive symptoms, such 
as ideas of reference, perceptual disturbances, etc. but at a frequency and intensity 
that would not meet diagnostic criteria for frank psychosis (Fusar-Poli et al, 2013; 
Yung et al, 2005).  Brief limited intermittent psychotic episodes (‘BLIPS’ or ‘BIPS’) 
may also occur during this late prodromal period and are defined as transient 
psychotic episodes lasting less than one week (e.g. unusual thought content, 
disorganised speech, unusal perceptual experiences, etc.), occurring together with 
functional decline or sustained low functioning (Olsen & Rosenbaum, 2006).  Finally, 
transition to frank psychosis is indicated by increased intensity and duration of these 
symptoms coupled with functional decline. 
 
1.2 Rationale for the current review 
 
 Given the concerning potential for sub-threshold psychotic symptomatology to 
lead to psychosis, and the possible influence of cannabis in exacerbating such 
symptoms or reducing the age of onset of psychosis, it is important for researchers to 
examine this relationship between cannabis, prodromal symptoms and risk of 
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transition (Minozzi et al, 2010).  A recent review of such studies suggests that there 
are several key factors involved in the pathways from cannabis use to transition to 
psychosis, including early, recent and lifetime use of cannabis, and genetic 
vulnerability to psychosis (Burns et al, 2013).  Hypotheses attempting to explain the 
association suggest that the relationship may be: (1) confounding (i.e. factors other 
than cannabis use are responsible for conversion), (2) that there is an interaction (i.e. 
cannabis use is in part a cause, with other vulnerability factors influencing 
conversion), (3) that people with psychosis or psychotic-like symptoms may be more 
likely to use cannabis as a form of self-medication, and (4) that cannabis alone may 
cause psychosis (Minozzi et al, 2010).  Yet while there may be an increased risk of 
psychotic symptomatology in cannabis users, there remain significant limitations in 
the literature as to the precise relationship between cannabis and psychosis, and 
whether the relationship is in fact causal to some degree (Minozzi et al, 2010; 
Richardson, 2010).  Among these limitations, which include differences in 
methodological quality, populations studied and outcomes analysed, differences in 
how cannabis use has been measured are significant. 
 Temple, Brown & Hine (2010) argue that significant limitations in the 
measurement of cannabis exposure impede researchers’ ability to draw conclusions 
about harms and risk associated with cannabis use.  Such limitations include 
variability in cannabis use measurement, such as lack of detail on rates of use, focus 
on self-report or retrospective reports, inclusion/exclusion of dependence measures, 
lack of objective measures which are also limited in measuring historical use; the 
classification of users, e.g. lifetime, frequent, ‘regular’, recreational users; and 
assumptions about consumption and dosage (i.e. more frequent use is often assumed 
to mean higher dose, irrespective of amount, type or potency of cannabis used) 
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(Temple et al, 2010).  Studies such as those mapping the relationship between 
cannabis and psychosis may also be limited by confounds in recruitment methods.  
Control groups may differ in significant other ways from cannabis users which are not 
measured, particularly when cannabis use among peers is normative behaviour 
(Temple et al, 2010).  Therefore, in the field of high risk treatment-seeking 
individuals, the risks associated with cannabis use generally might be inflated as the 
focus is on a constellation of specific symptoms for which users are seeking help; 
such studies may overlook the prevalence of cannabis users with schizotypal traits or 
psychotic-like symptoms that are not problematic and risk amplifying the alleged 
association between cannabis and psychosis. 
 
1.3 Aims 
 
 The purpose of the current review is to critically investigate how cannabis 
exposure has been measured in studies linking its use to the development of 
psychosis.  Given the recent emergence of studies utilising the ‘high risk’ construct to 
examine pathways to conversion to psychosis, it was decided to limit the review to 
more recent studies which examined the role of cannabis in transition to psychosis 
rather than simply to the risk of developing psychotic symptomatology, traits or sub-
threshold symptoms without conversion to frank psychosis.  Thus the focus was on 
studies that prospectively followed individuals that initially presented as high-risk and 
addressed the issue of whether or what proportion subsequently transitioned to 
psychosis throughout the course of the study. 
 The main aims of this review were to examine the following areas: 
 To assess how cannabis use is measured, including the reliability and validity 
of measures of cannabis use in longitudinal studies of at risk individuals 
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 Was cannabis found to be significantly associated with conversion to 
psychosis? 
 Apart from conversion from an at-risk mental state to psychosis, what other 
significant outcome variables were assessed (e.g. functioning)? 
 
 An examination of these areas in the included studies will be followed by a 
discussion of the limitations in the methods used to assess cannabis use. 
 
2. Review Methodology 
2.1 Search 
 
 A search of the relevant literature was carried out using the following keywords: 
cannabis, psychosis, positive symptoms and negative symptoms, prodrome, mania, 
bipolar disorder, schizoaffective disorder, schizophrenia, basic symptoms, and ultra-
high risk.  The truncated keyword ‘prodrom*’ was also included to include both 
‘prodrome’ and ‘prodromal’.  These words were entered into the thesaurus function in 
PsycInfo to ensure similar relevant terms were searched.  The AND/OR functions 
were used to combine search terms and results were limited to human studies 
published in English peer-reviewed journals between 2004 and the current date 
(2015).  The date limitation was employed as the concepts of prodromal psychosis 
and ‘at risk’ mental states for conversion to psychosis are recent constructs which 
have only begun to be formally investigated following the development of several 
measures since the early 2000s.  Therefore the focus of the current review is on more 
recently published studies. 
 PubMed was also searched using the same criteria to ensure inclusion of further 
relevant studies; the majority of results from this search were duplicates, which were 
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excluded.  No other relevant articles were found using PubMed.  (See Appendix 1 for 
details of searches.)  A hand-search of articles and relevant authors appearing in 
reviews was also carried out. 
 
2.2. Exclusion criteria 
 
 While studies that examined onset of high risk symptoms (or criteria that would 
classify cannabis users as ‘ultra-high risk’) were interesting and clinically relevant, 
those that did not go on to examine subsequent transition to psychosis were excluded.  
Further exclusion criteria were as follows: qualitative studies, studies with no 
reference to cannabis, studies focusing largely or exclusively on genetic mapping, 
psychiatric case studies, studies which focused on anti-psychotic medications, fMRI 
and other brain-scanning studies, studies not focusing specifically on cannabis and 
transition to psychosis (e.g. prevalence rates of cannabis use and/or clinical course of 
psychotic symptoms among patients with enduring psychoses; therapies for cannabis 
use disorder), studies of synthetic cannabis use, studies focusing exclusively on 
cannabis-induced psychosis, and studies on acute cannabis administration. 
 
2.3 Inclusion criteria 
 
 Inclusion criteria were: i) studies of individuals considered ‘at risk’ (e.g. ‘ultra-
high risk’ or ‘clinical high-risk’) based on clinical assessment, ii) those which 
assessed participants’ cannabis use, and iii) studies which included a longitudinal 
design to assess rates of transition of these high-risk samples to frank psychosis. 
 Studies were included if they used established diagnostic measures to assess ‘at-
risk’ mental states.  These included the Structured Interview for Prodromal 
Syndromes (SIPS, which contains the Scale of Prodromal Symptoms, SOPS; Miller et 
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al, 1999; 2002), the Comprehensive Assessment of the At-Risk Mental State 
(CAARMS; Yung et al, 2005), and the Schizophrenia Proneness Instrument – Adult 
Version (SPI-A; Schultze-Lutter, Addington, Ruhrmann, & Klosterkötter, 2007) or 
the Bonn Scale for the Assessment of Basic Symptoms – Prediction List (BSABS-P, 
Schultze-Lutter, & Klosterkötter, 2002), an abbreviated version of the SPI-A.  These 
instruments are internationally recognised and validated measures for the diagnosis of 
‘at-risk’ mental states, profiles of prodromal symptomatology which incorporate risk 
factors implicated in possible conversion to psychosis (Yung et al, 2004). 
 
2.4 Diagnosing high risk states 
 
 Despite individual variation, measures which diagnose ‘high risk’ mental states, 
and thus increased vulnerability for the development of psychosis, require inclusion in 
at least one of several categories, including ‘attenuated positive symptoms’ (APS), 
‘brief intermittent psychotic symptoms’, ‘genetic risk and deterioration’, and ‘Basic 
Symptoms’ (Addington & Heinssen, 2012).  The ‘attenuated positive symptoms’ 
category includes individuals who experience a minimum of one positive psychotic 
symptom (e.g. grandiose ideas, perceptual abnormalities, etc.) for at least one week in 
the past three months, but at a sub-threshold level for frank psychosis (Miller et al, 
2002).  ‘Brief intermittent psychotic symptoms’ involves the presence of at least one 
positive psychotic symptom experienced in the past three months ostensibly meeting 
threshold for psychosis but at a lesser frequency, i.e. lasting less than one week, and 
spontaneously remitting (Yung & McGorry, 1996a).  ‘Genetic risk and deterioration’ 
requires both functional decline (defined as a ≥ 30% reduction in functioning as 
assessed by the Global Assessment of Functioning scale, GAF-M) for at least one 
month in the previous year together with having either a close relative with a 
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psychotic disorder or having schizoptyal personality disorder, as diagnosed by DSM-
IV (Ruhrmann et al, 2010).  The ‘basic symptoms’ approach defines individuals at 
risk based on subtle self-experienced disturbances in cognition, perception and speech 
which do not meet threshold for psychosis symptomatology and are thought to be 
present from the earliest prodromal phase  (Klosterkötter, Hellmich, Steinmeyer & 
Schultze-Lutter, 2001; Ruhrmann, Schultze-Lutter & Klosterkötter, 2003). 
 
 
3. Results 
 
 The initial search produced 1244 potentially relevant articles.  Studies that were 
initially considered from this pool fell largely into two categories: those that 
examined the association between cannabis use and factors relating to expression of 
psychotic illness (e.g. age at onset in presentations of first-episode psychosis patients) 
and those that examined cannabis use in relation to psychotic symptoms (e.g. during 
prodromal period, prior to illness onset), sometimes including consideration of 
eventual transition to psychosis.  These studies were grouped according to population 
and design and assessed for inclusion if they in some way assessed the relationship 
between cannabis use and subsequent transition to psychosis.  Potential studies 
largely fell into several categories: those that assessed first-episode psychosis patients 
(tending to collect information on substance use at intake and retrospectively), general 
population-based studies (e.g. assessing incidence of psychotic-like symptoms and 
substance use in samples from the general population, or longitudinally), and studies 
of individuals considered ‘high-risk’ (i.e. fulfilling clinical criteria to be considered 
higher risk for the development of psychosis, e.g. ‘ultra-high risk’), often assessing 
cannabis and other substance use cross-sectionally, but also followed over time to 
track rates of transition to psychosis. 
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 Based on the inclusion and exclusion criteria, 11 studies were selected which 
reported on cannabis use in individuals defined as ‘at risk’ for the development of 
psychosis, and which referred to transition to psychosis (see Table 1).  One article 
from 2013 was found which reviewed 10 studies assessing substance use in clinical 
high risk for psychosis populations (Addington et al, 2014).  These studies were 
assessed and seven which included assessment of cannabis were included in the 
present review; one was excluded because it pre-dated inclusion criteria (i.e. 
published within past ten years), one because it did not report on substance abuse or 
dependence, and one because it did not report on cannabis use (Phillips et al, 2002; 
Ruhrmann et al, 2010; Thompson, Nelson & Yung, 2011).  In addition to these seven 
studies, four more recent studies were identified as meeting inclusion criteria (see 
Table 1). 
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Table 1. Research studies assessing cannabis use and transition to psychosis in clinical high risk samples, 2005-2015 
 
Study 
High risk 
population studied 
High-risk 
sample size 
(n) 
Comparison 
Group? Mean age per group 
Duration of 
follow-up 
(months) 
Frequency of 
follow-up 
High-risk 
criteria 
Number of high-
risk conversions to 
psychosis (n and 
% of high-risk 
sample) 
         
Auther et al, 
2012 
Recognition and 
Prevention (RAP), 
New York, USA 
101 
(66 M, 35 F) 
59 controls 
(30 M, 29 F) 
CHR = 16.09 
controls = 16.15 
35.64 
(mean) 
6 month 
intervals, 
or when 
conversion 
thought to have 
occurred 
SOPS 15* (14.9%) 
Buchy et al, 
2014 
Enhancing the 
Prospective 
Prediction of 
Psychosis' 
(PREDICT), 
Canada and USA 
 
170 
(96 M, 74 F) 
none non-converters = 19.8 
converters = 19.7 
48 not reported SIPS (COPS) 29 (17.1%) 
Buchy et al, 
2015 
North American 
Prodrome 
Longitudinal Study 
2 (NAPLS-2), 
Canada and USA 
 
735 
(423M, 312 F) 
278 controls 
(140 M, 138 
F) 
CHR = 18.5 
controls = 19.6 
24 6 month 
intervals 
SIPS (COPS) 90 out of 362 UHRs 
assessed at 24 
month completion 
(24.9% completers) 
Cannon et al, 
2008 
North American 
Prodrome 
Longitudinal Study 
2 (NAPLS-2), 
Canada and USA 
291 
(170 M, 121 
F)*** 
134 matched 
controls 
18.10 up to 30 6 month 
intervals 
SIPS 82 (out of 291, or 
28.2%) 
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Study 
High risk 
population studied 
High-risk 
sample size 
(n) 
Comparison 
Group? Mean age per group 
Duration of 
follow-up 
(months) 
Frequency of 
follow-up 
High-risk 
criteria 
Number of high-
risk conversions to 
psychosis (n and 
% of high-risk 
sample) 
Corcoran et al, 
2008 
Centre of 
Prevention and 
Evaluation (COPE), 
New York, USA 
32 none drug users = 20.9 
non-users = 17.4 
up to 24 3 month 
intervals; 
total varied per 
participant 
SIPS n not reported; 
no differences in 
conversion rates 
between drug users 
vs. non-users 
 
Dragt et al, 
2010 
Dutch Prediction of 
Psychosis Study, 
Amsterdam, 
Netherlands 
68 UHRs 
(47 M, 21 F) 
none 19.00 range: 2.5-
37 
not reported SIPS and/or 
BSABS-P 
17 (25%) 
Dragt et al, 
2012 
European Prediction 
of Psychosis Study, 
Germany, Finland, 
Netherlands and 
England 
242 CHRs none cannabis users = 22.9 
non-users = 22.3 
18 9 month 
intervals 
SIPS and/or 
BSABS-P 
37 (15.3%) 
Korver et al 
2010 
Dutch Prediction of 
Psychosis Study, 
Amsterdam, 
Netherlands 
63 UHRs 
(42 M, 21 F) 
58 controls 
(28 cannabis 
users, 30 non-
cannabis) 
cannabis UHRs = 20.4, 
non-cannabis UHRs = 18.8 
cannabis controls = 21.6 
non-cannabis controls = 19.8 
36 in-person at 9, 
18, and 24 
months, by 
telephone at 36 
months; 
total varied per 
participant 
 
SIPS and/or 
BSABS-P 
17 (27%) 
Kristensen & 
Cadenhead, 
2007 
Cognitive 
Assessment and 
Risk Evaluation 
(CARE), San Diego, 
USA 
 
48 'at risk' 
patients 
(26 M, 22 F) 
none 18.60 24 1 month 
intervals 
SIPS 6 (12.5%)** 
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Study 
High risk 
population studied 
High-risk 
sample size 
(n) 
Comparison 
Group? Mean age per group 
Duration of 
follow-up 
(months) 
Frequency of 
follow-up 
High-risk 
criteria 
Number of high-
risk conversions to 
psychosis (n and 
% of high-risk 
sample) 
Russo et al, 
2014 
CAMEO, 
Cambridgeshire, 
England 
60 HRs 
(31 M, 29 F) 
60 controls 
(26 M, 34 F); 
address-
matched 
high-risk = 19.89 
controls = 22.60 
24 3 month 
intervals 
CAARMS 3 (5%) 
Valmaggia et al, 
2014 
Outreach and 
Support in South 
London (OASIS), 
London, England 
182 UHRs 
(104 M, 78 F) 
none 22.90 24 at 24 months ‘UHR’ criteria 
(as in SIPS 
and 
CAARMS) 
26 (14.3%) 
 
* Auther et al (2012) did not report number of conversions to psychosis in main paper, only in abstract. 
** Analyses performed on transitions within one year, not 2 year study duration. 
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Table 2. Details of cannabis use assessment in studies assessing cannabis use and transition to psychosis in clinical high risk samples, 2005-
2015. 
 
 
Study 
Cannabis use 
measures at 
baseline 
Details on cannabis 
use assessment 
Primary cannabis 
measure  used in 
analyses of 
transition 
Cannabis use 
re-assessed at 
follow-up? 
Objective 
cannabis measure 
details 
Reported on 
cannabis 
dependence? 
Cannabis-psychosis 
analyses controlled 
for use of other 
drugs? 
Reports on anti-
psychotics? 
Auther et al, 2012 KSADS-E Lifetime cannabis use 
and use in past 6 
months 
Lifetime cannabis 
use/abuse 
Yes None reported Yes - 
dependence was 
exclusion 
criterion 
Yes No 
Buchy et al, 2014 DUS Severity of use Severity of 
cannabis use in 
past month (DUS) 
No Not assessed Yes Unclear Yes - use of anti-
psychotics was exclusion 
criterion 
Buchy et al, 2015 SCID, DUS 
and cannabis 
use 
questionnaire  
Severity of use and 
detailed assessment of 
rates and patterns of 
use over lifetime 
Severity of 
cannabis use in 
past month (DUS) 
Yes 
(DUS only) 
Not assessed Yes - 
dependence was 
exclusion 
criterion 
Yes Somewhat - use of anti-
psychotics was exclusion 
criteria for controls only 
Cannon et al, 2008 SCID or 
KSADS-PL 
N/A - assessed 
'substance abuse' 
History of 
substance abuse 
(DSM-IV 
diagnoses) 
No None reported No 
('substance 
abuse') 
N/A Somewhat - proportion 
were enrolled in studies of 
anti-psychotics and other 
treatments, but no further 
information on 
medication provided 
Corcoran et al, 
2008 
K-SADS-PL 
(ages 12-15), 
DIGS (16+) 
& cannabis 
use in past 30 
days 
Lifetime use at baseline 
and use in past 30 days 
at follow-up 
N/A 
(cannabis use 
assessment was not 
analysed in relation 
to transition) 
Yes None reported Yes Yes Somewhat - mentions 
anti-psychotics but no 
detail provided; controlled 
analyses for use of 
medication 
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Study 
Cannabis use 
measures at 
baseline 
Details on cannabis 
use assessment 
Primary cannabis 
measure  used in 
analyses of 
transition 
Cannabis use 
re-assessed at 
follow-up? 
Objective 
cannabis measure 
details 
Reported on 
cannabis 
dependence? 
Cannabis-psychosis 
analyses controlled 
for use of other 
drugs? 
Reports on anti-
psychotics? 
Dragt et al, 2010 CIDI and 
DSM-IV 
Lifetime use, age at 
onset of frequent use 
Lifetime cannabis 
use/abuse 
No None reported Yes Somewhat - use of 
'hard' drugs was 
exclusion criteria; no 
discussion of nicotine 
or alcohol use 
No 
Dragt et al, 2012 CIDI and 
DSM-IV 
Lifetime cannabis use 
and cannabis use 
disorder 
Lifetime cannabis 
use and cannabis 
use disorder 
No None reported Yes Somewhat - use of 
'hard' drugs was 
exclusion criteria; no 
discussion of nicotine; 
controlled for 'alcohol 
use disorder' in 
analyses (on which 
groups differed 
significantly) 
Yes  
Korver et al 2010 CIDI CHR group assessed on 
use, amount, onset, 
frequency and duration 
of cannabis use 
Lifetime or current 
cannabis use at 
baseline 
No None reported No No - use of 'hard' 
drugs was exclusion 
criteria (but no 
objective tests 
reported); no 
discussion of alcohol 
or nicotine 
No - some received 
treatment from referring 
mental health institutions, 
but no details 
Kristensen & 
Cadenhead, 2007 
SCID or 
KSADS-PL 
Division of sample into  
no/minimal use w/o 
impairment and abuse 
or dependence in 
remission 
Lifetime or current 
cannabis use, 
dependence/abuse 
(in remission) at 
baseline 
Yes Urine toxicology 
screen at baseline 
and 6-month 
intervals 
Yes - 
dependence was 
exclusion 
criterion 
Yes - nicotine also 
found to be predictive 
of transition and 4 of 6 
conversions smoked 
both cigarettes and 
cannabis; excluded use 
of other drugs in past 
30 days 
Yes, - varied by 
participant (referrals made 
if deterioration observed 
and subjects were allowed 
to use meds) 
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Study 
Cannabis use 
measures at 
baseline 
Details on cannabis 
use assessment 
Primary cannabis 
measure  used in 
analyses of 
transition 
Cannabis use 
re-assessed at 
follow-up? 
Objective 
cannabis measure 
details 
Reported on 
cannabis 
dependence? 
Cannabis-psychosis 
analyses controlled 
for use of other 
drugs? 
Reports on anti-
psychotics? 
Russo et al, 2014 Novel 
substance use 
tool 
Abuse/dependence, 
influence on psychotic-
like experiences, age of 
lifetime first substance 
use, prevalence and 
frequency of current 
and past use. 
N/A (cannabis use 
assessment was not 
analysed in relation 
to transition as 
only 3% 
transitioned) 
No Not assessed Yes Yes - current alcohol 
use also found to be 
significantly higher for 
high-risk group 
Yes (≥ 1 week prior 
treatment with anti-
psychotics was exclusion 
criterion) 
Valmaggia 2014 Modified 
Cannabis 
Experience 
Questionnaire 
(Barkus)  
Current use, age of first 
and last use, frequency 
and duration of use, 
and unpleasant 
experiences related to 
use 
Lifetime use, 
frequency of use, 
use starting before 
age 15, continued 
use during follow-
up period 
Yes None reported No Unclear; analyses were 
done separately per 
drug and no significant 
differences in 
transition rates 
between users/non-
users of other drugs 
were found; however 
tobacco and alcohol 
were not assessed 
(potential 
confounders) 
No 
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3.1 General characteristics of studies 
 
 All of the studies reviewed were naturalistic studies of treatment-seeking at-risk 
individuals and all formed part of clinical programmes designed to identify and 
monitor those meeting criteria for ‘high risk’ status for conversion to psychosis.  Six 
studies were based at several locations in North America, three in continental Europe 
and one in the UK.  One study’s programme (Kristensen & Cadenhead, 2007) 
formed part of a larger consortium of research centres, participants from which were 
included in Cannon et al’s (2008) study.  It was included here as more detailed 
analysis of the 48 participants was provided.  It is assumed that the sample in one 
study (Dragt, 2010) formed part of a larger study (Dragt, 2012), but this could not be 
confirmed at the time of completing the review. 
 A broad assessment of each study’s design suggests that there were three main 
types: (1) those that compared high risk individuals to healthy controls on substance 
(including cannabis) use patterns, (2) those that compared substance (including 
cannabis) using high-risk individuals to non-substance using high risk individuals, 
and (3) one study that followed high risk individuals over time (retrospectively 
comparing those who converted to psychosis against non-converters) (see Table 1). 
 The number of ‘at risk’ participants included in each study ranged between 32 
and 735 and there were significantly more males than females included in most 
samples (with the exception of Russo et al, 2014), while one study (Corcoran et al; 
2008) did not report on gender.  Five of the 11 studies included a comparison group 
of healthy controls; in some cases these were non-substance using controls, and in 
others, details of their substance use was also reported and assessed in a similar way 
as the high risk sample.   
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 Across all studies, the mean age ranged from 16.09 to 22.90 years for high-risk 
samples and 16.15 to 22.60 years for controls, which underscores researchers’ 
consensus regarding the significance of late adolescence and early adulthood as a 
critical period of risk of the onset of psychosis (Van Os, Linscott, Myin-Germeys, 
Delespaul, & Krabbendam, 2009). 
 A primary difference between the studies was how they assessed the relationship 
between cannabis use and subsequent transition to psychosis.  While all of the 
studies included were longitudinal in design, reporting on follow-up of the high-risk 
cohort over time to establish which ones transitioned to a state of frank psychosis, 
the majority of studies assessed current and/or past cannabis use at baseline only.  
Some studies which reported collecting data on cannabis use during follow-up 
assessments (Auther et al, 2012; Buchy et al, 2015; Corcoran et al, 2008; Kristensen 
& Cadenhead, 2007; and Valmaggia et al, 2014), but few of these actually reported 
follow-up cannabis use data. 
 Five of the 11 studies divided their high-risk samples into groups based on drug 
use for the purpose of analysis – four of these (Dragt et al, 2010; Dragt et al, 2012; 
Korver et al, 2010; Kristensen & Cadenhead, 2007) did so based on lifetime use of 
cannabis (i.e. ‘ultra-high risk’ lifetime cannabis users versus ‘ultra-high risk’ non-
cannabis users) and one (Corcoran et al, 2008) did this for lifetime drug use in 
general (i.e. ‘drug users’ and ‘non-drug users’).  One of these five studies (Korver et 
al, 2010) had a control group comparison and also divided controls into cannabis 
users and non-cannabis users. 
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3.1.1 Exclusion criteria re: substance and medication use 
 
 Only some of the studies incorporated use of illicit drugs and medicines in their 
exclusion criteria.  Exclusion of drug use differed between studies, with some 
focusing on substance dependence disorder, others on recent use of illicit drugs, and 
others on current or recent use of ‘hard drugs’.  While not all studies reported on use 
of other medications, several studies excluded participants based on use of anti-
psychotics. 
 Three of the 11 studies (Auther et al, 2012; Buchy et al, 2015; Kristensen & 
Cadehnhead, 2007) excluded high-risk participants if they met criteria for 
diagnosable DSM-IV substance dependence disorder; Buchy et al (2015) also 
excluded controls who met these criteria.  Kristensen & Cadenhead (2007) further 
excluded participants who had used illicit drugs within 30 days of initial assessment.  
Three studies listed use of “hard drugs” (e.g. cocaine, heroin, ecstasy, 
amphetamines) as exclusion criteria (Dragt et al, 2010; Dragt et al, 2012; Korver et 
al, 2010).  Three studies excluded participants if they experienced ‘attenuated 
positive symptoms’ attributable to current substance use (Corcoran et al, 2008; Dragt 
et al, 2010; Korver, et al 2010).  Three studies included varied exclusion criteria 
related to the use of anti-psychotic medication: Russo et al (2014) excluded 
participants who had previously used anti-psychotics for more than one week, Buchy 
et al (2014) excluded all prior and baseline anti-psychotic treatment, and Buchy et al 
(2015) reported on only excluding controls currently using psychotropic medication.  
As will be discussed, objective verification of these exclusionary criteria was only 
reported in one study (Kristensen & Cadenhead, 2007). 
 
32 
 
 
 
 
3.2 Clinical Diagnoses of High Risk Status 
 All 11 of the studies used internationally established criteria to ascertain ‘high-
risk’ status based on the four main domains of clinical high-risk symptomatology: 
attenuated positive symptoms, brief intermittent psychotic symptoms, genetic risk 
and deterioration, and basic symptoms.  The majority of studies used the SIPS – five 
employed this measure exclusively (Buchy et al, 2014; Buchy et al, 2015; Cannon et 
al, 2008; Corcoran et al, 2008; Kristensen & Cadenhead, 2007) and three used the 
SIPS and/or the BSABS-P (Dragt et al, 2010; Dragt et al, 2012; Korver et al, 2010).  
One study reported having only used the SOPS (a measure contained within the 
SIPS; Auther et al, 2012), while one used the CAARMS (Russo et al, 2014) and 
another reported using ‘ultra-high risk’ criteria as assessed in both the SIPS and 
CAARMS (Valmaggia et al, 2014).  One study lacked clarity in reporting whether all 
‘high-risk’ individuals in its sample met SIPS criteria (reporting that “at each site, 
from 30-50% of the referred case patients met [SIPS] criteria for study entry”), 
suggesting that a proportion of included participants did not meet ‘clinical high risk’ 
threshold (Cannon et al, 2008).  (See Table 1 for tabulation of screening tools used in 
each study.) 
 
3.3 Measurement of cannabis use 
 All studies assessed cannabis use at baseline and reported this, with the exception 
of Cannon et al (2008) who did not report specific details of cannabis use.  In 
general, studies differed in terms of the extent of their cannabis use assessments, 
with some reporting detailed information on current and past use.  Others grouped 
cannabis use together with use of other substances under the umbrella category of 
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‘substance use’ and did not provide detailed information on patterns of cannabis use, 
both past and present (i.e. at baseline). 
 
3.3.1 Self-report Measures 
 Cannabis use in the studies was assessed using a number of clinical measures 
which examine substance use, including abuse or dependence.  Eight studies 
included one or a combination of the following reliable and validated instruments: 
Structured Clinical Interview for DSM-IV Disorders (SCID; First, Spizter & Gibbon, 
1995), the Composite International Diagnostic Interview (CIDI; Andrews & Peters, 
1998), two versions of the Kiddie Schedule for Affective Disorders and 
Schizophrenia, Present and Lifetime version (K-SADS-PL; Kaufman, Birmaher, 
Brent, et al 1997) and Epidemiological version (K-SADS-E; Orvaschel, 1994), and 
the Diagnostic Interview for Genetic Studies (DIGS; Nurnberger et al, 1994). 
 The SCID was used in three studies to assess for a range of comorbid DSM-IV 
psychiatric disorders, which included diagnoses of current and lifetime substance 
(including cannabis) abuse and dependence (Buchy et al, 2015; Cannon et al, 2008; 
Kristensen & Cadenhead, 2007).  Three studies used the CIDI (rather than the SCID) 
to assess mental disorders according to DSM-IV and ICD-10 diagnostic criteria, 
including assessment of cannabis use, abuse and dependence (Dragt et al, 2010; 
Dragt et al, 2012; Korver et al, 2010).  The CIDI assesses a wide range of cannabis 
use behaviours including current use, amount, onset of use, frequency and duration 
of use (Korver et al, 2010)  Cannabis abuse and dependence in these studies was 
specifically assessed according to DSM-IV criteria (Dragt et al, 2010; Dragt et al, 
2012; Korver et al, 2010). 
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 To account for the inclusion of adolescent participants, four studies employed the 
K-SADS-PL or K-SADS-E for assessment of DSM-IV disorders in school-age 
children, including substance use disorders (Auther et al, 2012; Cannon et al, 2008; 
Corcoran et al, 2008; Kristensen & Cadenhead, 2007).  Cannon et al (2008) and 
Kristensen & Cadenhead (2007) used this measure in cases where the SCID was not 
age-appropriate.  Corcoran et al (2008) specified use of the K-SADS-PL for 12-15 
year olds and employed the DIGS for participants aged 16 and older, which similarly 
assesses for DSM-IV disorders.  Auther et al’s study used the K-SADS-E as their 
sole clinical measure, not only to assess cannabis and other substance use, but also to 
screen for psychotic disorders at baseline and to confirm later transition to psychosis 
(Auther et al, 2012).  Both versions of the K-SADS employed in these studies assess 
lifetime substance use; for cannabis use specifically, this included lifetime use, use 
in the six months prior to baseline, and frequency of lifetime use (Auther et al, 
2012). 
 Two studies (Buchy et al, 2014; Buchy et al, 2015) assessed cannabis use with the 
Drug Use Scale (DUS, Drake, Mueser & McHugo, 1996).  Buchy et al (2014) relied 
solely on this scale in assessing cannabis use, while Buchy et al (2015) employed 
this measure in addition to the SCID (assessing for dependence or abuse) and a 
further cannabis use questionnaire developed from previous literature.  The DUS 
assesses the severity and frequency of substance use in the past month, recording 
separate severity and frequency ratings for each of a number of different drugs (e.g. 
tobacco, cannabis, cocaine, etc.) (Drake et al, 1996).  The severity ratings range from 
1-4 (1 = abstinent, 2 = use without impairment, 3 = abuse, 4 = dependence) and the 
‘3’ and ‘4’ ratings are in line with DSM-IV diagnoses of abuse and dependence 
respectively (Buchy et al, 2014).  DUS frequency ratings consist of a five point scale 
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covering substance use in the past month (i.e., 0  = no use, 1 = once or twice per 
month, 2 = 3-4 times per month, 3 = 1-2 times per week, 4 = 3-4 times per week, 5 = 
almost daily; Drake et al, 1996).  Buchy et al (2015) collected DUS severity and 
frequency data for both CHRs and controls. 
 Three studies used cannabis use measures which captured a wider range of data 
regarding patterns of past and current use than the aforementioned standardised 
instruments which largely focus on abuse, dependence and very recent use.  Buchy et 
al (2015) devised a cannabis use questionnaire based on questions endorsed in 
previous literature, which elicited information on incidence of prior use, number of 
times used throughout lifetime, current and historical use, frequency, pattern, and 
social and temporal environment of use (Buchy et al, 2015).  This was used in 
addition to their inclusion of the SCID and DUS (Buchy et al, 2015).  Valmaggia et 
al (2014) similarly employed a more thorough assessment of cannabis use, using a 
modified version of the Cannabis Experience Questionnaire (Barkus, Stirling, 
Hopkins & Lewis, 2006) to assess lifetime use of cannabis and other substances.  
The Cannabis Experience Questionnaire also contains questions concerning 
subjective experiences of cannabis use, including subscales centred on pleasurable 
experiences, psychotic-like experiences and after-effects associated with cannabis 
use (Barkus et al, 2006).  They followed-up lifetime-endorsed substances with 
detailed questions regarding current use, age of onset and last use, and frequency and 
duration of use (Valmaggia et al, 2014).  Valmaggia et al (2014) also asked lifetime 
cannabis users about unpleasant experiences linked to their cannabis use and past 
users were asked further questions about decisions to quit (Valmaggia et al, 2014).  
One study (Russo et al, 2014) gathered a similar range of information as Valmaggia 
et al (2014), using what they termed a ‘novel substance use assessment tool’ which 
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assessed frequency, age of first use, the experience of unusual symptoms whilst 
intoxicated, whether substances were used to relieve any unusual or disturbing 
symptoms, current use/ use over the past three months, and period of greatest past 
use (Russo et al, 2014). 
 All of the cannabis use assessment tools discussed above are notably self-report 
measures, and are retrospective in their assessment of past cannabis use and 
associated experiences.  The main disadvantage of self-report measures is their 
reliance on the subjective motivation of participants to be truthful in reporting past 
experiences and behaviour, relying on memory for accurate reporting, aspects of 
which have been found to be impaired in chronic cannabis users (Solowij & Battisti, 
2008).  While previous research suggests that retrospective reports of drug use, and 
particularly cannabis use, are indeed reliable, various factors implicated in ‘at-risk’ 
mental states may have affected the reliability of such reports (Johnson & Mott, 
2001, in Dragt et al, 2010).  For example, Valmaggia et al (2014) suggest that help-
seeking individuals being interviewed in clinical settings may be incentivised to 
minimise current or recent use, impacting on self-reported cannabis use. 
 
3.3.2 Objective measures of cannabis use 
 Only one of the 11 studies reported on having objectively measured cannabis use.  
Kirstensen and Cadenhead (2007) carried out urine toxicology screens for cannabis 
use at baseline and at six-month follow-up intervals and reported that six participants 
tested positively for cannabis during the study (all of whom were included in their 
‘cannabis-using’ group, defined by cannabis abuse or dependence in remission).  
Interestingly, the authors only mention the urine screening once in their paper, and 
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do not elaborate on how positive test results for cannabis relate either to changes in 
cannabis use in these subjects or to eventual transition to psychosis.  However, they 
recommend more frequent drug-testing for future studies to gain a fuller picture of 
the relationship between cannabis use and transition to psychosis (Kristensen & 
Cadenhead, 2007).  None of the other studies reported on urine or other objective 
measures of cannabis use, with several having overtly acknowledged this (see Table 
2).  
 
3.3.3 Prevalence, ‘lifetime’ and frequency of cannabis use 
 As previously noted, despite all of the studies being longitudinal, most studies 
focused their analyses of cannabis use on data collected regarding current and 
historical use at baseline and, despite reporting that cannabis use was assessed at 
follow-up, did not report extensively on changes in use at follow-up assessment, 
with several exceptions (Buchy et al, 2015; Corcoran et al, 2008; Valmaggia et al, 
2014). 
 There was wide variation in how the studies defined cannabis users according to 
past and current use.  Five studies divided their high-risk samples into either ‘drug-
users’/’non-users’, or ‘lifetime cannabis users’/’non-users’ for the purpose of 
comparing variables such as prevalence of psychotic-like symptoms, functioning, 
transition to psychosis, etc.  The one study that employed a ‘drug user’/ ‘non-drug 
user’ paradigm based ‘drug use’ categorisation on dependence diagnoses for tobacco 
or alcohol or “prior exposure to any other drug of abuse” (Corcoran, 2008).  Two of 
these studies (Dragt et al, 2010, Dragt et al, 2012) defined ‘lifetime’ cannabis use as 
having used cannabis at least five times in the past, and for both, their category of 
‘high-risk’ lifetime cannabis user also included individuals who had used cannabis 
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much more frequently; e.g. in Dragt et al, 2010, 42.8% of ‘lifetime cannabis users’ 
currently used cannabis ranging from ‘almost daily’ to ‘1-3 days per month’ at 
baseline.  Korver et al (2010) similarly divided their ‘high-risk’ sample into 
‘cannabis users’/‘non-users’, with the cannabis using group varying widely in 
frequency of use – 42% of this group were reported to use cannabis frequently at 
intake (varying between daily use and 1-3 times per month).  There was similarly 
wide variation between the 58% of ‘high-risk’ cannabis users in Korver et al’s (2010 
study) who reported only past, not current, use of cannabis, ranging from two weeks 
to one year prior, and at varying frequencies during these past periods of use.  One 
study divided the ‘high-risk’ group into two based on lifetime cannabis use, but as 
current diagnoses of substance dependence were exclusion criteria, division was 
based on those with either (1) no use or (2) minimal use without impairment, versus 
those who met criteria for abuse or dependence in remission (Kristensen & 
Cadenhead, 2007).  While other studies also assessed lifetime cannabis use (defined 
either as use at least once in the past), no other studies used this criterion to divide 
their ‘high-risk’ samples into users versus non-users. 
 The three studies that undertook more detailed assessments of current and past 
cannabis use, beyond the standardised clinical measures assessing for abuse and 
dependence (e.g. the SCID), unsurprisingly provided richer data regarding patterns 
of cannabis use in their ‘high-risk’ samples, and in two of the studies also their 
control groups (Buchy et al, 2015; Russo et al, 2014; Valmaggia et al, 2014).  These 
three studies collected data on lifetime use, but rather than simply using it as a 
category of comparison to those who had not used cannabis, they obtained a wider 
range of detail in a number of dimensions. 
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 The majority of the studies included measures of frequency of cannabis use in 
their assessments; only four studies did not report on measures of frequency (Buchy 
et al, 2014; Cannon et al, 2008; Corcoran et al, 2008; Kristensen & Cadenhead, 
2007).  In many cases, reports of frequency centred on ‘lifetime frequency’ rather 
than current/recent frequency of use. 
 Among studies reporting on cannabis use frequency that compared high risk 
samples to controls, Auther et al (2012) found that high risk individuals in their 
sample reported significantly higher rates of lifetime cannabis use than healthy 
controls (35% of high risk sample vs. 11.9% of the healthy controls) and that the 
high risk participants were also likely to have used cannabis in the past six months.  
Along similar lines, Buchy et al (2015) found that the clinical high risk sample 
reported significantly greater lifetime cannabis use and greater mean number of 
occasions of past cannabis use than controls, although the two groups did not differ 
on current cannabis use frequency.  Korver et al (2010) did not provide details on 
frequency between cannabis-using controls and ultra-high risk patients in their 
sample, but they did report a significant correlation between frequency of cannabis 
use and several prodromal symptoms when combining cannabis users from both 
groups.  Finally, Russo et al (2014) reported that the median frequency of cannabis 
use in the past three months was significantly higher for high risk individuals than 
for the healthy volunteers in their study, while the groups did not differ in past 
frequency of cannabis use (with past use defined as the period of greatest past use 
prior to the previous three months).  Russo et al (2014) concluded that current and 
past rates of cannabis use were similar in their high risk sample. 
 Focusing on frequency of use in studies comparing cannabis-using and non-
cannabis using high risk groups, there was variation in the proportion of participants 
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reporting lifetime and recent use.  Dragt et al (2010) reported that 35 (or 51.5% of 
the total UHR sample) had used cannabis more than five times in the past, with 15 of 
these individuals having used recently, at varying frequencies.  In their larger sample 
of CHR individuals, Dragt et al (2012) found that a slightly smaller proportion of 
individuals reported more than five occasions of previous cannabis use (102, or 42% 
of the total sample), with 73.5% of these lifetime users having used in the past year 
and 25.5% having used in the month prior to intake.  Lastly, Valmaggia et al (2014) 
reported lifetime cannabis use in 73.6% (103 individuals) of their total high risk 
sample, with 52.2% reporting using cannabis at least once per week.  They found 
that 26.9% were using at baseline and 30.7% of the total sample had used cannabis 
for more than five years (Valmaggia et al, 2014). 
 
3.3.4 Cannabis use disorder or dependence 
 As previously reported, three studies excluded participants if they met criteria for 
any DSM-IV substance dependence disorder (Auther et al, 2012; Buchy et al, 2015; 
Kristensen & Cadehnhead, 2007), although in one of these (Buchy et al, 2015), 
several high risk participants reported dependence at follow-up and were included in 
subsequent transition to psychoses analyses.  This was the only study that reported 
on cannabis dependence at follow up. 
 Five studies reported rates of cannabis dependence or cannabis use disorder at 
baseline, with a range of between 0 and 32.4% of high-risk participants meeting 
dependence criteria (Buchy et al, 2014; Corcoran et al, 2008; Dragt et al, 2010; 
Dragt et al, 2012; Russo et al, 2014); two of these studies reported that no high-risk 
users were dependent at baseline (Corcoran et al, 2008; Russo et al, 2014), although 
one noted six cases of cannabis dependence in remission (Corcoran et al, 2008).  The 
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remaining three studies did not report on cannabis dependence or diagnosable 
cannabis use disorder.  
 
3.3.5 Age at onset of cannabis use 
 Only four studies reported on age of first cannabis use, sometimes termed ‘age of 
onset’ of cannabis use.  The only one of these studies with a control group, Buchy et 
al (2015), found a significant difference between their CHR and controls on mean 
age of first use of cannabis (15.7  for CHR group vs. 16.6 years in controls).   For the 
other three studies, the mean age of onset of cannabis use was reported as 16.8 years 
(Dragt et al, 2010), 17.3 years (Dragt et al, 2012), and 15.5 years (Valmaggia et al, 
2014).  Interestingly, Dragt et al (2010) found a significant association between 
younger age of onset of cannabis use and younger age of onset of prodromal 
symptoms, although the sample studied was relatively small. 
 
 
3.4 Assessment of relationship between cannabis use and conversion to psychosis 
 The majority of studies reported using established criteria to determine 
conversion to psychosis; in most cases this was the SIPS and in two cases this was 
the Interview for the Retrospective Assessment of the Onset of Schizophrenia 
(IRAOS; Häfner et al, 1992) which is reported to “sufficiently” document early onset 
of prodromal symptoms retrospectively (Dragt et al, 2010; Dragt et al, 2012). 
 Despite the fact that all of the studies included reference to cannabis use and 
subsequent conversion to psychosis in high risk samples, the studies varied widely in 
how they analysed the relationship between cannabis use and transition. 
 Excluding the study that did not disaggregate cannabis use from misuse of other 
substances generally (Cannon et al, 2008), the reported rates of transition in high-
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risk samples ranged between 5% (or 3 individuals in this sample; Russo et al, 2014) 
and 27% (or 17 high risk individuals; Korver et al, 2010; see Table 1 for further 
transition rates).  Corcoran et al (2008) did not report numbers of individuals who 
transitioned, but did report that there were no differences in conversion rates 
between drug users and non-users.  Cannon et al (2008), who reported a 35% 
transition rate in their sample, suggested that a history of substance use disorder was 
a major predictor of subsequent conversion to psychosis; however they did not 
specifically report on cannabis use disorder and transition. 
 Four studies did not perform analyses on rates of cannabis use and transition to 
psychosis.  One of these focused on ‘substance abuse’ and not cannabis use 
specifically (Cannon et al, 2008).  Two reported that only three participants 
transitioned, which was too few to analyse statistically (Russo et al, 2014 and Korver 
et al, 2010).  Finally the fourth, Corcoran et al (2008), did not analyse the 
relationship between cannabis use and transition, but rather focused on prodromal 
symptoms, finding that cannabis use was associated with increases in subthreshold 
psychotic (particularly perceptual disturbances) over time. 
 Seven out of the eleven studies performed statistical analyses on rates of cannabis 
use and transition to psychosis.  Both of the studies that did analyse cannabis use in 
relation to transition and included a healthy control comparison group found that 
baseline reports of lifetime cannabis use did not significantly predict conversion to 
psychosis (Auther et al, 2012; Buchy et al, 2015).  However, Buchy et al (2015) 
found however that of the proportion of individuals completing two years of follow-
up, controls had significantly lower rates of cannabis use than CHR participants who 
were psychotic. 
43 
 
 
 
 
 Among the other five studies that analysed cannabis and transition, three 
definitively found no significant relationship between cannabis use and transition 
(Buchy et al, 2014; Dragt et al, 2010; Dragt et al, 2012).  Buchy et al (2014) 
concluded that cannabis use severity was not predictive of subsequent conversion in 
their sample, while Dragt et al, (2010) found no significant differences in the 
transition rate between the high risk cannabis using and non-using groups.  Dragt et 
al, (2012) similarly found no relationship between cannabis use and transition or 
between cannabis use disorder and transition. 
 Only Kristensen and Cadenhead (2007) reported a significant association between 
cannabis abuse and dependence and conversion to psychosis, though four of the five 
high risk individuals in their study who transitioned also used nicotine (which was 
also found to be significantly associated with conversion).  
 Valmaggia et al’s (2014) study provided an arguably more nuanced assessment of 
the relationship, reporting that while there was no significant difference in transition 
rates between high risk cannabis users versus high-risk non-users, among cannabis 
users, those with more frequent and earlier first use (i.e. before age 15) were more 
likely to transition. 
 
3.5 Assessment of relationship between cannabis use and other major outcome 
variables (e.g. functioning) 
 Apart from various reports of prodromal symptomatology (which are not 
addressed in this review), most of the studies included here did not report on other 
significant outcome variables related to cannabis use.  Among the ones that did, as 
with cannabis use assessments, data was often reported at baseline but not tracked 
longitudinally and reported at follow-up. 
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 Auther et al (2012) and Corcoran et al (2008) were the only two studies to report 
on the relationship between cannabis use and social and role functioning.  The 
former utilised the Global Functioning: Role Scale (GF: Role; Niendam, Bearden, 
Johnson & Cannon, 2006) and Global Functioning: Social Scale (GF: Social; 
Auther, Smith & Cornblatt, 2006).  Auther et al (2012) found that at baseline, 
clinical high risk lifetime cannabis users had higher global functioning than non-
users, and this continued at follow-up, though there were no group differences in role 
functioning.  Clinical high risk cannabis abusers in their CHR sample (n = 10, a 
subsample of CHR cannabis users) were found to have higher social functioning 
(GF: Social) scores at baseline than non-cannabis using high risk individuals; these 
cannabis abusers had better social functioning scores at follow-up, though there were 
no statistical group differences at follow-up (Auther et al, 2012).  No group 
differences were found in role functioning (GF: Role) at baseline or follow-up. 
 Corcoran et al (2008) used the modified Global Assessment of Function (as in the 
SIPS; Miller et al, 2003) to assess global function.  While drug-using and non-using 
high risk individuals were comparable on global functioning at baseline, periods of 
reported increased use of cannabis was associated with increased functional 
impairment in cannabis users (Corcoran et al, 2008).  Their analyses controlled for 
use of other drugs and anti-psychotic medication, which suggests a distinct effect of 
cannabis use on functioning in this sample. 
 Dragt et al (2010) reported poor functioning (again using the mGAF) in their 
overall high risk sample at baseline, but did not report on the relationship between 
functioning and cannabis use, nor on functioning at follow-up.  Similarly, Dragt et al 
(2012) reported similar levels of poor functioning in both high risk lifetime cannabis 
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users and high risk non-users, but did not report follow up or comment on the 
relationship with cannabis use. 
 Cannon et al (2008) reported on functioning, suggesting that poorer functioning 
and heightened severity of prodromal symptoms in high risk individuals brought 
forward the risk of transition; however, functioning was not analysed in relation to 
cannabis use. 
 Two studies reported on the association between cannabis use and significant 
outcome variables other than functioning.  These were neuropsychological 
functioning (Korver et al, 2010) and the incidence of other psychiatric diagnoses 
such as anxiety and depression (Russo et al, 2014).  In the former, no relationship 
was found between frequency of cannabis use and any of the neuropsychological 
tests administered in total sample of high risk individuals (Korver et al, 2010).  
Russo et al (2014) reported on comorbid psychiatric diagnoses using the MINI 
DSM-IV in their high risk sample, finding that 69.1% had more than one diagnosis, 
but they did not map the association between cannabis use and comorbid diagnosis, 
nor did they examine stability of diagnoses longitudinally. 
 
 
4. Discussion 
  
 This review sought to examine how cannabis use was assessed in studies of 
clinical high risk individuals that address incidence of transition to psychosis.  The 
aims of the review included an examination of cannabis measurements, whether 
cannabis use was significantly associated with conversion to psychosis and whether 
the relationship between cannabis use and other significant outcome variables was 
assessed. 
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4.1 Strengths and limitations 
 The current studies all used standardised instruments to define their high risk 
samples and most utilised standardised self-report measures to assess cannabis use at 
intake, which represent significant strengths.  Similarly, most studies reported on 
established criteria used to determine conversion status (e.g. SIPS and IRAOS).  
Those studies that included a control group provided a useful means of comparing 
the high risk samples on cannabis use and transition, though in several cases the 
samples groups were relatively small.  A relative strength in some studies was 
controlling for use of other drugs and alcohol in analyses of transition to psychosis, 
though others were less clear in reporting this. 
 The main findings from the review support the hypothesised variability of 
cannabis use assessment between the studies.  While most of the studies used 
reliable and valid clinical instruments to assess dimensions such as lifetime use, 
cannabis dependence and severity of use in the past month, the majority of studies 
limited their assessment to these measures, focusing on retrospective assessments of 
lifetime use at baseline, and did not obtain broader assessments of patterns of use 
both historically and longitudinally, which may have impacted on their analyses of 
cannabis use and transition. 
 This is a significant shortcoming in these recent studies, as the high risk groups 
consisted of treatment-seeking individuals; accessing help and enrolling in such 
studies may have conferred benefits over time such as improved functioning and 
possible reductions in cannabis use.  Neither of these variables were frequently 
reported on or included in analyses of transition rates.  Most of the studies also relied 
on self-report, with only one of the eleven studies including an objective assessment 
(urine screening) of cannabis use.  Several of the included studies excluded DSM-IV 
47 
 
 
 
 
diagnoses of cannabis dependence, which will likely have impacted on how 
representative their high risk samples were, given the high prevalence rates of 
comorbid cannabis dependence in individuals with first-episode psychosis (Wisdom, 
Manuel & Drake, 2015).  There was also variability in the extent to which the studies 
reported on and controlled for use of medications such as anti-psychotics, with 
several studies listing anti-psychotic use as an exclusion criterion, and others 
allowing treatment with anti-psychotics but not reporting on rates of use or 
incorporating possible effects of medication in analyses of transition. 
 Several other limitations in cannabis measurement highlight methodological 
weaknesses in the current studies.  None of the included studies asked about types or 
amounts of cannabis used.  This is particularly worrying – not only is frequency of 
use not equivalent to amount of cannabis consumed, but given the saturation of 
Western markets with high-potency cannabis and the recent findings that high-
potency cannabis is associated with increased risk of psychosis compared to lower-
potency varieties (e.g. hashish), studies that overlook assessment of this dimension 
of cannabis use might only be able to make tentative speculations about the possible 
associations between heavier cannabis use and psychotic symptomatology (di Forti 
et al, 2009; Hardwick & King, 2008).  Also, while several studies used ‘age of 
[cannabis use] onset’ as a measurement variable, to determine whether younger age 
was significantly associated with other use variables or transition (as it has been 
found to be associated with age of onset of psychosis and first hospitalization in 
retrospective assessments of individuals with psychosis; Galvez-Buccollini et al, 
2012), the variable may be limited in its usefulness unless followed by reliable 
assessments of use frequency, as the age at which an individual first uses cannabis 
may be followed by broad variation in patterns of subsequent use.  For instance, 
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Dragt et al (2010) commenting on their examination of age of onset of prodromal 
symptoms and age of first cannabis use, report that 20 out of 35 of the cannabis users 
in their study stopped using cannabis at the time of intake.  They suggest that past 
cannabis use may have influenced early experiences of prodromal symptoms (Dragt 
et al, 2010).  However, without further information about patterns of use following 
first use, it is difficult to ascertain the homogeneity of the group. 
 Overall, there was relatively weak evidence among the included studies to suggest 
that transition to psychosis was associated with cannabis use.  This may accurately 
reflect the wider clinical picture.  Conversely, this may in large part relate to 
weaknesses and variability between studies in cannabis use measurement or small 
sample sizes with lower incidence of cannabis use.  The increasing emphasis on 
detection of risk factors and prodromal symptoms may be influencing reported 
declining rates of transition, either by providing earlier effective treatments, or via 
the identification of greater numbers of individuals who present as high risk but who 
do not transition (Yung et al, 2007; Addington et al, 2014). 
 
4.2 Theoretical and Clinical Implications 
 The studies that went beyond assigning all lifetime users to the overarching 
category of ‘cannabis users’ (vs. ‘non-cannabis users’) and provided more thorough 
data on past and recent patterns of use provided richer clinical pictures of their 
cannabis-using high risk samples.  Valmaggia et al (2014) reported that transition to 
psychosis was not associated with lifetime cannabis use per se, but that it was 
associated with higher frequency of use, earlier age of first use and continued use 
during follow up (during reported presence of prodromal symptoms) in high risk 
users.  These associations would not have been possible had the authors not obtained 
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extensive information about cannabis use both historically and over the study’s 
course.  Russo et al (2014)’s was another such study which compiled detailed 
information on patterns of substance use.  Although changes in cannabis use were 
not tracked throughout follow-up, the authors acknowledged that the substance use 
profiles of their high risk groups, including the relatively low frequency of cannabis 
use in their high risk sample (9%), low rates of weekly and absence of daily use 
relative to other studies (e.g. Dragt, 2010; Korver, 2010), and low transition rates 
might indicate that their high-risk sample was not broadly representative of other 
high risk individuals (Russo et al, 2014).  However, they highlight the important 
question of how substance, particularly cannabis, use may influence the development 
of sub-threshold psychotic-like symptoms and the extent to which such symptoms 
are implicated in eventual transition to psychosis (Russo et al, 2014).  Buchy et al 
(2015) noted that change in use severity may be an important factor in transition, as 
retrospective assessments of psychotic individuals showed that change in frequency 
of use to daily use prior to onset was associated with greater risk of prodromal 
symptoms.   Examining whether distinct patterns of substance use, including mono- 
and poly-drug user profiles and changes in use, may be more predictive of the onset 
of prodromal symptoms and subsequent development of psychosis would be an 
interesting avenue for future research.  Although there is already a body of literature 
assessing the association between substance use and psychotic-like symptomatology, 
it may be the case that existing studies suffer from similar limitations and confounds 
in drug assessment as in the present studies. 
 The inclusion of measures of functioning in several of the studies was helpful in 
linking cannabis use in high risk populations with broader clinical outcomes (Auther 
et al, 2012; Corcoran et al, 2008).  However, most did not examine associations 
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between cannabis use and such outcomes, which is somewhat unusual in light of 
studies of first-episode patients which highlight long-term prognoses that include 
various measures of poorer functioning (e.g. poorer cognitive functioning and 
premorbid adjustment, etc.; Waddington, 2005).  Given the relatively short duration 
of follow-up and rates of transition in the present studies, it is possible that 
longitudinal measures of functioning are not as yet standard practice in studies of 
clinical high risk populations. 
 
4.3 Limitations of current review 
 The current review was limited by its very specific inclusion criteria – studies of 
clinically assessed high risk individuals which included measures of cannabis use 
and transition to psychosis.  The small number of studies may reflect lack of research 
in this particular area, but was also a result of the date limitations at the outset of the 
search.  As discussed, many other studies share similarities to those included here, 
such as investigations of the links between cannabis use and prodromal symptoms in 
other populations or retrospective assessments of cannabis use in individuals already 
diagnosed with psychosis.  A widening of inclusion criteria (e.g. studies focusing on 
individuals with higher rates of psychotic-like symptoms, rather than those 
considered at high clinical risk) may therefore have allowed for a broader assessment 
of the relationships between cannabis use and psychosis.  
 
 
 
  
51 
 
 
 
 
 
References 
 
Addington, J., & Heinssen, R. (2012). Prediction and prevention of psychosis in 
youth at clinical high risk. Annual review of clinical psychology, 8, 269-289. 
 
Addington, J., Case, N., Saleem, M. M., Auther, A. M., Cornblatt, B. A., & 
Cadenhead, K. S. (2014). Substance use in clinical high risk for psychosis: a review 
of the literature. Early intervention in psychiatry, 8(2), 104-112. 
 
Andrews, G., & Peters, L. (1998). The psychometric properties of the composite 
international diagnostic interview. Social psychiatry and psychiatric epidemiology, 
33(2), 80-88. 
 
Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., & Moffitt, T. E. 
(2002). Cannabis use in adolescence and risk for adult psychosis: longitudinal 
prospective study. Bmj, 325(7374), 1212-1213. 
 
Auther, A. M., McLaughlin, D., Carrión, R. E., Nagachandran, P., Correll, C. U., & 
Cornblatt, B. A. (2012). Prospective study of cannabis use in adolescents at clinical 
high risk for psychosis: impact on conversion to psychosis and functional outcome. 
Psychological medicine, 42(12), 2485-2497. 
 
Auther, A. M., Smith, C. W., & Cornblatt, B. A. (2006). Global Functioning: Social 
Scale (GF: Social). Glen Oaks, NY: Zucker-Hillside Hospital. 
 
Barkus EJ, Stirling J, Hopkins RS, Lewis S (2006). Cannabis-induced psychosis-like 
experiences are associated with high schizotypy. Psychopathology 39, 175–178. 
 
Buchy, L., Perkins, D., Woods, S. W., Liu, L., & Addington, J. (2014). Impact of 
substance use on conversion to psychosis in youth at clinical high risk of psychosis. 
Schizophrenia research, 156(2), 277-280. 
 
Buchy, L., Perkins, D., Woods, S. W., Liu, L., & Addington, J. (2014). Impact of 
substance use on conversion to psychosis in youth at clinical high risk of psychosis. 
Schizophrenia research, 156(2), 277-280. 
 
Burns, J. K. (2013). Pathways from cannabis to psychosis: a review of the evidence. 
Frontiers in psychiatry, 4. 
 
Cannon, T. D., Cadenhead, K., Cornblatt, B., Woods, S. W., Addington, J., Walker, 
E., ... & Heinssen, R. (2008). Prediction of psychosis in youth at high clinical risk: a 
multisite longitudinal study in North America. Archives of general psychiatry, 65(1), 
28-37. 
 
Casadio, P., Fernandes, C., Murray, R. M., & Di Forti, M. (2011). Cannabis use in 
young people: the risk for schizophrenia. Neuroscience & Biobehavioral Reviews, 
35(8), 1779-1787. 
 
52 
 
 
 
 
Carey, M. P., Carey, K. B. & Meisler, A.W. (1991) Psychiatric symptoms inmentally 
ill chemical abusers.  Journal of Nervous and Mental Disease, 179,136^138. 
 
Compton, M. T., Kelley, M. E., Ramsay, C. E., Pringle, M., Goulding, S. M., 
Esterberg, M. L., ... & Walker, E. F. (2009). Association of pre-onset cannabis, 
alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis 
in first-episode patients. American Journal of Psychiatry, 166(11), 1251-1257. 
 
Corcoran, C. M., Kimhy, D., Stanford, A., Khan, S., Walsh, J., Thompson, J., ... & 
Malaspina, D. (2008). Temporal association of cannabis use with symptoms in 
individuals at clinical high risk for psychosis. Schizophrenia research, 106(2), 286-
293. 
 
Currie D, Small G, Currie C. (2005) Prevalence and profiles of substance and multi-
substance use by adolescents: UK and international perspectives. Advisory Council 
on the Misuse of Drugs. Home Office, London. 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/11906
1/Appendix8.pdf 
 
D’Souza C, Cho HS, Perry EB, et al. A cannabinoid model psychosis, dopamine-
cannabinoid interaction and implication for schizophrenia. In: Castle DJ and Murray 
R, eds. (2004) Marijuana and madness. Cambridge: Cambridge University Press, 
2004:142–65 
 
Di Forti, M., Sallis, H., Allegri, F., Trotta, A., Ferraro, L., Stilo, S. A., ... & Murray, 
R. M. (2014). Daily use, especially of high-potency cannabis, drives the earlier onset 
of psychosis in cannabis users. Schizophrenia bulletin, 40(6), 1509-1517. 
 
Dixon, L. (1999). Dual diagnosis of substance abuse in schizophrenia: prevalence 
and impact on outcomes. Schizophrenia research, 35, S93-S100. 
 
Dragt S, Nieman DH, Becker HE… & Linszen, DH (2010) Age of onset of cannabis 
use is associated with age of onset of high-risk symptoms for psychosis. Can J 
Psychiatry 2010; 55: 165–71. 
 
Dragt, S., Nieman, D. H., Schultze‐Lutter, F., Van Der Meer, F., Becker, H., De 
Haan, L., ... & Linszen, D. H. (2012). Cannabis use and age at onset of symptoms in 
subjects at clinical high risk for psychosis. Acta Psychiatrica Scandinavica, 125(1), 
45-53. 
 
Drake RE, Mueser K, McHugo G (1996). Clinical rating scales. In Outcomes 
Assessment in Clinical Practice (ed. L. Sederer and B. Dickey), pp. 113–116. 
Williams and Wilkins: Baltimore. 
 
Fergusson, D. M., Horwood, L. J., & Ridder, E. M. (2005). Tests of causal linkages 
between cannabis use and psychotic symptoms. Addiction, 100(3), 354-366. 
 
53 
 
 
 
 
First M, Spitzer RL, Gibbon M, Williams B, Williams JBW. Structured Clinical 
Interview for DSM-IV Axis I Disorders, Patient Edition. New York: Biometrics 
Research Department, New York State Psychiatric Institute, 1995. 
 
Fusar-Poli, P., Bonoldi, I., Yung, A. R., Borgwardt, S., Kempton, M. J., Valmaggia, 
L., ... & McGuire, P. (2012). Predicting psychosis: meta-analysis of transition 
outcomes in individuals at high clinical risk. Archives of general psychiatry, 69(3), 
220-229. 
 
Fusar-Poli, P., Borgwardt, S., Bechdolf, A., Addington, J., Riecher-Rössler, A., 
Schultze-Lutter, F., ... & Yung, A. (2013). The psychosis high-risk state: a 
comprehensive state-of-the-art review. JAMA psychiatry, 70(1), 107-120. 
 
Galvez-Buccollini, J. A., Proal, A. C., Tomaselli, V., Trachtenberg, M., Coconcea, 
C., Chun, J., ... & Delisi, L. E. (2012). Association between age at onset of psychosis 
and age at onset of cannabis use in non-affective psychosis. Schizophrenia research, 
139(1), 157-160. 
 
Häfner, H., Riecher-Rössler, A., Hambrecht, M., Maurer, K., Meissner, S., 
Schmidtke, A., ... & Van der Heiden, W. (1992). IRAOS: an instrument for the 
assessment of onset and early course of schizophrenia. Schizophrenia research, 6(3), 
209-223. 
 
Hardwick, S., & King, L. A. (2008). Home Office cannabis potency study 2008. 
United Kingdom: Home Office Scientific Development Branch. 
 
Hunt,G. E., Bergen, J. & Bashir,M. (2002) Medication compliance and comorbid 
substance abuse in schizophrenia: impact on community survival 4 years after a 
relapse. Schizophrenia Research, 54, 253-264. 
 
Johnson, T. P., & Mott, J. A. (2001). The reliability of self-reported age of onset of 
tobacco, alcohol and illicit drug use. Addiction, 96(8), 1187-1198. 
 
Kaufman, J., Birmaher, B., Brent, D., Rao, U. M. A., Flynn, C., Moreci, P., ... & 
Ryan, N. (1997). Schedule for affective disorders and schizophrenia for school-age 
children-present and lifetime version (K-SADS-PL): initial reliability and validity 
data. Journal of the American Academy of Child & Adolescent Psychiatry, 36(7), 
980-988. 
 
Klosterkötter, J., Hellmich, M., Steinmeyer, E. M., & Schultze-Lutter, F. (2001). 
Diagnosing schizophrenia in the initial prodromal phase. Archives of general 
psychiatry, 58(2), 158-164. 
 
Korver, N., Nieman, D. H., Becker, H. E., van de Fliert, J. R., Dingemans, P. H., de 
Haan, L., ... & Linszen, D. H. (2010). Symptomatology and neuropsychological 
functioning in cannabis using subjects at ultra-high risk for developing psychosis and 
healthy controls. Australian and New Zealand Journal of Psychiatry, 44(3), 230-236. 
 
54 
 
 
 
 
Kristensen, K., & Cadenhead, K. S. (2007). Cannabis abuse and risk for psychosis in 
a prodromal sample. Psychiatry research, 151(1), 151-154. 
 
Lambert, M., Conus, P., Lubman, D. I., Wade, D., Yuen, H., Moritz, S., ... & 
Schimmelmann, B. G. (2005). The impact of substance use disorders on clinical 
outcome in 643 patients with first‐episode psychosis. Acta Psychiatrica 
Scandinavica, 112(2), 141-148. 
 
McGorry, P. D., Purcell, R., Goldstone, S., & Amminger, G. P. (2011). Age of onset 
and timing of treatment for mental and substance use disorders: implications for 
preventive intervention strategies and models of care. Current Opinion in 
Psychiatry, 24(4), 301-306. 
 
Miller, T. J., McGlashan, T. H., Rosen, J. L., Somjee, L., Markovich, P. J., Stein, K., 
& Woods, S. W. (2002). Prospective diagnosis of the initial prodrome for 
schizophrenia based on the Structured Interview for Prodromal Syndromes: 
preliminary evidence of interrater reliability and predictive validity. American 
Journal of Psychiatry, 159(5), 863-865. 
 
Miller, T. J., McGlashan, T. H., Rosen, J. L., Cadenhead, K., Ventura, J., McFarlane, 
W., ... & Woods, S. W. (2003). Prodromal assessment with the structured interview 
for prodromal syndromes and the scale of prodromal symptoms: predictive validity, 
interrater reliability, and training to reliability. Schizophrenia Bulletin, 29(4), 703. 
 
Miller, T. J., McGlashan, T. H., Woods, S. W., Stein, K., Driesen, N., Corcoran, C. 
M., ... & Davidson, L. (1999). Symptom assessment in schizophrenic prodromal 
states. Psychiatric Quarterly, 70(4), 273-287. 
 
Minozzi, S., Davoli, M., Bargagli, A. M., Amato, L., Vecchi, S., & Perucci, C. A. 
(2010). An overview of systematic reviews on cannabis and psychosis: discussing 
apparently conflicting results. Drug and alcohol review, 29(3), 304-317. 
 
Mueser, K. T., Yarnold, P. R., Levinson, D. F., Singh, H., Bellack, A. S., Kee, K., ... 
& Yadalam, K. G. (1990). Prevalence of substance abuse in schizophrenia: 
demographic and clinical correlates. Schizophrenia Bulletin, 16(1), 31-56. 
 
The NHS Information Centre, Lifestyles Statistics (2011) Statistics on Drug Misuse: 
England 22 November 2011. 
http://www.drugscope.org.uk/Resources/Drugscope/Documents/PDF/Good%20Pract
ice/Statistics_on_Drug_Misuse_England_2011v3.pdf 
 
Niendam, T. A., Bearden, C. E., Johnson, J. K., & Cannon, T. D. (2006). Global 
Functioning: Role Scale (GF: Role). Los Angeles, CA: University of California, Los 
Angeles. 
 
Nurnberger, J. I., Blehar, M. C., Kaufmann, C. A., York-Cooler, C., Simpson, S. G., 
Harkavy-Friedman, J., ... & Reich, T. (1994). Diagnostic interview for genetic 
studies: rationale, unique features, and training. Archives of general psychiatry, 
51(11), 849-859. 
55 
 
 
 
 
 
Olsen, K.A., & Rosenbaum, B (2006). Prospective investigations of the prodromal 
state of schizophrenia: assessment instruments, Acta Psychiatrica Scandinavica, 113, 
273-282. 
 
Orvaschel H. P., Puig-Antich, J (1994). Schedule for affective disorders and 
schizophrenia for school-aged children – epidemiologic version. Fort Lauderdale, 
FL: Centre for Psychological Studies, Nova Southeastern University, 1994. 
 
Phillips, L. J., Curry, C., Yung, A. R., Pan Yuen, H., Adlard, S., & Mcgorry, P. D. 
(2002). Cannabis use is not associated with the development of psychosis in an 
‘ultra’high-risk group. Australian and New Zealand Journal of Psychiatry, 36(6), 
800-806. 
 
Regier, D. A., Farmer,M. E., Rae, D. S., et al (1990) Co-morbidity ofmental disorder 
with alcohol and other drug abuse: results froman epidemiological catchment area 
(ECA) study. JAMA, 264, 2511-2518. 
 
Richardson, T. H. (2010). Cannabis use and mental health: A review of recent 
epidemiological research. International Journal of Pharmacology, 6(6), 796-807. 
 
Ruhrmann, S., Schultze-Lutter, F., & Klosterkötter, J. (2003). Early detection and 
intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiatry, 
36, S162-7. 
 
Ruhrmann, S., Schultze-Lutter, F., Salokangas, R. K., Heinimaa, M., Linszen, D., 
Dingemans, P., ... & Klosterkötter, J. (2010). Prediction of psychosis in adolescents 
and young adults at high risk: results from the prospective European prediction of 
psychosis study. Archives of general psychiatry, 67(3), 241-251. 
 
Russo, D. A., Stochl, J., Painter, M., Jones, P. B., & Perez, J. (2014). Substance use 
in people at clinical high-risk for psychosis. BMC psychiatry, 14(1), 361. 
 
Schultze-Lutter, F., Addington, J., Ruhrmann, S., & Klosterkötter, J. (2007). 
Schizophrenia proneness instrument, adult version (SPI-A). Giovanni Fioriti Editore 
srl, Rome. 
 
F. Schultze-Lutter, J. Klosterkötter (2002) Bonn scale for assessment of basic 
symptoms – prediction list, BSABS-P, University of Cologne, Cologne. 
 
Schultze-Lutter, F., Ruhrmann, S., Berning, J., Maier, W., & Klosterkötter, J. (2010). 
Basic symptoms and ultrahigh risk criteria: symptom development in the initial 
prodromal state. Schizophrenia bulletin, 36(1), 182-191. 
 
Schultze-Lutter, F., Schimmelmann, B. G., & Ruhrmann, S. (2011). The near 
Babylonian speech confusion in early detection of psychosis. Schizophrenia bulletin, 
37(4), 653-655. 
 
56 
 
 
 
 
Solowij, N., & Battisti, R. (2008). The chronic effects of cannabis on memory in 
humans: a review. Current drug abuse reviews, 1(1), 81-98. 
 
Stefanis, N. C., Dragovic, M., Power, B. D., Jablensky, A., Castle, D., & Morgan, V. 
A. (2013). Age at initiation of cannabis use predicts age at onset of psychosis: the 7-
to 8-year trend. Schizophrenia bulletin, 39(2), 251-254. 
 
Swendsen J, Burstein M, Case B, et al. Use and Abuse of Alcohol and Illicit Drugs 
in US Adolescents: Results of the National Comorbidity Survey–Adolescent 
Supplement. Arch Gen Psychiatry. 2012;69(4):390-398. 
 doi:10.1001/archgenpsychiatry.2011.1503. 
 
Temple, E. C., Brown, R. F., & Hine, D. W. (2011). The ‘grass ceiling’: limitations 
in the literature hinder our understanding of cannabis use and its consequences. 
Addiction, 106(2), 238-244. 
 
Thompson, A., Nelson, B., & Yung, A. (2011). Predictive validity of clinical 
variables in the “at risk” for psychosis population: international comparison with 
results from the North American Prodrome Longitudinal Study. Schizophrenia 
Research, 126(1), 51-57. 
 
Valmaggia, L. R., Day, F. L., Jones, C., Bissoli, S., Pugh, C., Hall, D., ... & 
McGuire, P. K. (2014). Cannabis use and transition to psychosis in people at ultra-
high risk. Psychological medicine, 44(12), 2503-2512. 
 
Van Os, J., Linscott, R. J., Myin-Germeys, I., Delespaul, P., & Krabbendam, L. 
(2009). A systematic review and meta-analysis of the psychosis continuum: evidence 
for a psychosis proneness–persistence–impairment model of psychotic disorder. 
Psychological medicine, 39(02), 179-195. 
 
Volkow, N. D. (2001). Drug abuse and mental illness: progress in understanding 
comorbidity. American Journal of Psychiatry, 158(8), 1181-1183. 
 
Waddington, J. L. (2005). What have we learned from the new generation of 
prospective studies on first-episode psychosis?. Schizophrenia Bulletin, 31(3), 623-
623. 
 
Watson, S. J., Benson, J. A., & Joy, J. E. (2000). Marijuana and medicine: assessing 
the science base: a summary of the 1999 Institute of Medicine report. Archives of 
General Psychiatry, 57(6), 547-552. 
 
Weaver, T., Madden, P., Charles, V., Stimson, G., Renton, A., Tyrer, P., ... & Ford, 
C. (2003). Comorbidity of substance misuse and mental illness in community mental 
health and substance misuse services. The British Journal of Psychiatry, 183(4), 
304-313. 
 
Wisdom, J. P., Manuel, J. I., & Drake, R. E. (2015). Substance use disorder among 
people with first-episode psychosis: a systematic review of course and treatment. 
Psychiatric Services. 
57 
 
 
 
 
 
Yung, A.R., McGorry, P.D. (1996a). The initial prodrome in psychosis: descriptive 
and qualitative aspects. Australian and New Zealand Journal of Psychiatry, 30, 587-
599. 
 
Yung, A.R., McGorry, P.D. (1996b). The prodromal phase of first-episode psychosis: 
past and current conceptualizations. Schizophrenia Bulletin, 22, 353-370. 
 
Yung AR, Phillips LJ, McGorry PD, McFarlane CA, Francey S, Harrigan S, Patton 
GC, Jackson HJ (1998). Prediction of psychosis. A step towards indicated prevention 
of schizophrenia. British Journal of Psychiatry Supplement 172, 14–20. 
 
Yung A.R., Phillips L.J., Yuen H.P., McGorry P.D.  (2004) Risk factors for 
psychosis in an ultra high-risk group: psychopathology and clinical features. 
Schizophrenia Research, 67, 131–142. 
 
Yung, A. R., Yuen, H. P., Berger, G., Francey, S., Hung, T. C., Nelson, B., ... & 
McGorry, P. (2007). Declining transition rate in ultra high risk (prodromal) services: 
dilution or reduction of risk?. Schizophrenia bulletin, 33(3), 673-681. 
 
Yung, A. R., Yung, A. R., Pan Yuen, H., Mcgorry, P. D., Phillips, L. J., Kelly, D., ... 
& Buckby, J. (2005). Mapping the onset of psychosis: the comprehensive assessment 
of at-risk mental states. Australian and New Zealand Journal of Psychiatry, 39(11-
12), 964-971. 
 
 
  
58 
 
 
 
 
Appendix 1 
 
Search strategy 
 
PsycINFO search terms 
 
 Terms 
1 cannabis.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] or exp Cannabis/ 
2 exp Psychosis/ 
3 exp "Positive and Negative Symptoms"/ 
4 exp Prodrome/ 
5 mania.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] or exp Mania/ 
6 biploar disorder.mp. [mp=title, abstract, heading word, table of contents, 
key concepts, original title, tests & measures] 
7 schizoaffective disorder.mp. [mp=title, abstract, heading word, table of 
contents, key concepts, original title, tests & measures] or exp 
Schizoaffective Disorder/ 
8 schizophren*.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] or exp Schizophrenia/ 
9 basic symptoms.mp. [mp=title, abstract, heading word, table of contents, 
key concepts, original title, tests & measures] 
10 ultra-high risk.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] 
11 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
12 1 and 11 
13 limit 12 to (human and english language) 
14 limit 13 to yr="2004 -Current" 
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PubMed search terms 
 
 Terms 
1 psychosis.af. [af = all fields] 
 
2 (positive symptoms and negative symptoms).af. [af = all fields] 
3 (prodrom* or prodrome).af. [af = all fields] 
4 mania.af. [af = all fields] 
5 bipolar disorder.af. [af = all fields] 
6 schizoaffective.af. [af = all fields] 
7 schizophrenia.af. [af = all fields] 
8 basic symptoms.af. [af = all fields] 
9 ultra-high.af. [af = all fields] 
10 risk [Medical Subject Heading / MeSH Terms] or exp risk 
11 9 and 10 
12 cannabis/ or cannabis.mp. [Medical Subject Heading / MeSH Terms] 
 
13 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 11 
14 12 and 13 
15 limit 14 to [humans [MeSH Terms] and English [language]] 
16 limit 15 to [2004/06/06 [Publication Date] : 2015/06/06 [Publication Date] 
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Part 2: Empirical Paper 
 
 
 
 
 
Psychotic-like symptomatology and reward responsivity in 
chronic ketamine and cannabis users  
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Abstract 
 
Background: Drug use has been linked to psychosis, but the relationship has not yet 
been fully understood.  Further, chronic drug use has been hypothesised to increase 
sensitivity to drug rewards while decreasing sensitivity to non-drug rewards and has 
been found to model symptomatology of prodromal psychosis, which may aid our 
understanding of how psychosis develops.   
 
Aims: Anhedonia, a key feature of depression and substance misuse, and a negative 
symptom of psychosis, has particularly been linked to deficits in reward 
responsivity.  The present study aimed to build on previous research by (1) assessing 
prodromal psychosis symptomatology in chronic cannabis and ketamine users, and 
(2) objectively assessing their reward responsivity. 
 
Participants: Sixty participants, 25 women and 35 men aged 18-43, completed the 
study. 
 
Design: A between subjects design compared three groups – 20 dependent ketamine 
users, 20 dependent cannabis users, and 20 control participants (who occasionally 
used illicit drugs).  Participants completed a drug use history interview, self-report 
questionnaires (Beck Depression Inventory, BDI; Temporal Experience of Pleasure 
Scale, TEPS; O-Life; Prodromal Questionnaire – Brief, PQB) and two cognitive 
tasks examining reward sensitivity (probabilistic reward task, PRT) and effort-based 
decision-making (Effort-Expenditure for Rewards Task, EEfRT). 
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Results: Both drug using groups had higher levels of schizotypy (O-LIFE) and 
positive psychosis symptomatology (PQ-B) than controls.  The drug-using groups 
demonstrated differences on the probabilistic reward task: controls had greater 
response bias than the cannabis users and also greater discriminability than the 
ketamine users.  The groups did not differ on the effort-based decision-making task. 
 
Conclusion: These findings support previous research demonstrating high levels of 
positive and negative psychosis-like symptoms in chronic cannabis and ketamine 
users.  The mixed results in the drug-using groups’ reward responsiveness may be 
partly explained by group differences in depression and tobacco use.  These findings 
have clinical implications for the assessment and treatment of individuals at higher 
risk of developing psychosis. 
 
Key words: Addiction, chronic effects, cannabis, ketamine, psychosis, psychosis 
proneness, schizotypy, anhedonia, motivation 
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Psychotic-like symptomatology and reward responsivity in chronic ketamine 
and cannabis users 
 
Drug use and psychosis 
 Rates of drug misuse, including alcohol, tobacco, cannabis and other illicit drugs, 
are higher in patients with psychotic disorders.  Higher substance use rates in 
psychotic patients are seen both at onset (first episode of psychosis) and in those 
with chronic psychotic illness (Regier, Farmer, Rae et al, 1990; McCreadie, 2002; 
Barnett, Werners, Secher et al, 2007).  Further, drug use has been found to be a key 
predictor of conversion from an ‘at risk’ or prodromal state to full-blown 
schizophrenia (Cannon et al, 2008). 
 Over 200 studies have focused on the potential associations between cannabis, the 
most widely used illicit drug in the world, and psychosis, noting the high prevalence 
of cannabis use among psychosis patients and exploring how cannabis potency, 
frequency, duration and age of first use may influence the risk of transition to 
psychosis (Arseneault, Cannon, Witton & Murray, 2004; Barnet et al, 2007; Green, 
Young & Kavanagh, 2005; di Forti et al, 2014; Moore et al, 2007).  Cannabis use has 
particularly been linked to higher levels of prodromal symptoms and higher 
incidence of transition to psychosis in individuals considered to be ‘high risk’ in a 
number of studies (Kristensen et al, 2007; Miettunen et al, 2008; Rosen et al, 2006). 
 Higher potency cannabis strains (‘skunk’) have saturated the market in recent 
years and have been particularly linked with the development of psychosis (Di Forti 
et al, 2009; 2015; Moore et al, 2007; Wylie et al, 1995).  Research also suggests that 
a less frequently used drug of abuse, ketamine, a non-competitive N-methyl-D-
aspartate (NMDA) receptor antagonist with marked psychotomimetic properties, 
may be associated with psychosis (Anis, Berry, Burton & Lodge, 1983).  Chronic 
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ketamine use has also been found to mimic some symptoms of psychosis and its 
more potent relative, phencyclidine (PCP), also an NMDA-receptor antagonist, has 
been associated with prolonged psychotic reactions in some users (Allen & Young, 
1978; Krystal et al, 1994). 
 As yet, the nature of any relationship between using recreational drugs and 
psychosis has not been established.  Recent research examines i) possible causal 
links (i.e. drug use causing psychosis), ii) common risk factors implicated in both 
addiction and psychosis, iii) whether presence of psychosis increases the risk of 
substance use, and iv) whether accessing treatment for one disorder (addiction or 
psychotic illness) might facilitate detection of the other and thus raise reported rates 
of comorbidity (Barkus & Murray, 2010). 
 
Addiction and reward processing 
 Animal and human studies of drug addiction have shown that increasing exposure 
to drugs leads to the development of compulsive drug-seeking and taking 
behaviours, which are characterised by intensive and rigid directedness towards drug 
use and neglect of other previously important and pleasurable activities 
(Wolffgramm & Heyne, 1995; Robinson & Berridge, 2000; Deroche-Gamonet, 
Belin & Piazza, 2004; Vanderschuren & Everitt, 2004, 2005; Anselme, 2009). 
 Drug addiction can be understood as a chronic brain disease involving motivation, 
memory and reward systems, and chronic drug use has been hypothesised to 
influence the development of neuroadaptations in the mesocorticolimbic dopamine 
system, stimulating pathological desire for drugs, so that ‘wanting’ the drug 
supersedes its pleasurable effects, which reduce over time as tolerance develops 
(Anselme, 2009; Robinson & Berridge, 1993).  These changes in the neurobiological 
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reward system are hypothesised to contribute to an imbalance in the processing of 
drug and non-drug rewards, resulting in hypersensitivity to drug rewards and 
hyposensitivity to non-drug rewards (Anselme, 2009; Blum et al, 2000; Goldstein & 
Volkow, 2002; Kalivas & Volkow, 2005; Koob & Le Moal, 1997; Bühler et al, 
2010).  Craving and acute abstinence is thought to exacerbate this imbalance and 
thereby influence the vicious cycle of cessation of drug use and subsequent relapse 
characteristic of drug addiction (Goldstein & Volkow, 2011; Koob & Le Moal, 
2008; Koob & Volkow, 2009).  While laboratory and neuroimaging studies support 
this hypothesised hypersensitivity to drugs and drug-related stimuli in addicted 
individuals, evidence for hyposensitivity to non-drug rewards is more mixed, 
limiting our understanding of how non-drug rewards are processed (Lawn et al, 
2015). 
 
Anhedonia – a key feature of drug addiction, depression and psychosis 
 Anhedonia, the inability to experience pleasure or react to pleasurable stimuli, is 
understood to be a fundamental symptom of depression (APA, 2000).  It is also a 
core negative symptom of schizophrenia and a potentially significant symptom 
preceding its onset, with associated impacts on social functioning (Cohen et al, 2010; 
Yung & McGorry, 1996b). 
 It has been argued that hedonic capacity is a trait in that the capacity to 
experience pleasure differs between people, with some individuals having a lower 
capacity for pleasure (Meehl, 1975).  According to this theory, the anhedonic 
individual is inherently less responsive to positive reinforcers and thus anhedonia has 
been considered a potential trait related to vulnerability to depression (Loas, 1996; 
Meehl, 1975).  Recent findings however suggest that the construct of anhedonia is 
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more complex; for example, individuals with schizophrenia diagnoses exhibit high 
anhedonia when assessed using ‘trait’ measures but do not demonstrate anhedonia 
using controlled lab-based measures (Cohen et al, 2011).  This example illustrates 
the difficulty in clinical assessment and treatment implications of anhedonia and has 
led researchers to call for a more refined conceptualisation of anhedonia which 
distinguishes between its different functional aspects, e.g. ‘consummatory 
anhedonia’ or hedonic responsivity to rewards and ‘anticipatory’ or ‘motivational 
anhedonia’(reward ‘wanting’) which relates to the drive to pursue rewards, as 
research has shown that depressed and schizophrenic patients can experience in-the-
moment pleasure despite deficits in motivation to pursue such rewards (Treadway & 
Zald, 2010).  More recently, the concept of ‘decisional anhedonia’ has been 
proposed as a means of capturing the role of anhedonic symptoms in decision-
making, as anhedonia has been hypothesised to play a key role in reward 
responsivity and has been associated with dysfunction in the brain reward system, 
specifically related to motivation and effort-based decision-making (Pizzagalli et al, 
2008; Treadway & Zald, 2010; Treadway & Zald, 2013). 
 Research has also examined the relationship between anhedonia and substance 
misuse.  Anhedonia has been associated with the transition from recreational to 
excessive drug use and also in withdrawal symptomatology, abstinence and relapse 
to drug taking (Hatzigiakoumis, Martinotti, Giannantonio, Janiri, 2011; Martinotti et 
al, 2012; Volkow et al, 2002).  Evidence suggests that acute cessation of drug taking 
in chronic users may result in diminished processing of non-drug rewards coupled 
with an increase in anhedonia, (Lawn et al, 2015; Goldstein & Volkow, 2011; Koob 
& Le Moal, 2008; Koob & Volkow, 2009; Pizzagalli et al, 2005).   Heinz et al 
(1994) found anhedonia to be a common symptom shared by schizophrenic, 
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depressed and alcohol dependent patients during withdrawal and they theorised that 
this was related to hypoactivity of dopaminergic transmission in the brain’s reward 
system, which was supported by neuroimagining evidence (Heinz, Schmidt & 
Reischies, 1994). 
 
Prodromal psychosis: symptomatology 
 Research on transition to psychosis postulates the existence of a prodromal period 
where changes in functioning and sub-threshold diagnostic symptoms (including 
changes in affect, perception, thought processes and drive) are frequently 
experienced before the onset of threshold psychosis symptoms (Yung et al, 2005).  It 
has been characterised as the period of time between initial self-experienced or self-
reported changes and the onset of the first observable psychotic symptoms.  This 
time period lasts between months and years although identifying discrete time points 
in the onset and ‘offset’ of the prodrome is difficult as the boundary between ‘pre-
psychotic’ and ‘psychotic’ is blurred (Yung & McGorry, 1996b, Yung et al, 2003).  
Studies of first-episode psychosis have identified common features of the prodromal 
period including reduced attention, reduced drive and motivation, depressed mood, 
sleep disturbance, anxiety, social withdrawal, suspiciousness, deterioration in role 
functioning and irritability (Yung & McGorry, 1996b). 
 By developing knowledge of the specific presentations and mechanisms 
underlying the onset and progression of psychosis, early assessment and 
interventions which aim to minimise or prevent the onset of full-blown psychosis 
may be possible (Yung & McGorry, 1996a; McGorry, 1998).  Research has shown 
that lack of early intervention and an extended ‘duration of untreated psychosis’ 
leads to poorer prognosis and outcomes among adolescents (NICE Guidelines, 
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2013).   For early intervention to be effective, clinicians need valid methods of 
diagnosis to reliably identify symptoms that put individuals at risk of developing 
full-blown psychosis (Yung et al, 2004).  This is particularly true since the wide 
range of prodromal psychosis symptoms has very limited predictive power in 
determining whether presence of any cluster of these symptoms will in fact lead to 
psychosis (McGorry, 1998; Yung et al, 2003).  The prodromal period cannot be 
defined by ‘necessary and sufficient’ symptoms as symptoms are non-specific 
(Olsen and Rosenbaum, 2005). 
 A number of measures have been used in an attempt to accurately define the 
initial prodromal period and its progressive stages (Klosterkotter et al, 2001; Yung et 
al, 2003).  Two approaches to detecting and measuring prodomal symptoms have 
emerged – the ‘basic symptoms’ approach and ‘attenuated positive symptoms’ 
(Olsen & Rosenbaum, 2005).  The basic symptoms approach assesses symptoms 
characterising the earliest prodromal phase, but also thought to be present during the 
entire progression of psychosis; basic symptoms are subtle self-experienced deficits 
in areas such as perception, cognition, language, motor function, initiative, energy, 
etc. (Olsen and Rosenbaum, 2005; Simon et al, 2007; Yung et al, 2005).  Assessment 
instruments employing this approach include the Bonn Scale for the Assessment of 
Basic Symptoms (BSABS), the Schizophrenia Prediction Instrument – Adult 
Version (SPI-A), and the Early Recognition Inventory (ERIaos).  The second 
approach operationalises ‘Attenuated Positive Symptoms’, focusing on symptoms in 
the late prodromal phase and includes the Comprehensive Assessment of At-Risk 
Mental States (CAARMS) and the Structured Interview of Prodromal Syndromes 
(SIPS) as the main assessment instruments (Olsen and Rosenbaum, 2005). 
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 While a review of these instruments suggests that they are all able to detect 
individuals at increased risk of psychosis, they generally give more weight to 
positive symptoms and underestimate negative symptoms and other symptoms 
unrelated to full-blown psychosis (e.g. anomalous self-experience) (Olsen and 
Rosenbaum, 2005).  Interestingly, in a study of ‘ultra-high risk’ young people, high 
levels of ‘negative’ type symptoms (including disturbances of affect and cognition, 
decreased energy and difficulty tolerating stress) were found to be more predictive of 
psychosis than sub-threshold ‘positive’ symptoms (Yung et al, 2005).  This may 
suggest a greater role for negative symptoms in fuelling the transition from non-
troublesome positive symptoms to actual psychosis (Van Os, 2002; Yung et al, 
2005).  The role of negative symptomatology in the prodrome period cannot be 
underestimated given the high incidence of drug use in individuals with psychosis 
and the significance of anhedonia in schizophrenia, depression and substance 
abusing populations. 
 
Prodromal symptomatology and chronic drug use 
 Chronic patterns of drug use may not only influence the risk of psychosis but also 
can offer useful models for understanding psychosis and the prodromal profile.  
Acutely, both ketamine and cannabis induce psychosis-like symptoms in healthy 
individuals (Morgan, Mofeez, Brandner et al, 2008; D’Souza et al, 2004).  Using the 
‘basic symptoms’ approach, Morgan et al (2012) assessed schizophrenia proneness 
and neurocognitive function in non-psychotic individuals dependent upon ketamine, 
cannabis and cocaine, and found that ketamine and skunk users demonstrated high 
levels of attentional and cognitive disturbances.  This was the first study of its kind 
to assess schizophrenia proneness in users of these drugs and to identify distinct 
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profiles consistent with those of individuals who subsequently transitioned from 
prodrome to psychosis.  Chronic ketamine users in particular exhibited the greatest 
levels of basic symptoms compared to the other two drug groups, demonstrating a 
high level of affective symptoms comparable to clinically assessed prodromal 
patients who transitioned to psychosis.  This was consistent with increased 
depressive symptoms characteristic of chronic ketamine use (Morgan et al, 2012; 
Muetzelfeldt et al, 2008). 
 
Aims 
 The present study has two main aims.  First, it seeks to build on Morgan et al’s 
(2012) findings by assessing prodromal symptomatology using self-report measures 
(O-LIFE, PQ-B) in dependent cannabis and ketamine users, and to compare these to 
healthy controls.  If the drug groups score highly on measures of schizotypy and 
positive psychosis symptomatology relative to controls, this may provide further 
support for the recommendation that future studies on the risk of transition to 
psychosis should dissociate symptoms associated with chronic drug use from those 
that are characteristic of prodromal psychosis. 
 The second aim focuses on reward processing aspects of anhedonia and will 
objectively measure differences in reward motivation and hedonic processing in the 
two groups of dependent drug users (cannabis and ketamine), comparing these to 
healthy controls.  A self-report trait anhedonia measure, the Temporal Experience of 
Pleasure Scale (TEPS; Gard, Gard, Kring & John, 2006) will be administered 
alongside two laboratory-based tasks.  The first will assess reward sensitivity using a 
probabilistic reward task based on signal detection theory (Pizzagalli et al, 2005), 
and will attempt to capture differences in participants’ ability to modulate behaviour 
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as a function of prior reinforcements, which may aid our understanding of which 
aspects of hedonic processing might be dysfunctional in dependent drug users.  The 
second task, the ‘Effort-Expenditure for Rewards Task’ (or ‘EEfRT’, Treadway et al, 
2009) will assess reward motivation and effort-based decision-making by measuring 
willingness to expend effort for rewards (which would be expected to be low in 
individuals exhibiting anhedonia).  Given the co-morbidity of psychiatric conditions 
in which anhedonia is a significant factor and our current limited understanding of 
motivational deficits for non-drug rewards in drug dependent populations, 
objectively examining motivated behaviour may inform treatment strategies for 
anhedonia (e.g. the development of behavioural therapies to reinforce behaviour 
motivated towards non-drug rewards). 
 
Hypotheses 
 On the basis of Morgan et al’s (2012) study of chronic ketamine and cannabis 
users and previous studies examining reward responsivity in depressed and 
schizophrenic patients, the following predictions were made: 
 
1)  It is predicted that the cannabis and ketamine using groups will score higher than 
controls on measures of psychosis-like symptomatology as indexed by the four 
subscales of the O-LIFE and PQ-B. 
 
2)  On the probabilistic reward task (‘PRT’), it is hypothesised that there will be 
differences between groups in response bias toward more frequently rewarded 
stimuli (the main outcome variable in this task), with the two drug-using groups 
showing weaker response bias relative to controls (Bogdan & Pizzagalli, 2006; 
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Heerey, Bell-Warren & Gold, 2008; Pizzagalli, Jahn & O’Shea, 2005; Pizzagalli, 
Iosifescu & Hallett, 2009).  Due to potential cognitive effects of long-term drug use, 
we also predicted group differences in accuracy, reaction time and discriminability, 
with the drug using groups performing less accurately, more slowly and with less 
ability to discriminate between stimuli than controls. 
 
3)  On the effort-based decision making task (‘EEfRT’), it was hypothesised that 
groups would differ on propensity to choose the task requiring greater effort (‘hard’ 
task), with the cannabis and ketamine groups making less ‘hard’ choice tasks as the 
probability of winning decreases. 
 
4) Further exploratory within-group correlations between drug use, self-report 
measures and task outcomes will be carried out. 
 
 
METHOD 
 
Power Calculation 
 The power calculation was based on Morgan et al’s (2012) study investigating 
psychosis-proneness and neurocognitive function in individuals dependent on 
ketamine, cannabis or cocaine.  They found significant differences in SPI-A scores 
between controls, dependent cannabis and dependent ketamine users, with a large 
effect size across domains.  Using the ‘G*Power 3’ program (Faul, Erdfelder, Lang 
and Buchner, 2007), statistical power analysis estimated a total sample size of 42, or 
14 participants per group to obtain statistically significant results with a power level 
of 0.80 and alpha level of 5% (based on the ‘Pizzgalli’ probabilistic reward task and 
likelihood of obtaining an interaction between three groups across two time points).  
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The number was slightly lower than that used in Morgan et al’s study and, as our 
initial design incorporated a similar clinical interview to Morgan et al’s (2012) study, 
we increased the sample to 60 in total (20 per group). 
 
Participants and Design 
 A between-subjects design was used to compare ketamine users, frequent 
cannabis users and controls who reported no regular illicit drug use.   Participants 
were recruited through advertisement and via snowball sampling (Solowij, Hall & 
Lee, 1992).  All participants provided written informed consent and were paid £20 
for their participation upon completion of the study.  Inclusion criteria were: men 
and women aged 18-50 years, native English speakers or fluent in English if a 
second language, no use of psychiatric medication or use of mental health services in 
the past six months, and no diagnosis of alcohol use disorder.  Further, each group 
had to meet specific criteria for illicit drug use as rated by the Severity of 
Dependence Scale (SDS, Gossop et al, 1992), as follows: 
 
 The ketamine using group scored at least 3 or more on the SDS for ketamine 
use. 
 Cannabis users reported using high potency cannabis (‘skunk’) on more than 
50% of the occasions they consumed cannabis and scored 3 or more on the 
SDS for cannabis use. 
 Use of other illicit drugs in the cannabis and ketamine groups was 2 or less 
on the SDS for other drugs (e.g. benzodiazepines).  One exception was use of 
cannabis in the ketamine group, which is common, and the SDS cut-off for 
cannabis in this group was raised to 3. 
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 Controls were recreational poly-drug users (i.e. infrequent use of illicit drugs 
in the past and/or present) and had to score 2 or less on the SDS for any illicit 
drug use. 
 
Joint Thesis 
 This thesis formed part of a joint research project and was completed together 
with one fellow trainee clinical psychologist, Lisa Harvey (UCL: Ultra high risk for 
psychosis? Chronic ketamine and cannabis users’ performance in attribution 
assignment and auditory hallucination tasks).  See Appendix 1 for further details of 
contributions made by each trainee. 
 
Ethics 
 The study was approved by the UCL Graduate School Ethics Committee (see 
Appendix 2). 
 
Procedure 
 Prior to taking part, participants were given either a hard or electronic copy of the 
study information sheet (see Appendix 3) outlining details of the testing procedure.  
Participants were invited to an individual testing session and were asked to abstain 
from using drugs and alcohol for 12 hours prior to the start.  At the start of the 
session, they were asked to provide written, informed consent (see Appendix 4).  
They were asked for information on demographics, use of drugs and alcohol over the 
past two days, and their current and past drug use.  They then completed the series of 
assessments given below.  A urine sample was collected to give an objective index 
of recent drug use.  
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Assessments 
 Tests were chosen to assess substance dependence, mood (including aspects of 
depression and anhedonia) and psychotomimetic symptoms.  Computer-based 
cognitive tasks were used to assess motivated behavior and a structured interview 
explored subjective views of individual performance on and perceived aims of these 
tasks.  Assessments were administered in the same order to all participants as 
follows: SDS (one each for cannabis, ketamine, and other frequently used-drugs), 
Spot the Word, EEfRT computer task, BDI, TEPS, O-LIFE, PQ-B, Probabilistic 
Reward Task, and brief interview about tasks following completion of testing.  
(Three other computer-based tasks relevant to the other researcher were included in 
the testing protocol but are not included here.) 
 
Objective Measure of Recent Drug Use 
 Urinalysis was carried out for all participants using DrugCheck® NxStep Onsite 
Urinalysis Test Cups, which indicated presence or absence of 12 drugs: 
amphetamine, barbiturate, buprenorphine, benzodiazepine, cocaine, MDMA/ecstasy, 
methamphetamine, methadone, oxycodone, phencyclidine, and cannabis. 
 
Subjective Rating Scales 
 
Severity of Dependence Scale (Gossop, Griffiths, Powis & Strang, 1992) 
 The Severity of Dependence Scale (SDS) consists of five questions related to 
problems of recent drug dependence and asks respondents if they have experienced 
these at any time in the past year, e.g. ‘During the past year, did you think your use 
of cannabis was out of control?’  Respondents choose from the following answers: 
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‘never/almost never’, ‘sometimes’, ‘often’, or ‘always/nearly always’, scored on a 
four-point scale (0-3; 0 is ‘never/almost never’, 3 is ’always/nearly always’).  A total 
score is based on scores for the five items was derived to assess overall dependence 
per drug.   All participants completed an SDS each for cannabis, ketamine and other 
illicit drugs if used more than once a month over the past year.  The SDS was used 
both as a screening tool in determining eligibility for inclusion in the drug-using 
groups, and was also administered during the testing session. 
 
Spot-the-Word Test: Version B (Baddeley, Emslie & Nimmo-Smith, 1993) 
 This lexical decision test was administered to provide an estimate of premorbid 
verbal intelligence (as it correlates with such estimates, e.g. NART).  This measure 
was used both as a means of matching groups for premorbid intelligence and also for 
comparing scores on cognitive tasks to premorbid intelligence across groups.  It was 
chosen as it is a non-anxiety inducing estimate. 
 The task instructs respondents to tick the item they believe to be the real word 
from each of 60 pairs of words and nonsense words (e.g. ‘wraith – stribble’, 
‘palindrome – lentathic’, ‘drobble – infiltrate’).  The sum of correctly identified 
words constitutes a score denoting pre-morbid IQ, with a maximum score of 60.  
This version of the task produces a measure of IQ that, when tested in a large sample 
of wide ranging age and ability, has produced a correlation of 0.859 with 
performance on the NART, widely regarded as a valid and reliable predictor of 
verbal intelligence (Baddeley et al, 1993). 
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The Beck Depression Inventory (BDI-II: Beck, Steer, & Brown, 1996) 
 This is a 21-item self-report questionnaire assessing the presence and severity of 
depression symptoms as outlined in the Diagnostic and Statistical Manual of Mental 
Disorders Fourth Edition (DSM-IV: APA, 1994).  This measure was used to explore 
the relationship between low mood, drug use and performance on cognitive tasks.  
Previous studies have demonstrated that low mood impacts on cognitive task 
performance, with an association between greater severity of depression and reduced 
performance in the domains of episodic memory, executive function and processing 
speed (McDermott & Ebmeier, 2009).  Thus it was necessary to include a measure of 
depressive symptomatology so as to examine the relationship between mood and 
performance on cognitive tasks across groups in this study.  Also, as the theoretical 
construct of anhedonia, a key component of depressive symptomatology, is central to 
the research aims, it was important to have a subjective measure of mood which 
contains an anhedonia subscale, which the BDI-II does (Pizzagalli et al, 2005; Joiner 
et al, 2003).  
 The BDI-II requires subjects to rate themselves on measures of the following 
dimensions: sadness, pessimism, past failure, loss of pleasure, punishment feelings, 
self-dislike, self-criticalness, suicidal thoughts, crying, agitation, loss of interest, 
indecisiveness,  worthlessness, loss of energy, changes in sleeping, irritability, 
changes in appetite, concentration difficulty, tiredness or fatigue, and loss of interest 
in sex (Beck et al, 1996).  Each item asks participants to choose from 4 options of 
Likert-scale type responses which range from a score of 0 (‘not applicable’) to 3 
(‘severe ‘rating for recent experience of the item in question). 
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 A score for overall severity of depression is calculated by adding together totals 
for all BDI-II items, with 63 as a maximum possible total score.  The BDI-II also 
contains two subscales, comprising ‘Cognitive’ and ‘Somatic’ symptoms, which 
have been found to be valid constructs within the more robust dimension of general 
depression (Steer, Ball, Ranieri & Beck, 1999; Wang & Gorenstien, 2013).  The 
Cognitive subscale consists of eight items (pessimism, past failures, feelings of guilt, 
self-dislike, self-criticalness, suicidal thoughts, and worthlessness) and the Somatic 
subscale 13 items (sadness, loss of pleasure, crying, agitation, loss of interest, 
indecisiveness, loss of energy, changes in sleep pattern, irritability, change in 
appetite, concentration difficulty, tiredness/fatigue, and loss of interest in sex).  
Finally, other research has devised a separate construct of an anhedonic subscore for 
the BDI-II, comprised of four items which specifically tap features of anhedonia 
(loss of pleasure, loss of interest, loss of energy and loss of libido) (Joiner et al, 
2003; Pizzagalli et al, 2005).  Each subscale score results from totaling the relevant 
items. 
 
Short Oxford-Liverpool Inventory of Feelings and Experiences Questionnaire (O-
LIFE) (Mason, Claridge & Jackson, 2005) 
 The O-LIFE is a self-report measure comprised of 43 items, and has been 
developed as a questionnaire measuring ‘psychosis-pronenesss’, or schizotypy, in 
healthy populations.  It was included in this study to index psychotic-like traits 
across groups. 
 The O-LIFE has been used widely in experimental and clinical studies and, at the 
time of its development, its contents were based on the most extensive study of 
schizotypal traits to date, involving factor analysis of 15 psychosis-proneness scales 
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in over 1000 subjects (Claridge, McCreery, Mason et al, 1996).  This measure adopts 
a dimensional view of schizotypal characteristics and breaks down the construct of 
schizotypy into four factors: (i) unusual experiences, (ii) cognitive disorganisation, 
(iii) introvertive anhedonia, and (iv) impulsive nonconformity (Claridge et al, 1996).  
The O-LIFE has high internal consistency (Mason et al, 1995), high test-retest 
reliability (Burch, Steel & Hemsley, 1998), and high construct validity, having been 
used in studies across a wide range of research domains (Mason et al, 2006). 
 
Sample items of questions included in the O-LIFE include: 
(12)  Do you ever feel that your speech is difficult to understand because the 
words are all mixed up and don’t make sense? 
(23)  Can some people make you aware of them just by thinking about you? 
 
 Participants are asked to tick ‘yes’ or ‘no’ for each item.  1 point is given to yes 
responses and 0 to no responses for most items, with the exception of several items 
in which scores are reversed (items 4, 9, 17, 27, 30, 37, 39, 31).  A total O-LIFE 
score is obtained by summing all items, and scores for each of the four subscales is 
obtained by summing scores for relevant items as follows: 
1. Unusual Experiences – items relate to ‘positive’ psychotic-like 
symptomatology, propensity for unusual perceptual experiences (e.g. 
hallucinations), ‘magical thinking’ or beliefs and interpretations (e.g. 
delusions); includes 12 items (2, 5, 6, 8, 10, 13, 19, 23, 26, 29, 34, 35) 
2. Cognitive Disorganisation – items relate for tendency for thoughts to be 
disordered or tangential, attention difficulties, etc.; includes 11 items (1, 7, 
12, 16, 20, 24, 31, 33, 36, 38, 42). 
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3. Introvertive Anhedonia – items relate to negative psychotic-like 
symptomatology, or a tendency to introversion, anhedonia and asocial 
behavior; includes 10 items (4, 11, 15, 17, 22, 25, 27, 30, 32, 41) 
4. Impulsive Nonconformity – items relate to tendency toward unstable mood 
and behavior (e.g. risk-taking or impulsive behavior that disregards social 
convention); includes 10 items (2, 9, 14, 18, 21, 28, 37, 39, 40, 43) 
 
 The first three subscales are in line with the three factor model of psychoses 
theorised by Liddle (1987) and consensus suggests that schizotypy reliably relates to 
these three components (both positive and negative psychosis symptomatology and 
cognitive disorganisation) (Mason & Claridge, 2006; Vollema & Hoijtinkm, 2000).  
The fourth subscale relating to ‘impulsive nonconformity’ reflects clinical evidence 
of the need for a boarder concept of psychosis-proneness (e.g. the identification of 
common features between schizophrenia and bipolar disorder, which give weight to 
the theoretical view of psychosis as a unitary illness) (Mason & Claridge, 2006). 
 
Temporal Experience of Pleasure Scale (TEPS; Gard, Gard, Kring & John, 2006) 
 The TEPS is a self-report scale designed to assess individual trait characteristics 
relating to two distinct aspects of the experience of pleasure (Gard et al, 2006).  
Based on neuroscience, social psychology and clinical psychology studies which 
give weight to conceptualising these aspects of pleasure as distinct processes, its 
authors developed the TEPS with two subscales distinguishing between anticipatory 
pleasure, which relates to pleasure experienced in anticipation of future pleasurable 
activities, and consummatory pleasure, which is pleasure experienced in the moment, 
upon reward attainment (Gard et al, 2006; Gard, Kring, Gard, Horan and Green, 
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2007).  The authors hypothesise that anticipatory pleasure (the experience of 
wanting) activates motivational processes, which pushe the individual to go after a 
particular stimulus that will induce in-the-moment consummatory pleasure (Gard et 
al, 2006).  The TEPS focuses on these two aspects of physical pleasure (as this type 
of hedonic experience is common across humans) and consists of 18 statements 
which participants are asked to rate in terms of how true or false the statements are 
for them.  Sample items for each subscale include: 
Anticipatory pleasure subscale: 
(1) When something exciting is coming up in my life, I really look 
forward to it. 
(2) When I think about eating my favorite food, I can almost taste how 
good it is. 
Consummatory pleasure subscale: 
(6) I enjoy taking a deep breath of fresh air when I walk outside. 
(15) Looking forward to a pleasurable experience is in itself pleasurable. 
 
 Items are scored on a scale from one to six, where one is ‘very false for me’ and 
six is ‘very true for me’.  The ‘anticipatory pleasure’ subscale consists of 10 items 
(items 1, 3, 7, 11, 12, 14, 15, 16, 17, 18 – item 7 is reverse-scored) and the 
‘consummatory pleasure’ subscale is 8 items (items 2, 4, 5, 6, 8, 9, 10, 13) (Gard et 
al, 2006).  An overall score is obtained from summing all items, while subscale 
scores are obtained by totalling relevant items. 
 The TEPS is brief and has been found to be reliable, temporally stable and valid, 
as exploratory factor analysis in four independent samples of US students supports 
the theoretical differentiation of these two constructs of pleasure, though 
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confirmatory factor analysis has produced mixed results in terms of the measure’s 
construct validity (Gard et al, 2006; Ho, Cooper, Hall, Smillie, 2014). 
 
Prodromal Questionnaire – Brief (PQ-B; Loewy, Pearson, Vinogradov, Bearden & 
Cannon, 2011) 
 The PQ-B is a brief self-report screening measure for psychosis risk syndromes, 
developed in response to the need for more efficient and accurate methods of 
identifying psychosis risk in young people (Loewy et al, 2011; Loewy, Bearden, 
Johnson, Raine & Cannon, 2005).  Evidence supports its effectiveness as a first-level 
screening instrument to identify at-risk individuals who would then undergo further 
clinical assessment (e.g. the CAARMS) to establish diagnosis (Loewy et al, 2011; 
Sandberg, Richards & Erford, 2013).  It has been shown to be effective in 
differentiating between those with a prodromal or psychosis diagnosis and non-
psychotic spectrum patients, as diagnosed by the SIPS (Structured Interview for 
Prodromal Syndromes), and has been recommended for use in screening help-
seeking individuals for psychotic disorders (Loewy et al, 2011; Miller et al, 2003; 
Sandberg et al, 2013). 
 The PQ-B consists of 21 items pertaining to positive psychosis symptoms for 
which participants are asked to answer yes or no (scored 1 for ‘yes’ and 0 for ‘no’).  
Totaling the items for these main questions results in a PQ-B total score.  For items 
marked ‘yes’, participants are asked to indicate their agreement with the statement, 
“When this happens, I feel frightened, concerned, or it causes problems for me,” on a 
5 point Likert-style rating scale which ranges from ‘strongly disagree’ (scored as 1) 
to ‘strongly agree’ (scored as 5) (Loewy et al, 2011).  A total PQ-B ‘distress score’ is 
obtained by adding together values for these secondary questions. 
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Cognitive Tasks 
 The cognitive assessments used were chosen to objectively examine hedonoic 
capacity, which was operationalised as reward sensitivity and responsiveness in each 
task. 
 
1. Probabilistic Reward Task (Pizzagalli, Jahn & O’Shea, 2005; Pizzagalli, 
Iosifescu, Hallett, Ratner and Fava, 2009; Tripp & Alsop, 1999) 
 The probabilistic reward task, or PRT, was developed by Pizzagalli et al (2005) 
and is rooted in signal detection theory.   The PRT objectively assesses participants’ 
tendency to respond to reinforcements by modulating their behaviour.  Specifically, 
reward responsiveness is operationalised in this task by the degree of response bias 
participants display towards the more frequently reinforced of two different stimuli.  
Importantly, in signal-detection tasks such as the PRT, unequal frequency of reward 
between two types of correct responses to stimuli typically engenders a systematic 
preference for the response paired with the more frequent or greater reward 
(Macmillan and Creelman, 1991; McCarthy, 1991; Pizzagalli et al, 2005).  Initial 
studies using the PRT hypothesised that reduced responsiveness to reinforced stimuli 
would serve as a behavioural expression of diminished hedonic capacity (Pizzagalli 
et al, 2005; Pizzagalli et al, 2009). 
 The PRT lasts approximately 20 minutes and was presented to participants on a 
15.6 inch PC laptop monitor using Matlab 7.13 (R2011b).    In each trial, participants 
focused on a fixation cross which appeared for 500ms, followed by a mouthless 
cartoon face for 500ms.  Next, the stimulus appeared in the form of a straight line 
mouth on the previously mouthless face, which was shown for 97ms.  After the 
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mouth disappeared, the mouthless face remained on the screen for 1500ms or until 
the participant made a response.  Participants were instructed to make a choice as to 
whether the mouth displayed was short (8.2 mm) or long (9.1 mm) by pressing the 
appropriate button to indicate their choice – ‘v’ for a short mouth and ‘m’ for a long 
mouth. 
 The task was virtually identical to those used in prior studies that employed this 
paradigm (Pizzagalli et al, 2005; Pizzagalli et al, 2009; Tripp and Alsop, 1999), with 
several minor exceptions.  The PC screen size was slightly smaller (1.4 cm smaller 
than the 17 inch screen used in Pizzagalli et al, 2009) and thus stimuli were 
proportionally reduced in size compared to the previously cited studies.  Also, the 
task included two blocks comprised of 100 trials each rather than three blocks of 
trials as in previous studies, in an attempt to minimise cognitive fatigue, as the 
overall testing protocol was approximately two hours in duration. 
 As outlined in previous studies using this task, the duration of stimulus exposure 
and mouth sizes were selected after piloting so as to achieve overall hit rates of 75-
85%.  Differences between mouth sizes and length of stimulus exposure were small 
so as to provide a model environment for the development of response bias without 
unduly encouraging performance at chance level (Pizzagalli et al, 2009). 
 An asymmetric reinforcement ratio was used to generate a response bias using 
two versions of the task (McCarthy & Davison, 1979; Tripp & Alsop, 1999, as in 
Pizzagalli et al, 2009).  In Version A, correct identification of the short mouth was 
rewarded three times more frequently than correct identification of the long mouth; 
thus, in this version, the short mouth was considered the ‘rich stimulus’ and the long 
mouth was the ‘lean stimulus’.  The reward was indicated by a message appearing on 
the screen after participants pressed the button for the correct mouth, saying, 
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“Correct!! You won 5 pence.”  Version B was reversed, so that the long mouth was 
the ‘rich stimulus’ and was reinforced three times more frequently than the ‘lean 
stimulus’ (the short mouth).  Task versions, and therefore reinforcement allocation, 
were counterbalanced across participants. 
 
 
Figure 1.  Schematic illustration of PRT design.  Each trial asked participants to 
decide whether the mouth shown was short (8.2 mm) or long (9.1 mm) by pressing 
‘v’ (short) or ‘m’ (long).  The reinforcement allocation was counterbalanced across 
subjects. 
 
 At the start of the task, participants were instructed to win as much money as 
possible by correctly identifying the mouth in each trial.  They were informed that 
sometimes correct responses would be rewarded (“Correct!! You won 5 pence”), but 
that not all correct responses would be rewarded.  Non-rewarded responses, which 
included both correct and incorrect responses, were followed by the message, “You 
did not win anything.”  As in previous studies, a controlled reinforcer procedure was 
implemented, so that all participants would be rewarded for only 40 correct trials, 30 
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‘rich’ and 10 ‘lean’ (Johnstone & Alsop, 2000; McCarthy & Davison, 1979).  This 
ensured that the reinforcement ratio remained constant irrespective of participants’ 
performance.  Effectively, if participants responded incorrectly on a trial that was 
scheduled to be rewarded, the reward feedback would be delayed until the correct 
identification of the same stimulus type (‘rich’ or ‘lean’) in a later trial.  Feedback 
(whether reward or non-reward) appeared on the screen for 1500ms immediately 
following a correct response and was followed by a blank screen for 2000ms.  
Importantly, participants were not told that one stimuli would be disproportionately 
rewarded. 
 
2. ‘Effort-Expenditure for Rewards Task’ (EEfRT) (Treadway, Buckholtz, 
Schwatzman, Lambert and Zald, 2009) 
 The Effort-Expenditure for Rewards Task (EEfRT) is an objective measure of 
effort-based decision-making that aims to examine the link between anhedonia and 
theorised reward ‘wanting’ (or anticipatory pleasure) in human participants 
(Treadway et al, 2009).  It adapts a concurrent choice paradigm exploring effort-
based decision-making in rodents (Salamone, Cousins, McCullough, Carriero & 
Berkowitz, 1994) in which participants are presented with a series of trials in which 
they are asked to choose between completing a ‘hard’ or ‘easy’ task, with the aim of 
earning changing amounts of money, with each trial differing in terms of probability 
that it will be rewarded (Treadway et al, 2009).  The task therefore allows for an 
analysis of how reward magnitude, probability of being rewarded and expected 
reward (reward magnitude x probability) influence effort-based decision-making and 
anhedonia (Treadway et al, 2009).  Performance on the EEfRT has been correlated 
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with trait anhedonia (as assessed by the Chapman Anhedonia scale), demonstrating 
construct validity (Treadway et al, 2009). 
 A modified version of the original EEfRT (Treadway et al, 2009) was used in this 
study; the main modification is that it was shortened and all participants completed 2 
practice trials and 21 actual trials in total.  Unlike Treadway et al’s (2009) study, our 
task ended after 21 trials, rather than after an allotted period of time.  This was done 
to shorten the overall testing protocol and simplify the task. 
 Each trial within the task began with a fixation cross appearing on the screen for 
1000ms, followed by the presentation of details on the trail, including probability of 
winning and monetary values rewarded for easy versus hard task choice.  
Participants were informed that they had 5 seconds to choose either the ‘easy’ or 
‘hard’ task, otherwise the program would make a random choice.  This was followed 
by a 1000ms ‘Ready?’ screen, and then the actual button-press task.  Participants 
were required to make repeated and fast manual button presses within the allotted 
time, by pressing the spacebar quickly with the little finger on their non-dominant 
hand.  Each button press increased the level of a bar on the screen and participants 
were informed that raising the bar to the ‘top’ would result in successful completion 
of the trial.  Hard-task trials required participants to make 100 button presses within 
21 seconds, while easy-task trials required 30 button presses within 7 seconds.  A 
2000ms feedback screen following completion of each trial informed participants 
whether they successfully completed the trial or not.  If completed successfully, 
another feedback screen appeared for 2000ms with reward feedback (i.e. whether 
they had won money for that trial).  (Treadway et al, 2009). 
88 
 
 
 
 
 
Figure 2.  Schematic diagram of a single trial of the ‘EEfRT’  A) Participants 
begin by seeing a 1000ms fixation cue.  B) 5000ms choice period in which 
participants are presented with information regarding the reward magnitude of the 
hard task for that trial and the probability of receiving any reward for that trial.  C) 
1000ms ‘ready’ screen.  D) Participants make rapid button presses to complete the 
chosen task for 7000ms (easy task) or 21000ms (hard task).  A bar fills up with each 
button press until task is finished and bar is full.  E). Participants are told whether 
they completed the task.  F) Participants receive reward feedback as to whether they 
received any money for that trial.  
 
 For easy-task trials, participants could win 50 pence if the trial was rewarded.  
Hard-task trials varied in potential win amounts; participants could win one of five 
amounts ranging between 70 and 200 pence.  As only some completed trials were 
considered ‘win’ trials, participants were given probability cues at the start of each 
trial, with each trial being one of three probability levels: ‘high’ (88% probability of 
being a win trial), ‘medium’ (50% probability of win) and ‘low’ (12% probability of 
win).  Probability levels applied to both hard and easy-task choice in each trial, and 
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each level was equally distributed across the task.  Also, each probability level 
appeared once together with each level of monetary reward value for the hard task.  
The order of trials was randomised and participants were presented trials in the same 
(randomised) order (Treadway et al, 2009). 
 Before the start of the EEfRT, participants were informed that they would receive 
winnings for only two successfully completed and rewarded trials, which would be 
selected at random upon completion of the task.  Participants were not given any 
further information about the distribution of hard vs. easy tasks.  The variation in 
probability and reward values meant that participants had to make decisions within a 
brief amount of time, without the ability to calculate optimal response selection.  The 
task was designed in this way so as to generate individual patterns of responses in 
participants’ willingness to expend effort for differing expected rewards (Treadway 
et al, 2009). 
 
Data Preparation for Cognitive Assessments 
1. PRT 
 Performance on the task was measured in terms of response bias, discriminability, 
reaction time (RT), and accuracy, based on previous studies (Pizzagalli et al, 2005, 
Pizzagalli et al, 2009, Bogdan & Pizzagalli, 2006).  Response bias, the main 
outcome variable, reflects the participant’s propensity to select the response paired 
with the more frequent reward, and thus the extent to which participants modulate 
their behavior by reinforcement history (Pizzagalli et al, 2009; Pizzagalli et al, 
2005).  Response bias was calculated as follows: 
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Response Bias:  log b = 
1
2
 log (
𝑅𝑖𝑐ℎ 𝑐𝑜𝑟𝑟𝑒𝑐𝑡 X 𝐿𝑒𝑎𝑛 𝑖𝑛𝑐𝑜𝑟𝑟𝑒𝑐𝑡
𝑅𝑖𝑐ℎ 𝑖𝑛𝑐𝑜𝑟𝑟𝑒𝑐𝑡 𝑋 𝐿𝑒𝑎𝑛 𝑐𝑜𝑟𝑟𝑒𝑐𝑡
) 
 
 High rates of correct response for the ‘rich’ stimulus (hits) and high miss rates for 
the ‘lean’ stimulus result in a high response bias. 
 Discriminability indexes participants’ ability to differentiate between the two 
stimuli and is therefore used as a measure of task difficulty.  It was computed as 
follows: 
 
Discriminability:  log d = 
1
2
 log (
𝑅𝑖𝑐ℎ 𝑐𝑜𝑟𝑟𝑒𝑐𝑡 𝑋 𝐿𝑒𝑎𝑛 𝑐𝑜𝑟𝑟𝑒𝑐𝑡
𝑅𝑖𝑐ℎ 𝑖𝑛𝑐𝑜𝑟𝑟𝑒𝑐𝑡 𝑋 𝐿𝑒𝑎𝑛 𝑖𝑛𝑐𝑜𝑟𝑟𝑒𝑐𝑡
) 
 
 Other analyses were carried out on hit rate scores (percent correct responses) and 
RT to explore general task performance. 
 
2. EEfRT Task 
 Data from the EEfRT was exported from Matlab into SPSS (version 22) for 
further analysis.  Mean proportions of hard task choices were created for all subjects 
across each level of probability (12%, 50% and 88%), as in Treadway et al’s (2009) 
study. 
 
Statistical Analyses 
 Statistical Package for Social Sciences (SPSS Version 22) was used to perform all 
analyses.  Group differences were analysed using one-way ANOVAs and, where 
data were non-parametric, Welch’s t-test.  Where an effect of group was found, 
simple effects were explored using Bonferroni post hoc comparisons.  Independent 
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samples t-tests were used to compare groups on drug use variables.  Mann-Whitney 
U tests were used where data were non-parametric.  Chi-squared tests were used to 
analyse categorical (e.g. dichotomous) data. 
 The PRT data were analysed using a number of 2 x 3 repeated measures analyses 
of variance (RMANOVA) with block (Block 1 and Block 2) as the within-subjects 
factor and group (control, cannabis, ketamine) as the between-subjects factor.  Post 
hoc comparisons were Bonferroni corrected. 
 Data for the EEfRT were analysed using the same two methods as specified by 
Treadway et al (2009).  The first method used repeated measures ANOVA with 
group as the between subjects factor and probability level (12%, 50% or 88%) as the 
within subjects factor. 
 EEfRT data was also analysed using generalized estimating equations (GEE), 
which allows for trial-by-trial modelling of time-varying parameters (in this case, 
changes in reward value of the hard choice task) and fixed effects (e.g. gender, 
group, anhedonia subscale scores, etc.) (see Treadway et al, 2009).  GEE models 
were exploratory and were carried out using SPSS 22 using an unstructured 
correlation matrix, with the dependent variable as hard or easy task choice.  A binary 
logistic distribution was used to model the probability of participants choosing the 
hard task.  For all models, independent variables included probability, reward value, 
expected reward value, trial number, BDI-II total score, cigarettes smoked per day, 
and baseline button-pressing speed.  Six models were tested in total.  Each model 
included group and gender as factors.  Covariates were probability level, hard-task 
reward value, expected value (probability x reward value), and baseline button 
pressing speed.  Depression (BDI-II total scores) and cigarettes smoked per day were 
included as covariates as these were found to differ between groups. 
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 Correlations were performed using Pearson correlations.  Correlations were 
applied to three categories of data – drug use data, subjective ratings and task results 
(for PRT and EEfRT) and were conducted when significant group differences were 
found.   The alpha-level was raised to p = 0.01 for all correlations to reduce Type I 
errors. 
 
RESULTS 
 
1. Demographics and Reported Drug Use (Tables 1-5) 
 There were 60 participants in total: 20 ketamine users (12 females), 21 cannabis 
users (7 females), and 20 controls (6 females).  The ethnicities of participants in the 
ketamine, cannabis and control groups were respectively:  Black/British (0/5/0), 
Indian (0/1/0), White British (17/9/13), White Other (4/3/3), Other – mixed race 
(0/2/3).  There were no statistically significant differences between groups with 
respect to ethnicity (χ2(10, N = 60) = 17.462, p = 0.065), nor were there group 
differences in gender (χ2(2, N = 60) = 4.251, p = 0.119).  There were no significant 
group differences in age or Spot-the-Word scores. 
 The highest level of educational attainment by ketamine, cannabis and control 
participants respectively were: GCSEs (4/5/2), College Diploma/NVQ/BTEC Levels 
2-3 (8/3/2), A-Levels (5/1/5), Undergraduate degree (2/10/9), Post-graduate degree 
(1/1/2).  There were no statistically significant group differences in highest 
educational attainment (χ2(8, N = 60) = 14.880, p = 0.062).  There were no 
significant group differences in employment status (χ2(4, N = 60) = 4.391, p = 
0.356); the current employment status for ketamine, cannabis and control 
participants respectively was: Unemployed (3/3/5), employed (17/15/12), student 
(0/2/3). 
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 There were significant group differences in BDI total scores (F(2, 56) = 5.623, p 
= 0.006), reflecting significantly lower scores in controls compared to both ketamine 
(p = 0.018) and cannabis users (p = 0.013) (Table 1).  There were also group 
differences in BDI Cognitive-Affective subscale scores (F (2, 56) = 5.805, p = 
0.005), with ketamine users differing significantly from controls (p = 0.004).  Group 
differences in BDI Somatic subscale scores (F (2, 56) = 4.540, p = 0.015) emerged 
with cannabis users differing significantly from controls (p = 0.018).  There were 
significant group differences on the BDI anhedonia sub-scale, which is comprised of 
4 items from the BDI, including ‘loss of pleasure’ (item 4), ‘loss of interest’ (item 
12), ‘loss of energy’ (item 15), and ‘loss of interest in sex’ (item 21): F (2, 56) = 
3.992, p = 0.024.  The cannabis group had higher scores on anhedonia than controls 
(p = 0.031).  
 While only one control participant had clinically significant depression levels 
(BDI depression category ‘moderate’ or ‘severe’), the cannabis and ketamine groups 
had 7 and 8 participants respectively with clinically significant depression (BDI 
depression category: ‘mild’ – 5 cannabis / 6 ketamine; ‘moderate’ – 1 cannabis / 2 
ketamine, ‘severe’ – 1 cannabis / 1 ketamine).  There was a statistically significant 
association between group and clinical depression,   χ(2) = 6.9, p = 0.032, with the 
drug using groups more likely to meet the BDI cut-off for clinical depression. 
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Table 1.  Group means (sd) for demographics (One-Way ANOVAs, Bonferroni 
corrected). 
 Controls Cannabis Users Ketamine Users 
Age (years) 27.25 (6.80) 27.75 (7.31) 26.85 (3.25) 
Spot the word score 
(no. correct) 
48.30 (3.36) 45.35 (3.84) 47.25 (5.20) 
BDI Total (n=59) 
BDI Cognitive-
Affective 
BDI Somatic 
BDI Anhedonia 
5.32 (5.56) 
1.74 (1.69) 
 
3.58 (4.32) 
1.21 (1.40) 
12.20 (9.00)a 
3.95 (3.59) 
 
8.25 (6.09)a 
2.65 (2.03)a 
12.45 (7.47)b 
5.15 (3.73)b 
 
7.30 (4.66) 
2.40 (1.57) 
a = Can > Con, b =Ket > Con,   (Bonferroni corrected p values)  
 
 As expected based on inclusion criteria, there were significant differences 
between groups in terms of days per month of current cannabis use (Welch’s F(2, 
30.427) =  252.76, p < 0.001) and mean amount of cannabis used in a typical session 
(Welch’s F(2,31.487) = 37.564, p < 0.001).  The cannabis group used cannabis more 
frequently (p < 0.001 compared to controls; p = 0.002 compared to ketamine users) 
and used more cannabis in a typical session than the other groups (both p < 0.001).  
There were also differences between groups on the Severity of Dependence Scale for 
cannabis (F(2, 26.536) = 44.313, p < 0.001), with cannabis participants rating 
themselves as significantly more concerned than both controls and ketamine users 
about their cannabis use (both p < 0.001) (see Table 2).  The numbers of participants 
in the control, cannabis and ketamine groups who reported using cannabis at least 
once per month at the time of testing was 8, 20, and 13 respectively. 
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Table 2.  Mean (sd) use of cannabis across groups (n = 20 per group). 
  Controls Cannabis Users Ketamine Users p (group) 
Number of 
days used in 
typical month 
 
1.62 (2.23) 28.19 (4.74)***a, c 10.10 (11.75)**b p < 0.001 
Amount used 
in a typical 
session (mg) 
 
63.75 (147.48) 1175.00 (553.34) ***c 223.75 (292.56) p < 0.001 
Severity of 
cannabis 
dependence 
score 
0.10 (0.44) 7.30 (3.39)***c 1.05 (2.50) p < 0.001 
Difference significant at p <0.05*, p < 0.01 ** p < 0.001*** 
a = Can > Con, b =Ket > Con, c= Can>Ket   (Bonferroni corrected p values)  
 
 Similarly, there were group differences in ketamine use, again as expected.  The 
mean (sd) days of current ketamine use per month for the control, cannabis, and 
ketamine groups were 0.02 (0.06), 0.00 (0.00) and 2.98 (6.60) respectively.  A 
Mann-Whitney U test confirmed a significant difference between controls and the 
ketamine group in days per month of ketamine use (U = 367.00, p < 0.001) and also 
amount of ketamine (mg) currently used in a typical session (U = 365.00, p < 0.001)  
 Groups differed significantly in ketamine SDS scores (F (2, 57) = 266.391, p < 
0.001) with ketamine users scoring significantly higher than controls (ketamine 
mean = 9.55 (2.56); controls mean = 0.10 (0.45).  Also, despite less frequent current 
use in ketamine users compared with their previous (pre-draught) heavy use, 
ketamine users rated themselves as more concerned than the other groups about their 
96 
 
 
 
 
ketamine use on the Severity of Dependence Scale, and their high mean rating is 
indicative of a higher level of self-reported dependence (Table 3). 
 The ketamine group used ketamine much more heavily in the past compared to 
currently, due mainly to widespread availability of the drug prior to the ‘ketamine 
drought’ at the time of data collection (Table 3).   
 
Table 3.  Mean (sd) and median use of ketamine in ketamine group (n = 20), 
comparing past heavy use with current reported use. 
 
 Current reported use Past reported use 
Number of years of heavier use n/a (n = 17)* 
5.647 (2.29) 
Number of days used in typical 
month 
2.98 (6.60) 29.29 (2.20) 
Amount currently used in 
typical session (mg) 
 
1355 (1055.42) 6075 (4104.48) 
Median amount used in typical 
session (mg) 
 
1250 4750 
Mean severity of ketamine 
dependence score 
9.55 (2.56) N/A 
* data missing for 3 participants 
 
 Current use of ketamine in the past month in the ketamine group was therefore 
relatively low across participants (Figure 3). 
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Figure 3. Histogram depicting days of ketamine use in past month in ketamine 
group (n = 20). 
 
  
 
 Groups did not differ significantly in their current use of most other drugs, with 
the exception of tobacco (Welch’s F (2, 34.893) = 18.085, p < 0.001) and 
amphetamine (Welch’s F (2, 25.495) = 4.912, p = 0.016).  The cannabis group used 
tobacco significantly more days per month than the control group (p < 0.001); the 
ketamine group used amphetamine significantly more than both the control group (p 
< 0.001) and the cannabis group (p < 0.01) (See Table 4). 
  
98 
 
 
 
 
Table 4.  Use of other drugs across groups (n = 20 per group). 
 % regular drug use 
(current use ≥ 1 day per month) 
Mean (sd) no. of days used per month 
 Controls Cannabis Ketamine Controls Cannabis Ketamine 
Alcohol 100% 90% 95% 14.11 (7.49) 10.99 (8.61) 11.60 (8.59) 
Tobacco 45% 95% 75% 8.71 (12.59) 27.80*** (7.25)a 20.05 (13.32) 
MDMA 35% 30% 35% 0.58 (0.82) 0.38 (0.67) 0.58 (1.04) 
Amphetamine 0% 5% 40% 0 1.00 (0.00) 4.22 (2.73)**bc 
LSD/Hallucin. 10% 5% 10% 0.5 (0.7) 1.00 (0.00) 2.00 (0.00) 
Cocaine 45% 20% 55% 1.14 (1.08) 1.50 (1.85) 1.81 (1.95) 
Benzodiazepine 5% 15% 50% 0.27 (0.64) 1.21 (1.63) 3.03 (5.26) 
Difference significant at p <0.05*, p < 0.01 ** p < 0.001*** 
a = Can > Con, b =Ket > Con, c = Ket > Can   (Bonferroni corrected p values)  
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 Urinalysis results for all 60 participants across the 3 groups are given in Table 5. 
 
Table 5.  Urine screening results – % of urine sample analyses detecting each drug 
(n = 20 per group). 
 
 Control Cannabis Ketamine 
Missing data 15% 0% 10% 
No drug 55% 5% 5% 
THC 15% 95% 40% 
PCP/Ketamine 5% 0% 5% 
MDMA 0% 0% 0% 
Amphetamines 0% 0% 10% 
Benzodiazepines 5% 0% 65% 
Cocaine 5% 10% 15% 
LSD 0% 0% 0% 
Buprenorphine 10% 0% 15% 
Opioids 5% 10% 10% 
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2. Subjective Ratings – TEPS, O-LIFE, PQ-B 
 
Table 6.  Mean (sd) scores on O-LIFE total and subscale scores in the control, 
cannabis and ketamine groups (n = 20 per group). 
 Controls Cannabis Ketamine 
O-LIFE Total 
Score 
11.85 (1.49) 19.50 (7.25)**a 20.25 (6.61)**b 
Unusual 
Experiences 
2.10 (1.55) 6.10 (3.71)***a 5.15 (2.70)**b 
Cognitive 
Disorganisation 
5.45 (3.97) 6.40 (2.64) 7.45 (2.95) 
Introvertive 
Anhedonia 
1.35 (1.23) 2.40 (2.01) 1.90 (1.62) 
Impulsive 
Nonconformity 
2.95 (1.73) 4.60 (2.04)*a 5.70 (1.78)***b 
Difference significant at p <0.05*, p < 0.01 ** p < 0.001*** 
a = Can > Con, b =Ket > Con, (Bonferroni corrected p values)  
 
 There was a main effect of group for O-LIFE total score, F (2, 57) = 9.221, p < 
0.001, reflecting higher O-LIFE total scores in both cannabis (p = 0.002) and 
ketamine (p = 0.001) users compared to controls; there were no significant 
differences between cannabis and ketamine users.  There were main effects of group 
on two of the four O-LIFE subscales: Unusual Experiences (F (2, 57) = 16.014, p < 
0.001) and Impulsive Nonconformity (F (2, 57) = 11.146, p < 0.001).  Bonferroni 
corrected post hoc tests on these subscales revealed higher scores for both the 
cannabis and ketamine users compared with controls (Unusual Experiences: p < 
0.001 & p  = 0.003 respectively; Impulsive Nonconformity: p = 0.020 & p < 0.001 
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respectively).  The cannabis and ketamine groups did not differ significantly from 
each other on these subscales. 
 
Table 7.  Mean (sd) scores on TEPS total and subscale scores in control, cannabis 
and ketamine groups (n = 20 per group). 
 Controls Cannabis Users Ketamine Users 
TEPS Total score 86.10 (11.74) 81.90 (12.64) 81.95 (13.61) 
Anticipatory 
pleasure 
46.45 (6.69) 46.10 (7.45) 43.75 (7.57) 
Consummatory 
pleasure 
39.25 (6.21) 35.80 (6.74) 40.15 (4.90) 
Difference significant at p <0.05*, p < 0.01 ** p < 0.001*** 
 
 There were no significant differences between groups on TEPS total scores or the 
‘Anticipatory Pleasure’ subscale.  However, there was a trend toward significant 
group differences on the ‘Consummatory Pleasure’ TEPS subscale (F (2, 57) = 
2.927, p = 0.062), driven by a trend difference between the cannabis and ketamine 
groups (ketamine scoring higher than the cannabis group: p = 0.077). 
 
Table 8.  Mean (sd) scores on PQ-B total and distress scores in control, cannabis 
and ketamine groups (n = 20 per group; n = 19 for distress score in ketamine 
group only). 
 Controls Cannabis Users Ketamine Users 
PQ-B Total score 3.30 (3.48) 9.15 (4.66)***a 8.55 (3.87)***b 
Distress score 9.10 (11.43) 28.16 (19.83)*a 25.25 (12.25)*b 
Difference significant at p <0.05*, p < 0.01 ** p < 0.001*** 
a = Can > Con, b =Ket > Con,   (Bonferroni corrected p values)  
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 There were significant differences between groups on PQ-B Total scores (F(2, 57) 
= 12.728, p < 0.001) and on PQ-B Distress scores (Welch’s F(2, 35.451) = 11.813, p 
< 0.001).  Both the cannabis and ketamine groups scored higher than controls on PQ-
B total score (both p < 0.001), and both drug groups scored higher on distress than 
controls (both p < 0.05).  There were no differences between the cannabis and 
ketamine groups. 
 
3.  Cognitive Assessments 
 
I. PRT (Probabilistic Reward Task) 
i. Response bias 
 Data for one participant was removed from analysis of response bias, as the bias 
score was more than 3 standard deviations above the mean.  Figure 3 shows response 
bias data across task blocks.  There was a trend towards an interaction of group x 
block (F (2, 56) = 3.015, p = 0.057).  For Block 1, there were no significant group 
differences.  Controls differed significantly from the cannabis group in Block 2: 
t(39)=2.8, p = 0.022 (control vs. cannabis).  There was only a trend level difference 
between controls and ketamine users in Block 2:  t(38)= 2.23, p = 0.090 and no 
difference between the cannabis and ketamine groups, t(38)= 0.52, p = 1.00.  Within-
group Bonferroni post hoc comparisons revealed that only the control group differed 
significantly in response bias between blocks (p < 0.001), reflecting an increase in 
response bias from Block 1 to Block 2. 
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 There was a significant main effect of block on response bias, F (2, 56) = 9.480, p 
= 0.003, with response bias being significantly higher in block 2 than block 1 across 
all groups (which is in keeping with findings from previous studies that response 
bias generally increases across blocks; Bogdan et al, 2006; Pizzagalli et al, 2009). 
 There was a trend towards a main effect of group (F (2, 56) = 2.998, p = 0.058), 
reflecting a tendency for the cannabis group to have lower scores than controls (p  = 
0.059) when Bonferroni corrected. 
 
 
 
Figure 4. PRT response bias for the more frequently rewarded (‘rich’) and the less 
frequently rewarded (‘lean’) stimulus for control (n = 20), cannabis (n = 20) and 
ketamine participants (n = 19) 
 
ii. Discriminability 
 Figure 4 shows data for discriminability (d’) across task blocks.  There was a 
trend for a group x block interaction, F (2, 57) = 2.740, p = 0.073.  There was a 
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significant main effect of group, F (2, 57) = 4.942, p = 0.010, with mean d’ 
significantly lower in the ketamine group than in the control group (t(39) = 3.126 p = 
0.008).  There were no differences between cannabis versus control or cannabis 
versus ketamine group.  There was no significant main effect of block on d’, F (2, 
57) = 1.802, p = 0.185.  
 
 
Figure 5.  PRT discriminability (d’) for the ‘rich’ and ‘lean’ stimulus for control (n 
= 20), cannabis (n = 20) and ketamine participants (n = 20). 
 
iii. Reaction Time 
  There was a significant main effect of group, F (2, 57) = 3.185, p = 0.049, with 
mean reaction times fastest in the ketamine group.  However, Bonferroni post-hoc 
comparisons revealed no significant differences between groups. 
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 There was a significant block x stimulus interaction, F(2, 57) = 8.301, p = 0.006, 
with reaction times to the rich stimulus being faster than to the lean stimulus in 
Block 2 ( t(59) = 4, p < 0.001), but not in Block 1 (see Table 9). 
 There was a significant main effect of stimulus, F (2, 57) = 10.730, p = 0.002; 
reaction times to the rich stimulus were faster than to the lean stimulus over the 
entire task. 
 
Table 9.  Mean (sd) PRT reaction times (seconds) per block and stimulus in control, 
cannabis and ketamine groups (n =20 per group). 
 
 Controls Cannabis Ketamine Total 
Block 1, Rich 0.369 (0.125) 0.403 (0.163) 0.307 (0.091) 0.360 (0.133) 
Block 1, Lean 0.381 (0.133) 0.400 (0.156) 0.306 (0.093) 0.362 (0.134) 
Block 2, Rich 0.393 (0.137) 0.385 (0.154) 0.294 (0.107) 0.358 (0.139)*** 
Block 2, Lean 0.408 (0.138) 0.412 (0.168) 0.313 (0.149) 0.377 (0.149) 
Total 0.388 (0.029) 0.400 (0.029) 0.305 (0.029) 0.364 (0.017) 
Difference significant at p <0.05*, p < 0.01 ** p < 0.001*** 
 
 
iv. Hit Rates/Accuracy (percentage of correct responses) for each stimulus (rich or 
lean) type 
 With respect to accuracy (proportion of correct responses, i.e. ‘hit rates’), there 
was a significant main effect of group, F (2, 57) = 3.830, p = 0.027, with the control 
group achieving significantly greater hit rates than the ketamine group for both types 
of stimuli (p = 0.028). 
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 There was a significant block by stimulus interaction, F(2, 57) = 6.641, p = 0.013, 
which was driven by higher hit rates (i.e. greater accuracy) for the ‘rich’ stimulus in 
Block 2, t(59) = 2.154, p = 0.034.  There was no significant difference in hit rates for 
the lean stimulus between blocks (see Table 10). 
 
Table 10.  Mean (sd) PRT hit rates per block for rich and lean stimuli (n = 20 per 
group) 
 Control Cannabis Ketamine Total 
Block 1, Rich 0.732 (0.127) 0.685 (0.129) 0.651 (0.122) 0.689 (0.122) 
Block 1, Lean 0.608 (0.152) 0.636 (0.139) 0.571 (0.124) 0.605 (0.139) 
Block 2, Rich 
 
0.806 (0.124) 
 
0.702 (0.137) 
 
0.644 (0.151) 
 
0.717 (0.149)* 
Block 2, Lean 0.594 (0.124) 0.619 (0.185) 0.545 (0.153) 0.586 (0.157) 
Total 0.685 (0.022)*a 0.661 (0.022) 0.603 (0.022)  
Difference significant at p <0.05*, p < 0.01 ** p < 0.001*** 
a = Con > Ket (Bonferroni corrected p values)  
 
Replicating prior studies, there was a main effect of stimulus, F (2, 57) = 25.130, p < 
0.001, with greater accuracy for the ‘rich’ than for the lean stimuli.   Mean (sd) hit 
rates were 0.703 (0.015) for the rich stimulus and 0.596 (0.018) for the lean stimulus. 
 
 
II. ‘EEfRT’ (Effort-Expenditure for Rewards Task) 
 
 A 3 x 3 repeated measures ANOVA (hard-task choices at 12%, 50% and 88% 
probability level x group) revealed no significant group by probability level 
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interaction (Table 11).  There was a significant main effect of probability level, F (2, 
56) = 55.176, p < 0.001 (Greenhouse-Geisser corrected) which reflected increasing 
number of hard choice tasks as the probability of winning increased. 
 
Table 11.  Mean (sd) hard choices made for 12%, 50% and 88% probability of 
winning levels for control, cannabis and ketamine groups (n = 20 per group) 
 
No. of hard choices Control Cannabis Ketamine Total 
12% probability 3.05 (2.61) 2.35 (2.16) 2.40 (2.31) 2.60 
(2.31) 
50% probability 4.95 (1.57) 4.90 (1.37) 4.30 (2.20) 4.72 
(1.75) 
88% probability 5.95 (1.73) 6.00 (1.41) 5.55 (1.64) 5.83 
(1.59) 
 
 
Generalised Estimating Equations 
 Six models using generalised estimating equations (GEE) were tested.  For all 
models, the dependent variable was the dichotomous outcome of hard or easy task 
choice.  A binary logistic distribution was used to model the probability of choosing 
the hard task.  (See Appendix 3 for GEE results tables.) 
 Model 1 tested for main effects of trial number, probability, value (reward 
magnitude), baseline button pressing speed, expected value (EV), BDI-II Total Score 
and cigarettes smoked per day.  Increases in probability of reward receipt, reward 
magnitude, and expected reward value were significant predictors of making hard-
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task choices.  There was a trend effect of cigarettes smoked per day on reducing the 
likelihood of making a hard task choice (b = -0.010, p = 0.052).  Also as trial number 
increased, this reduced the likelihood of making a hard task choice (b = -0.008, p < 
0.001). 
 Model 2 tested for an interaction between group and probability level.  The model 
revealed no significant group by probability interaction for controls versus cannabis 
(b = 0.090, p = 1.095) nor ketamine users (b = -0.079, p = 0.924) 
 Model 3 tested for an interaction between group and reward magnitude (or trial 
value).  No significant interaction between group and reward magnitude was found 
for controls versus cannabis users (b = 0.062, p = 0.620) or for controls versus 
ketamine users (b = -0.052, p = 0.603) which suggests that group did not 
significantly predict hard choice trials of differing reward magnitudes. 
 Model 4 tested for an interaction between group and expected value (i.e. 
probability x reward magnitude).  There was no significant interaction between 
group and expected value for controls versus cannabis users (b = 0.216, p = 0.334) or 
for controls versus ketamine users (b = -0.139, p = 0.491). 
 Model 5 tested for an interaction between group, reward magnitude and 
probability.  No significant interaction was found between these variables for the 
control versus cannabis group (b = 0.083, p – 0.344) nor for controls versus 
ketamine users(b = -0.054, p = 0.504). 
 Model 6 tested for a main effect of BDI Anhedonia subscale scores.  The model 
revealed no main effect of anhedonic scores on whether participants made hard 
choices (b = -0.049, p = 0.178).  
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 In summary, none of models 2-5 revealed significant effects for the interactions 
tested, nor did model 6 reveal significant main effects for the main variable 
(anhedonia) tested. 
 
4. Correlations 
 
I. Drug use and self-report measures 
 
i. Controls  
There was a trend towards a significant correlation between days per month of 
cannabis use and TEPS total (r = 0.543, - = 0.013).  There was also a significant 
correlation between mg of cannabis used in typical session and days per month use 
of MDMA (r = 0.649, p = 0.003). 
 
ii. Cannabis group 
Significant correlations were found between alcohol use (number of days per month) 
and the O-LIFE Impulsive Nonconformity subscale (r = 0.643, p = 0.002) (See 
Figure 3).  There were also trends towards significant correlations between SDS 
cannabis scores and BDI total scores (r = 0.469, p = 0.037) and between SDS 
cannabis scores and BDI Somatic subscale scores (r = 0.501, p = 0.025). 
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Figure 6.  Correlation between alcohol use and O-LIFE Impulsive Nonconformity 
subscale in cannabis users (n = 20) 
 
 
 
iii. Ketamine group 
Significant correlations were found between days per month of cannabis use and 
amount (mg) used in a typical session (r = 0.606, p = 0.005), and a nearly significant 
correlation between days per month of cannabis use and number of days per month 
of alcohol use (r = .558, p = 0.011).  Amount of tobacco consumed per day was 
correlated with amount of alcohol used in a typical session (r = 0.663, p = 0.002).   
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II. Task Correlations 
i. EEfRT  
Within-group correlations revealed no significant correlations between EEfRT 
outcome variables any of the self-report measures (BDI, TEPS, O-LIFE and PQ-B). 
 
ii. PRT 
No significant correlations were found between PRT outcomes and any of the three 
groups’ self-report measures. 
 
 
DISCUSSION 
 
 To the best of our knowledge, this is the first study of chronic cannabis and 
ketamine users to investigate reward processing.  The three groups studied were 
remarkably similar in age, gender, pre-morbid IQ, education, employment and use of 
other drugs.  The cannabis users were highly dependent on cannabis and the 
ketamine users were highly dependent on ketamine.  In line with hypotheses, the two 
drug using groups had significantly higher schizotypy (O-LIFE and PQ-B) scores 
than controls.  On the probabilistic reward task, the control group showed a greater 
response bias than the cannabis group, and controls had greater discriminability 
scores than the ketamine group.  There were no group differences on the ‘Effort 
Expenditure for Rewards Task’. 
 
Task Performance: PRT 
 
 We used the probabilistic reward task (PRT; Pizzagalli et al, 2005) to compare 
groups in terms of their response bias towards the more frequently rewarded 
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stimulus, their ability to discriminate between stimuli, their accuracy, and reaction 
times.  There were two main findings.  Firstly, partly in line with hypotheses, the 
control group showed a significantly greater response bias in Block 2 towards the 
more frequently rewarded stimuli than the cannabis group.  However, the predicted 
difference between controls and ketamine users did not reach significance in Block 2 
(though there was a trend towards a difference).  Secondly, the ketamine group was 
less able to discriminate between stimuli and less accurate overall than the control 
group.  The cannabis group did not differ from the control group on discrimination 
or overall accuracy.  The ketamine group was generally faster (smaller mean reaction 
times) than the other two groups, although no significant differences were found in 
post-hoc comparisons of groups. 
 There are several ways of interpreting these PRT findings.  The first relates to 
differences in learning between the three groups.  Only the control group 
demonstrated learning across blocks, showing a significant increase in response bias 
in Block 2 relative to Block 1. This learning suggests that the control group 
participants were able to modulate their behaviour increasingly over the two task 
blocks.  Neither the cannabis group nor the ketamine group showed response bias 
changes across blocks, which indicates no evidence of any learning taking place.  In 
Block 2, controls showed greater response bias than the drug using groups but only 
significantly so compared with cannabis users.  Because positive reinforcers are, by 
definition, stimuli that increase the likelihood of behaviour and reinforcers play a 
crucial role in the formation of associations between salient cues and internal 
rewarding events, one can argue that diminished responsiveness to reinforcers may 
be a behavioural demonstration of hedonic hypofunctioning, or anhedonia (Rescorla 
& Wager, 1972; Spangel & Weiss, 1999; Pizzagalli et al, 2005).  These findings may 
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therefore suggest that the cannabis users’ (and to a lesser extent, the ketamine users’) 
performance on the task reflected diminished reward responsiveness, or anhedonia, 
relative to controls. 
 On the PRT, the ketamine group discriminated less between stimuli than the 
control group, generally performed less accurately (i.e. had lower hit rates) than 
controls, and had faster response times than the other two groups.  The cannabis 
group did not differ significantly from either controls or ketamine users on 
discriminability.  The ketamine group’s lower discriminability scores than controls 
may indicate that ketamine participants found the task more difficult, which might be 
explained by a number of factors.  Visual discrimination between ‘rich’ and ‘lean’ 
stimuli may have been difficult, given the very small difference between mouth sizes 
(0.9mm).  Performance on the task may have reflected more global cognitive 
impairments in the ketamine group, such as in working memory and aspects of 
executive functioning, which have previously found to be associated with frequent 
ketamine use (Morgan et al, 2009; Morgan et al, 2012).  However, it should be noted 
that chronic cannabis use has also been found to be associated with deficits in 
attention, working memory and other aspects of executive function (Solowij, 
Stephens, Roffman et al, 2002; Crean, Crane & Mason, 2011). 
 Mean reaction times for the ketamine group were faster than for the other two 
groups’ responses across both blocks.  In light of their less accurate performance, 
this might indicate that the ketamine group sacrificed accuracy for speed on the task.  
This speed-accuracy trade-off may have influenced the ketamine group’s diminished 
ability to discriminate between task stimuli relative to controls.  Previous research 
has revealed mixed findings with respect to reaction time on the PRT.  Pizzagalli et 
al (2005) did not find group differences in reaction time when comparing high versus 
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low BDI participants on PRT performance.  However, a later study found 
significantly longer reaction times in subjects meeting clinical criteria for Major 
Depressive Disorder compared to controls (Pizzagalli et al, 2009).  These findings 
highlight the importance of considering how group differences in depression in the 
present study may have influenced task performance, and will be discussed below. 
 
Task Performance: EEfRT 
 
 The EEfRT was used in previous studies as an objective measure of effort-based 
decision making to test the relationship between anhedonia and reward ‘wanting’.  It 
was used here to determine the extent to which drug using groups might be less 
likely to make hard-task choices as the probability of winning decreased.  Our 
hypothesis was not confirmed as neither the cannabis nor ketamine group 
demonstrated differences relative to controls in effort-based decision-making as 
operationalised in the EEfRT.  We found that increases in the probability of reward 
receipt, reward magnitude and expected reward value were all predictors of 
participants making hard-task choices.  These findings show that the task itself 
appears to have worked (Treadway et al, 2009).  Further, hard-task choices 
decreased across groups as the task proceeded, which is also in line with previous 
findings (Treadway et al, 2009) and suggests the possibility of fatigue effects.   In 
light of similar findings across groups, it is possible that the groups did not differ in 
effort-based decision making.  Alternatively, the EEfRT may not have been sensitive 
to differences in performance between the three groups.  Order effects may also have 
influenced EEfRT performance, as it was the first computer task in the two-hour 
testing protocol, which meant participants may have been particularly motivated to 
perform well.  Treadway et al’s (2009) initial study found that participants with 
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higher trait and state anhedonia demonstrated a reduced willingness to make choices 
requiring greater effort in exchange for greater reward, which supports the notion 
that the EEfRT is a valid measure of putative reward ‘wanting’ (Treadway et al, 
2009).  However it may have been the case in the present study that the groups’ 
performance on this task of effort-based decision-making differed for reasons 
unrelated to substance use, comorbid depression or anhedonic traits. 
 
Psychological well-being 
 
 Both drug groups had high self-report scores on depression (BDI-II total scores) 
relative to controls, with 35% and 40% of the cannabis and ketamine samples 
respectively meeting criteria for clinical depression.  Also interesting is the finding 
of higher BDI Cognitive-Affective subscale scores in the ketamine group relative to 
controls, suggesting greater incidence of depressive symptoms relating to cognitions 
and affect.  Cannabis users had higher BDI somatic and BDI anhedonia subscale 
scores than controls, suggesting more physical symptoms of depression as well as 
higher clusters of anhedonic symptoms in this group.  These findings suggest an 
association between chronic use of the respective drugs and depression, replicating 
previous studies (Morgan et al, 2010; Lev-Ran et al, 2013). 
 One longitudinal study of frequent and ex-ketamine users revealed increased BDI 
scores in both groups over one year of follow-up (Morgan et al, 2010).  The authors 
hypothesised that depression in frequent users may be associated with increasing 
patterns of dependence on the drug, as depression is often comorbid in opiate and 
alcohol-dependent individuals (Morgan et al, 2010).  The elevated depression scores 
in the ketamine group relative to controls in this study were therefore consistent with 
increased depressive symptoms characteristic of chronic ketamine use (Morgan et al, 
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2012; Muetzelfeldt et al, 2008), although other factors apart from ketamine use per 
se may have affected depression levels.  Without measures of depression prior to and 
during heavier periods of ketamine use, it is difficult to delineate the relationship 
between the high levels of ketamine dependence and clinical depression in those 
who previously used the drug heavily but were experiencing a lack of ketamine as a 
result of the drought in supply which occurred during the present study. 
 Significantly higher depression relative to controls in the cannabis group may 
similarly suggest an association between frequent use of skunk and depressive 
symptomatology.  Within the cannabis group, cannabis SDS scores and BDI-II total 
scores tended to moderately (r = 0.469, p = 0.037) correlate, as did cannabis SDS 
and BDI Somatic subscale scores (r = 0.501, p = 0.025), which further suggest a 
possible association between cannabis dependence and depressive symptomatology.  
As mentioned, significantly higher scores on both the BDI cognitive and anhedonic 
subscales in cannabis users (but not ketamine users) relative to controls suggests that 
different facets of depressive symptomatology may be implicated in frequent use of 
high-potency cannabis.  A systematic review which controlled for baseline 
depression found that heavy cannabis use may be associated with an increased, 
though modest, risk for developing depression (Lev-Ran et al, 2013).  A separate 
analysis found a dose-response relationship between cannabis use and depressive 
symptoms, with a highly significant effect across four separate Australian cohorts in 
the association between frequency of cannabis use and mean scores on depression 
measures (Horwood et al, 2012).  However, again, without assessment of wider 
contextual factors, including baseline depression prior to the development of chronic 
skunk use, it would be difficult to draw any conclusions about causal relationships 
between cannabis use and depression in our sample. 
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 Despite group differences in BDI anhedonia subscores, there were no group 
differences in the primary measure of trait anhedonia (TEPS) and we did not include 
a measure of state anhedonia.  It is therefore difficult to parse anhedonia from the 
wider range of depressive or negative symptomatology which differed between the 
three groups here.  Use of additional anhedonia measures such as the Chapman 
physical and social anhedonia scales (Chapman, Chapman & Raulin, 1976) or the 
Snaith-Hamilton Pleasure Scale (SHAPS; Snaith, Hamilton, Morley et al, 1995) may 
have allowed for a more robust assessment of whether there were differences 
between groups on anhedonia.   
 As hypothesised, both cannabis and ketamine users exhibited higher schizotypy 
(or psychosis-like traits; O-LIFE) and higher levels of positive psychosis 
symptomatology (PQ-B) than controls.  Cannabis and ketamine users both had 
higher scores than controls on two O-LIFE subscales: Unusual Experiences (relating 
to unusual perceptual experiences, delusional beliefs, etc.) and Impulsive 
Nonconformity (relating to unstable mood and behaviour). 
 These findings are broadly in line with previous research which used the 
Schizophrenia Proneness Instrument (SPI-A; Schultze-Lutter, Addington, 
Ruhrmann, et al, 2007) to examine cognitive, affective and perceptual profiles of 
ketamine and cannabis users using a ‘basic symptoms’ approach (Morgan et al, 
2012).  They found that ketamine and skunk users demonstrated higher levels of 
attentional and cognitive disturbances than both illicit drug naïve controls and 
recreational poly-drug users.  Chronic ketamine users in particular exhibited the 
greatest levels of basic symptoms compared with controls, poly-drug users and the 
cannabis group.  Indeed, the ketamine users demonstrated high levels of cognitive 
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and affective symptoms which were very similar to clinically (SPI-A) assessed 
prodromal patients who subsequently transitioned to psychosis (Morgan et al, 2012).   
 Cannabis and ketamine users in Morgan et al’s (2012) study scored similarly on 
symptoms related to cognition, attention and cognitive disturbances as indexed by 
the SPI-A.  They differed on affective symptoms and perceptual disturbances, with 
the ketamine group scoring much higher on these indexes than cannabis users.  In the 
present study, there were no group differences on the O-LIFE Cognitive 
Disorganisation subscale.  However, both drug groups scored significantly higher 
than controls on measures of unusual perceptual experiences (O-LIFE Unusual 
Experiences subscale) and on positive symptoms, as assessed by the PQ-B. 
 Apart from essential differences in the way that psychosis-proneness was 
measured in our study compared to Morgan et al’s (2012), there were also 
differences with respect to the groups and their drug use.  The cannabis and ketamine 
groups were better matched in our study; Morgan et al’s groups differed more in age 
and depression.  Our cannabis group was on average 6.9 years older than that of 
Morgan et al (2012) and our ketamine (BDI score 12.45 ± 7.5) users were less 
depressed than theirs (BDI score 19.20 ± 10.92).  Morgan et al’s ketamine users 
were more depressed than both their cannabis users and controls.  In contrast, our 
study found no difference in depression between the cannabis and ketamine groups 
(both scoring higher than controls).  This finding might relate to the ketamine 
‘drought’ (discussed below) and thus recent changes to drug-taking behaviours in the 
ketamine group.  As ketamine has recently been reclassified both in the UK (now 
carrying more severe penalties for sale and possession than previously) and also in 
India, where much of the UK’s ketamine supply was until recently produced, this has 
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led to changes both in public perceptions of the drug’s harms as well as a reduction 
in street-level supply (Nutt & King, 2004; Power, 2014). 
 Morgan et al (2012)’s ketamine sample were similar in profile to prodromal 
patients, scoring highly on the following SPI-A subscales: ‘Affective-Dynamic 
Disturbances’ (e.g. impaired tolerance of stress, changes in general mood and 
decreased emotional responsiveness), ‘Cognitive-Attentional Impediments’ (e.g. 
attention and short-term memory deficits, difficulties in concentration, slowed down 
thinking, etc.), and ‘Cognitive Disturbances’ (e.g. indecisiveness regarding minor 
decisions, thought interference and blockages, disturbances in immediate recall and 
in receptive and expressive speech) (Morgan et al, 2012).  The ketamine group also 
scored more highly than all other groups in the study, including the prodromal group, 
on two subscales relating to unusual perceptual experiences: ‘Body Perception 
Disturbances’ (i.e. unusual bodily perceptual experiences) and ‘Perception 
Disturbances’ (e.g. hypersensitivity to visual or auditory stimuli, depersonalisation, 
changes in intensity or quality of perceived stimuli) (Morgan et al, 2012). 
 The cannabis group in Morgan et al’s (2012) study closely matched the ketamine 
group in scoring highly on the ‘Cognitive-Attentional Impediments’ and ‘Cognitive 
Disturbances’ SPI-A subscales.  As previously noted, cognitive-attentional deficits 
have been linked in previous research to chronic use of both of these drugs (Morgan 
et al, 2009; Morgan et al, 2012; Solowij, Stephens, Roffman et al, 2002; Crean, 
Crane & Mason, 2011).  The cannabis users also scored much lower than ketamine 
users on the ‘Affective-Dynamic Disturbances and the two ‘Perception 
Disturbances’ subscales (Morgan et al, 2012). 
 In the present study, our ketamine group scored more highly on both the O-LIFE 
Unusual Experiences and PQ-B (total and distress scores) relative to controls, which 
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suggests similarities in positive psychosis-like symptomatology to Morgan et al’s 
(2012) ketamine users.  It should be noted however that O-LIFE clinical norms have 
not yet been established and our drug groups had means that were similar to UK-
based population norms (Mason & Claridge, 2006).  The ketamine drought is a key 
difference between Morgan et al (2012) and the present study which may have 
impacted on differences in our ketamine group profile. 
 Our cannabis users were significantly more depressed than controls, but their 
mean depression scores were comparable to Morgan et al’s (2012) cannabis group.  
Higher PQ-B and O-LIFE Unusual Experiences subscale scores in our cannabis 
group compared to controls indicate a degree of positive psychosis symptomatology 
that was not found in Morgan et al’s (2012) cannabis users.  Cannabis users in 
Morgan et al’s (2012) study were younger on average and reported using much 
larger amounts of skunk than our group, which may have influenced differences in 
their profiles. 
 Higher scores in both our ketamine and cannabis groups on the O-LIFE Impulsive 
Nonconformity subscale relative to controls suggest that the drug-using groups had 
similarly greater tendencies towards impulsive and/or ‘non-conforming’ behaviour.  
Interestingly, the O-LIFE Impulsive Nonconformity subscale was positively 
correlated with frequency of alcohol use in the cannabis group.  This highlights the 
association between impulsivity as both a determinant (e.g. trait impulsivity 
increasing the tendency to use drugs) and as a potential consequence of chronic drug 
use (de Wit, 2009).   These findings are interesting in light of Mason & Claridge’s 
(2006) argument that a broader construct of psychosis-proneness should account for 
the clinical reality of overlap between schizophrenia and bipolar symptomatology to 
include the risk-taking behaviour characteristic of bipolar disorder (Mason & 
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Claridge, 2006).  Research demonstrating that substance abuse is associated with 
sensation-seeking or impulsivity in non-psychotic individuals, and that lifetime drug 
misuse or dependence has been found in schizophrenic patients with high impulsive 
and sensation-seeking personality traits, highlights the importance of this dimension 
of schizotypy in the association between drug addiction and psychosis (Johnson et al, 
1996; Dervaux et al, 2001; Gut-Fayand et al, 2001). 
 
Demographics and drug use of the groups 
 
 A main strength of this study is how well the three groups were matched on 
demographic variables including gender, age, ethnicity, education, and employment, 
on a premorbid estimate of intelligence, and on use of most other drugs.  The two 
drug using groups also exhibited significantly high levels of dependence on cannabis 
and ketamine respectively.   
 Greater use of tobacco in the cannabis group may be because cannabis was 
mostly consumed on a daily basis as ‘spliffs’ with tobacco, and tobacco use has been 
found to be associated with cannabis dependence, independently of cannabis use 
frequency (Hindocha, Shaban, Freeman et al, 2015).  The high SDS scores for 
cannabis dependence in the cannabis group (mean 7.3 ± 3.4) suggest that these 
participants were very concerned about their cannabis use (the cut-off score is three 
for cannabis dependence; Swift et al, 1998; Hides et al, 2006). 
 The timing of our study had a significant impact on the selection of ketamine 
using participants in that all users that we spoke to anecdotally reported a ‘ketamine 
drought’ which they observed had begun around late 2013 and had continued 
through 2014, during recruitment for the study.  This ‘drought’, the reduction in 
street-level supply and quality of ketamine over the past several years in the UK, has 
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also been discussed widely on drug internet forums.  Many of the participants we 
tested reported that prices had trebled within a year, with a widespread reduction in 
quality and subjectively experienced effects of the drug.  Because of the drought, the 
participants we recruited were not currently using ketamine anything like as heavily 
as before.  Most participants described having experienced a cycle of dependence on 
the drug prior to the drought, in that they had gradually built up a tolerance to its 
effects and were therefore using much larger quantities more frequently, with 
negative impacts on their health, finances and social lives. 
 A number of studies have shown the potential for ketamine dependency among 
users, (Morgan, Muetzelfeldt, & Curran, 2009; Muetzelfeldt et al, 2008; Tang et al, 
2015).  While SDS norms for ketamine users have not been established, a recent 
study of treatment-seeking ketamine users in China (where ketamine abuse has 
sharply increased in recent years) found a Chinese version of the SDS (SDS-K) to be 
a reliable and valid measure of severity of ketamine dependence in this population 
(Tang et al, 2015).  The high SDS scores for ketamine dependence in the ketamine 
group (mean 9.55 ± 2.56), suggest extreme concern about their use of the drug and 
were particularly interesting in light of the drought.  Many participants also said that 
if the ketamine supply were to revert to previous levels of availability, they would 
likely return to previous levels of consumption.  Greater use of amphetamines and 
benzodiazepines in the ketamine group might be due to the ‘ketamine drought’ 
encouraging use of these other relatively inexpensive drugs which have increased in 
availability in recent years (DrugScope Street Drug Trends Surveys, 2011 & 2014). 
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Methodological considerations 
 
 This study has methodological limitations characteristic of many studies on 
recreational drug users (Curran, 2000).  Despite general success in matching the 
groups on demographic and other drug use variables, there may have been other 
unknown factors which contributed to group differences. 
 Verification of level of drug use in the samples would need blood samples which 
were not feasible to take in this study.  Urinanalysis was used to index general drug 
use. Self-reported level of drug use may not be accurate as both ketamine and 
cannabis impair memory and people may underestimate drug use.  Future research 
may benefit from objective measures of chronic drug use (e.g. hair samples) but 
these are costly (e.g. £90 per hair sample) and are affected by hair treatments (dyes, 
shampoos, etc.). 
 The fact that testing was carried out by different researchers may have introduced 
experimenter bias, possibly influencing self-report measures and task performance.  
Also, there was some variation in test settings, with a number of participants tested 
in their own homes.  Many of the ketamine participants in particular were tested in 
more chaotic environments than controls and cannabis users, which may have 
influenced their performance. 
 Finally, the PRT and EEfRT tasks are proxies for examining real world decision-
making and as such their external validity is as yet unknown.  
 
Clinical Implications 
 
 High levels of schizotypy and relatedly positive psychosis-like symptomatology 
were shown in chronic users of both cannabis and ketamine using questionnaire 
measures which were resonant of those previously shown using a structured 
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interview (Morgan et al, 2012).  Taken together, these findings suggest that clinical 
assessments of psychosis symptoms should index use of these drugs, as some 
symptoms which align with those present in prodromal psychosis may in fact be 
drug induced.  Early intervention assessments in particular should take into account 
the potential overlap between the cognitive, affective and schizotypal symptom 
profiles of regular cannabis and ketamine users with those of at risk (or ‘prodromal’) 
individuals. 
 A recent exploratory factor analysis found similarities in symptom dimensions 
between chronic ketamine users and schizophrenia, although extreme psychiatric 
responses (i.e. drug-induced psychoses) to repeated ketamine use are thought to be 
atypical in community-based samples of ketamine users (Morgan et al, 2010; Xu, 
Krystal, Ning et al, 2014).  However, as suggested in Morgan et al’s (2012) study, 
the presence of these symptoms in chronic drug users may be a mechanism by which 
heavy drug use facilitates transition to psychosis in those with genetic and/or other 
vulnerabilities. 
 Given the recent finding that daily cannabis use, particularly of high-potency 
cannabis, is associated with earlier onset of psychosis in cannabis users, and that 
increasing numbers of young people are using ketamine and skunk, it is vital that 
early intervention programmes promote reduction in drug taking and abstinence to 
determine whether this reduces symptoms classed as ‘prodromal’ (di Forti, Sallis, 
Allegri et al, 2014; di Forti, Marconi, Carra et al, 2015; McCambridge, Winstock & 
Hunt, 2007).  Educational campaigns regarding the risks of cannabis use, particularly 
frequent use of high-potency types, are necessary and should particularly target 
young adolescents, as this is an age when many start experimenting with drugs and 
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when early prodromal symptoms may emerge (di Forti, Morgan, Dazzan et al, 2009; 
di Forti et al, 2014). 
 The present study did not undertake a broader clinical assessment that might shed 
light on history and patterns of drug use in the respective groups.  However the high 
levels of depression found in our sample of cannabis and ketamine users highlights 
the wider issue of assessment, treatment and prevention of comorbid mood, anxiety 
and substance use disorders.  While our study was carried out on a non-treatment 
seeking sample of drug users, research has shown that substance use disorders are 
more prevalent in individuals with severe mental illness than in the general 
population, and that such comorbidity is associated with poorer treatment outcomes 
(Davis, Uezato, Newell & Frazier, 2008; Lai, Cleary, Sitharthan & Hunt, 2015).  A 
number of theories attempt to explain such comorbidity, including the notion that 
one mental disorder may influence the development of another (e.g. drug misuse 
contributing to depression), that sustained use of drugs as self-medication or distress 
relief leads to dependence or addiction, or that multiple disorders share common 
vulnerability factors (e.g. genetic or socio-economic such as the intergenerational 
transmission of trauma) (Lai et al, 2015).  Further research on comorbidity is needed 
in order to better understand the nature of the relationship between two co-occurring 
disorders (whether correlational or causal), which may inform prevention and 
treatment (Lai et al, 2015). 
 As discussed, poorer learning on the Probabilistic Reward Task in the cannabis 
and ketamine users may have indicated poorer reward responsiveness relative to 
controls.  The implications of this possible explanation are that chronic users of these 
drugs may exhibit deficits in motivated behaviour in daily life, including decreased 
motivation for non-drug rewards.  The cycle of chronic drug use initially increases 
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the salience of drug rewards while decreasing that of non-drug rewards.  Given the 
relationship of anhedonia to craving and withdrawal symptomatology, further 
research on hedonic processing in chronic drug users is warranted, as treatment of 
anhedonia may hold promise for treating the underlying mechanisms of addiction. 
 
Conclusion 
 
The present study compared cannabis dependent, ketamine dependent and healthy 
control groups on reward processing and prodromal psychosis symptomatology.  It 
revealed mixed findings in terms of the drug groups’ reward responsiveness – on the 
probabilistic reward task, the control group showed greater response bias than 
cannabis users and controls had greater discriminability than the ketamine group.  
However there were no significant group differences on the effort-related decision-
making task.  These results may be partly explained by comorbid levels of clinical 
depression which were found in both drug-using groups but not in controls.  The 
drug using groups also had higher rates of schizotypal and positive psychosis-like 
symptomatology than controls.  Despite some differences in overall profiles, these 
findings support previous research (Morgan et al, 2012) in demonstrating the 
presence of both positive and negative symptoms of prodromal psychosis in chronic 
users of cannabis and ketamine.  Therefore, these findings have clinically important 
implications for the assessment of at-risk individuals. 
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Critical Appraisal 
 
Overview 
 
 This critique serves as a reflection on the process of completing the DClinPsy 
thesis.  I will discuss my experience working as part of a research group, reflections 
on recruiting and working with drug-using populations, and how the focus of the 
research relates to clinical issues.  I will also briefly discuss social constructs 
implicated in research on prodromal symptomatology and psychosis more generally. 
 
Working jointly and as part of a research group 
 
 As my research experience prior to training involved working as part of a team of 
researchers, I enjoyed the opportunity to do the same during the formulation and 
development stages of the thesis project.  Joining forces with my fellow trainee, Lisa 
Harvey, and receiving input from other researchers working in UCL’s Clinical 
Psychopharmacology Unit (CPU) allowed for initially very broad discussions and 
ideas about possible projects to become more refined and focused, drawing on the 
expertise of our supervisors and the CPU team.  This process of defining the project 
and developing a research question and protocol that would be feasible within the 
constraints of the thesis project was more time-consuming than I initially anticipated, 
but I appreciated the many meetings and discussions which eventually led to the 
rationale for the project, focusing on anhedonia and reward processing in drug users. 
 The initial aim of the project was to build on previous findings by a group of 
researchers working in the CPU (including several former DClinPsy trainees) which 
had demonstrated that frequent cannabis and ketamine users exhibited more 
psychotic-like symptoms than controls and recreational poly-drug users, and that 
ketamine users in particular had neurocognitive and affective profiles very similar to 
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prodromal patients who later developed frank psychosis (Morgan et al, 2012).  
Initially, Lisa and I chose to focus our research solely on non-treatment seeking 
cannabis users, with her project relating more to chronic ‘skunk’ use as a model for 
psychosis and mine focusing on reward processing deficits in chronic users.  We 
initially hoped to combine two quantitative research methodologies – a semi-
structured interview and experimental tasks – with the addition of a short qualitative 
interview which we would devise ourselves.  Early on, we planned to use a different 
semi-structured interview to assess prodromal symptomatology from the one used by 
Morgan et al (2012), the Schizophrenia Prediction Instrument – Adult Version (SPI-
A), which focused on ‘basic symptoms’ present throughout the entire progression 
from earliest to late prodromal phase.  We learned that this tool was not considered a 
‘gold-standard’ by researchers in the field, so we initially chose to use the 
Comprehensive Assessment of At-Risk Mental States (CAARMS), which focuses on 
‘attenuated positive symptoms’, typically present in the late prodromal phase, and 
has been used more widely in clinical settings than the SPI-A.  In addition to 
carrying out the CAARMS with our sample, we each planned to administer one or 
two computer-based cognitive tasks to assess our respective areas of focus.  Our 
CPU colleagues suggested the ‘probabilistic reward task’ (PRT; Pizzagalli et al, 
2005) and ‘Effort-Expenditure for Rewards Task’ (or ‘EEfRT’, Treadway et al, 
2009) as possible objective measures of reward processing for my arm of the project, 
neither of which, to our knowledge, had been used with chronic drug users. 
 The project shifted focus when we decided to include both skunk and ketamine 
users as participants, so as to be able to make comparisons of chronic drug users 
within our study design and to further build on Morgan et al’s (2012) study.  We also 
reluctantly decided to exclude the CAARMS interview, due to concerns about 
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feasibility.  Initially I felt these constraints were frustrating; I had a personal 
preference for carrying out semi-structured clinical interviews over experimental 
tasks, based on previous research experience, as I felt the interview process allows 
for much richer descriptions of participants’ experiences and would be more 
engaging for both participants and myself.  However I eventually accepted the need 
to limit the scope of the project due to concerns about the amount of time we would 
have needed both to familiarise ourselves with administering the CAARMS and to 
carry out the interviews.  Again, it was useful to have a number of colleagues to 
advise whilst deciding on this and on the self-report measures we would use, as well 
as supporting us with statistical analyses after completing data collection. 
 I appreciated being able to work jointly with Lisa throughout the planning and 
data collection phases of the project, as this allowed for much discussion and debate 
between us before then going back to our supervisors and other colleagues for 
further discussions and feedback.   Our conversations were wide ranging, drawing 
upon our previous experience (mine in non-clinical research and Lisa’s from her 
experience as a drugs worker in central London as well as her past thesis on ecstasy 
users), our developing knowledge of theory underpinning our research questions 
(e.g. drug models of psychosis, models of addiction, etc.), our more recent clinical 
experience during training, and our own life experience.  This joint working was also 
incredibly useful when it came to the recruitment phase, as we could screen potential 
participants for each other to test. 
 
Recruitment of chronic drug users 
 
 Recruitment was a particular challenge of the research project.  Despite the 
increasing openness in Western societies towards recreational drug use and the 
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widening of debates around legalisation and regulation of illicit substances, both 
cannabis and ketamine have been upgraded to Class B drugs in the UK in recent 
years, carrying severe penalties for their possession and supply.  While we knew that 
it would be possible to recruit participants meeting our eligibility criteria, it was 
necessary to go about this carefully and to be particularly mindful of confidentiality. 
 We initially began recruitment via our network of friends and acquaintances, but 
this yielded too few potential participants so we widened our strategy, placing ads on 
online forums.  This provided a vast number of enquiries, mostly from cannabis 
users.  Following up their queries and screening them proved a challenge, and it soon 
became clear which ones were more or less motivated to take part.  After screening 
and testing several cannabis users, we realised that our screening criteria needed re-
evaluation due to confusion over whether we should be emphasising drug 
dependence as the main criterion or amount/frequency of drug consumed.  Initially 
we were somewhat flexible, using both these criteria, but we found out that quite a 
number of users did not meet the minimum dependence criterion despite consuming 
cannabis frequently.  We decided it would be important to devise firmer criteria 
focusing on dependence (using the Severity of Dependence Scale, or SDS, Gossop et 
al, 1992) as the main defining feature of our chronic drug-using samples, over and 
above frequency or amount of drug consumed regularly. 
 This decision to define our drug users according to their level of dependence was 
also influenced by our first trip to Bristol to test a group of ketamine users.  These 
potential participants were friends and acquaintances of one of our contacts and were 
keen to take part in the study.  Prior to this, we had been informed about the 
‘ketamine drought’ hitting the UK in recent months, but it was not until we arrived 
and began speaking to our potential participants that we got a fuller sense of how this 
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had affected their use of the drug.  They reported how the availability of ketamine 
had reduced sharply beginning around late 2013 and early 2014, and that it 
continued to be much less accessible.  They described how the quality had reduced 
considerably while the price had shot up from approximately £15 per gram to £40 or 
more.  They shared a similar narrative to explain the drought saying that many of the 
factories in India which had been producing the drug had been closed and supplies 
seized by authorities, with much of the current poorer quality supply now coming 
from China.  This was confirmed in several media reports online, which linked the 
reduced availability to seizures in India and the UK and subsequent governmental 
reclassification of ketamine in India to its most severe level (schedule X) (Power, 
2014).  Many of the potential participants we spoke to were frustrated with this 
situation and wished that the supply would return to pre-drought levels.  However, 
many were ambivalent and also expressed the sense that the drought was a blessing 
in disguise, as they acknowledged how seriously dependent they had become while it 
was cheap and widely available, which had, in some cases, severely impacted on 
their health and functioning.  Some spoke about doing up to 7 or 8 grams of 
ketamine per day at the peak of their dependence before the drought, spending the 
whole day in their room taking ketamine and not doing much else, struggling with 
extremely painful ‘k cramps’ and bladder problems.  Several potential participants 
reported that they rarely took ketamine now since heavy use had contributed to 
relationship difficulties and had prevented them from pursing their life goals.  
Despite the drought however, the majority anecdotally told us that if quality 
ketamine were currently available to them, they would not hesitate to buy and 
consume it.  This suggested to us that despite the current drought, these individuals 
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continued to be somewhat dependent on ketamine, which was confirmed in nearly all 
cases when they were screened with the SDS. 
 Another challenge with recruitment was the issue of participants’ motivation to 
take part in the study.  One aspect of this was the repeated frustration of screening 
potential participants who would then fail to attend their scheduled testing sessions.  
This seemed to happen with screened individuals from all three groups (including 
controls), but perhaps more with the cannabis users.  This may have been due to the 
slightly different recruitment strategy we used for cannabis users, the majority of 
whom found out about the study via several online classifieds websites, whereas 
many of the controls and ketamine users were found via snowball sampling.  While 
it is not clear whether the proportion of DNAs we had are considered typical for this 
type of research project, irrespective of whether participants were drug users or not, 
this proved not only frustrating (particularly towards the end of the data collection 
phase) but also may have impacted on findings, given the study’s focus on 
examining motivated behaviour.  A further issue related to motivation to take part 
was the fact that participants were paid for their participation.  While paying 
participants is widespread practice in many types of research, it was interesting that a 
high proportion of participants from the two drug groups told us prior to testing that 
they were not volunteering for monetary gain but because they wanted to help 
further drugs-related research, with one participant even refusing payment upon 
completing testing.  Thus, while the groups were well-matched, there may have been 
a priori differences in reasons for participating that could have impacted on our 
findings, particularly regarding the motivation-based tasks and measures of 
anhedonia. 
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 Overall, I found testing the participants to be a very pleasant experience and was 
struck by the warmth and openness of many of the people I tested.  In retrospect I 
feel it was unfortunate that we could not provide more of a forum for the participants 
to discuss their experiences given the fact that many of them anecdotally described 
what they perceived to be very idiosyncratic relationships with drug taking, which 
seemed to me to be much more complex and ambivalent than could be captured by 
our measures. 
 
Limitations of Study Design 
 
 The study design was naturalistic and single-blind, which may have introduced 
potential bias based on participant characteristics, as mentioned (e.g. those who were 
motivated to take part may have had less trait anhedonia), or experimenter effects.  
Although it is often good practice to have more than one experimenter to reduce 
demand characteristics, having several people administer the testing protocol may 
also have introduced an element of bias.  The fact that testing took place in different 
environments may also have influenced our findings.  Many of the ketamine users 
were tested in their homes, which were at times chaotic environments with minor 
disruptions (e.g. noise, pet dogs requiring attention, etc.).  Most of the ketamine 
users also came from the same group of friends and acquaintances which may have 
influenced the socio-demographic and drug-use profile of the ketamine group. 
 One aspect of the design that could have been improved was the assessment of 
participants’ current and past drug use.  Our data indicated wide variation in the 
amount of information obtained from these interviews, which seemed to be a 
consequence of imprecise interview questions which sometimes neglected key 
information in bringing together a more complete picture of each individual’s pattern 
147 
 
 
 
 
of drug use.  This was particularly the case for the ketamine group – upon realising 
at the start of testing this group that most of the participants’ patterns of ketamine 
consumption had changed, we agreed to add further questions to our drug use 
interview which would give us an idea of their habits during periods of heavier use.  
However, this was hastily decided upon and therefore we did not have a set list of 
questions regarding past heavy use, and thus the data we were able to analyse 
regarding past use was limited.  The retrospective nature of self-reported drug use 
was also potentially problematic.  Although it is likely that the one-to-one format of 
the drug use interview encouraged participants to be truthful about their drug, 
retrospective assessment relied heavily on memory, which may be affected by drug 
use itself or simply the passage of time (Dragt et al, 2010).  Given that research 
suggests that individuals frequently under-report frequency and amounts of drug use, 
it is difficult to ascertain how likely this was in our samples and whether there was 
significant between-group variation.  Finally the impact of testing fatigue may have 
affected results, as the testing protocol was lengthy and the tasks repetitive. 
 
Schizotypy and psychosis as constructs 
 
 One significant frustration that I experienced with the project design and methods 
of inquiry was the need to accept and utilise the constructs of the psychosis 
prodrome, schizotypy and even psychosis itself.  For example, research on 
schizotypy argues for a range of ‘normal’ trait schizotypy, yet studies employing 
measures of schizotypy often assume that elevated levels are inherently 
psychopathological, although more recent research has explored creative or adaptive 
aspects of what is termed ‘benign schizotypy’.  From less psychiatric perspectives 
(e.g. social constructionist, humanistic or existential), one can argue that these 
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constructs exist because of the dominance of positivist, medical models of illness 
and disability within the field of psychological research, and they persist because of 
social and academic consensus.  My clinical experiences throughout training, albeit 
limited, have thus far exposed me to completely different ways of seeing the world, 
different not just from my own subjective viewpoint but from the models (e.g. CBT, 
systemic) which the field of clinical psychology at times so adamantly espouses.  
While models are useful in guiding therapeutic interventions, I could not shake my 
sense that the research project was missing important aspects of participants’ core 
concerns and experiences relating to their drug use.  Even the literature included in 
the review seemed to neglect the essential disturbance in the sense of self that may 
be at root of vulnerability to psychosis, which Nelson, Yung, Bechdolf & McGorry 
(2008) comment on.  They argue that modern psychiatry lacks a means of addressing 
human subjectivity, quoting Maslow: ‘‘ ‘If the only tool you have is a hammer, you 
tend to treat everything as if it were a nail.’ That is, the subjective has been 
approached in operational terms..." (Nelson et al, 2008: 382).  Reflecting on these 
issues has reminded me of my initial interest in taking a phenomenological approach 
to anomalous experience and to those murkier areas of psychological inquiry, like 
psychosis, that are less amenable to straightforward diagnosis and treatment.  Nelson 
et al’s (2008) proposal that research on individuals at clinical high risk for psychosis 
may benefit from further means of identifying ‘self-disturbance’ is interesting and 
provides a novel challenge to future researchers in this field who want to further 
examine what may be one of the core components of psychotic illness. 
 To this end, I often finished testing sessions with participants feeling as though an 
opportunity had been missed to get a much deeper understanding of the context 
influencing their drug-using behaviour.  I think this may have been helped had we 
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chosen to include a semi-structured interview, which would have encouraged more 
of a meaningful dialogue about their experiences, which sometimes only happened 
before or after the testing sessions or not at all.  This was particularly the case in my 
encounters with the ketamine users, as many of them expressed a sense of 
vulnerability and desire to help others through recounting their painful struggles with 
ketamine dependence.  
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Appendix 1 
 
Details of joint thesis 
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The thesis was completed as part of a joint project to investigate psychotic-like 
symptomatology and cognitive functioning in chronic users of cannabis and 
ketamine. 
 
Two separate theses were completed as a result of the project.  They were entitled: 
 
1) Psychotic-like symptomatology and reward responsivity in chronic ketamine and 
cannabis users 
 (Alyssa Joye, Trainee Clinical Psychologist, UCL) 
 
2) Ultra high risk for psychosis? Chronic ketamine and cannabis users’ performance 
in attribution assignment and auditory hallucination tasks 
 (Lisa Harvey, Trainee Clinical Psychologist, UCL) 
 
Both trainees collaborated on the study design and shared participants and data 
collection. 
 
An outline of each trainee’s contribution to the project is as follows: 
1) Alyssa Joye: Compiled the testing protocol, including obtaining self-report 
measures, in collaboration with Lisa Harvey.  Piloted initial testing protocol with 
Lisa and supervisor Val Curran.  Placed advertisements for participants on classified 
websites and screened potential cannabis and control participants.  Collected data as 
outlined in methodology (including two additional computer-based tasks relevant to 
Lisa Harvey’s study – ‘Ambiguity of Attribution’ and ‘White Noise’ tasks) from 22 
participants (3 controls, 11 cannabis users, and 8 ketamine users), and performed 
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own data analyses with support from Clinical Psychopharmacology Unit colleagues.  
Data for 22 participants tested by Lisa Harvey and 16 participants tested by Will 
Lawn (UCL PhD candidate) was used in analyses. 
 
2) Lisa Harvey: Collaborated on designing testing protocol alongside Alyssa Joye.  
Piloted testing protocol with Alyssa and supervisor Val Curran.  Contacted and 
screened potential ketamine participants.  Collected data as outlined in her 
methodology for 22 participants (6 controls, 6 cannabis users, and 10 ketamine 
users).  Performed own data analyses on participants she tested in addition to 22 
Alyssa Joye tested and 16 Will Lawn tested. 
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Participant Information Sheet 
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RESEARCH DEPARTMENT OF CLINICAL, EDUCATIONAL & HEALTH PSYCHOLOGY 
UCL PSYCHOLOGY 
 
 
 
INFORMATION LEAFLET FOR VOLUNTEERS 
 
Version 1 February 2014 
 
The determinants and psychological consequences of ketamine and high potency 
cannabis use 
 
Investigators: Lisa Harvey, Alyssa Joye, Will Lawn, Prof. H.Valerie Curran 
  
Purpose of the study: 
 
To determine the long term effects of high potency cannabis and ketamine use 
 
You are being invited to take part in a research study.  Before you decide, it is important for 
you to understand why the research is being done and what it will involve.  Please take time 
to read the following information carefully and discuss it with friends and relatives if you 
wish. Ask us if there is anything that is not clear or if you would like more information.  Take 
time to decide whether or not you wish to take part. 
 
WHAT IS THE PURPOSE OF THE STUDY? 
 
To determine the effects of using different types of recreational drugs upon mental 
functioning and mood.  
 
SOME BACKGROUND TO THE RESEARCH 
 
Many drugs have long term effects; for instance people who drink lots of alcohol often find 
their memories are not as good as they were. This can often be affected by factors such as the 
length of time they have been drinking and the quantity that they drink. The present study 
aims to find out what the long-term effects of using recreational drugs may be on mental state 
and cognition. 
 
WHAT WILL BE STUDIED?  
                                                          
We will ask people who regularly use ketamine and cannabi, as well as healthy non-drug 
using participants, a series of questions about their drug use and their psychological well-
being. After these, participants will then be asked to complete a series of computer tasks 
designed to look at attention and memory. 
 
HOW WOULD I BE INVOLVED IF I AGREED TO TAKE PART? 
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If you do decide to take part you will be given this information sheet to keep and be asked to 
sign a consent form.  If you decide to take part you are still free to withdraw at any time and 
without giving a reason.  
 
If you agree to participate, on the testing day you will come to the Psychopharmacology 
Laboratories at UCL or, if you do not live locally, the researchers will come to your home.  
We will collect a urine sample to test for the drug being studied and to screen for use of other 
drugs; the results will be kept confidential and the sample disposed of at the end of the testing 
session. You will be paid for participation upon completing the various research tasks.  The 
full testing session will last approximately 2 hours. 
 
 
CONFIDENTIALITY 
 
Any information collected about you will be held in accordance with the 1998 Data Protection 
Act.  All the information that is collected about you during the course of the research will be 
kept strictly confidential. Your results will have your name and any other details about you 
removed first so that you cannot be identified from them.  
 
 
If you would like further information please ask the investigator 
 
Thank you for reading this leaflet and we hope that you will be able to take part in the study.   
 
 
You do not have to take part in the study if you do not want to. If you decide to take 
part, you may withdraw at any time without having to give a reason. 
 
 
Contacts: 
Lisa Harvey ucjtlh2@ucl.ac.uk;  
Alyssa Joye: a.joye@ucl.ac.uk;  
Will Lawn:  will.lawn.12@ucl.ac.uk;  
Prof. H.Valerie Curran: v.curran@ucl.ac.uk; 0207-678-1898 
 
 
 
Clinical Psychopharmacology Unit 
Research Dept of Clinical, Educational and Health Psychology 
University College London Gower Street London WC1E 6BT 
Email: v.curran@ucl.ac.uk 
Tel: +44 (0)20 7679 1898 
Assistant: Sharinjeet K Dhiman   
Email: s.dhiman@ucl.ac.uk  
Tel: +44 (0)20 7679 8231 
Fax: +44 (0)20 7916 1989 
www.ucl.ac.uk/clinical-health-psychology 
 
 
All proposals for research involving human subjects are reviewed by an ethics committee 
before they can proceed. This proposal was reviewed by the UCL Committee for the Ethics 
of non-NHS Human Research. 
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SUB-DEPARTMENT OF CLINICAL HEALTH PSYCHOLOGY 
UCL PSYCHOLOGY 
 
 
 
 
 
 
 
Consent Form   
Version 1 January 2014 
 
CONFIDENTIAL 
The determinants and psychological consequences of ketamine and high potency 
cannabis use 
 
Investigators: Prof. Val Curran, Lisa Harvey, Alyssa Joye, Will Lawn.  
  
Please complete the following:    delete as neccessary 
            
1. Have you read the information sheet?   YES / NO 
 
 
2. Have you had an opportunity to ask  
   questions and discuss this study?           YES / NO 
 
 
3. Have you received satisfactory answers 
   to all your questions ?                      YES / NO 
 
4. Have you received enough information  
   about this study ?      YES /NO 
  
 
5. Which investigator have you spoken to 
   about this study ?                                           ...............……………………………. 
 
6. Do you understand that you are free to withdraw from 
   this study: 
* at any time              YES / NO 
 
* without giving a reason for withdrawing          YES / NO 
 
 
7. Do you agree to take part in this study?                                 YES/ NO 
 
8. Would you be interested in having your details stored     YES/ NO 
    on a database to be contacted for inclusion in further  
     studies? 
 
 
Signed........................................……………..  Date............……….. 
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Name (please print) .............................................………………………….  
  
   
Investigator........................……………………………………… 
 
 
Clinical Psychopharmacology Unit 
Sub-department of Clinical Health Psychology 
University College London Gower Street London WC1E 6BT 
Tel: +44 (0)20 7679 8231 
Email: s.dhiman@ucl.ac.uk Tel: +44 (0)20 7679 823 Fax: +44 (0)20 7916 1989 
www.ucl.ac.uk/clinical-health-psychology 
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Generalised Estimating Equations for EEfRT 
  b Coefficient SE p 
Model 1 
 
Group: 
Control vs. Cannabis 
Controls vs. Ketamine 
Gender 
Trial Number 
Probability  
Reward Value 
Expected Value 
Baseline Button Press 
BDI Total Score 
Cigarettes/day 
 
0.064 
-0.032 
0.095 
-0.013 
0.338 
0.266 
0.298 
0.010 
-0.007 
-0.010 
 
0.1288 
0.1237 
0.1288 
0.0029 
0.0826 
0.0787 
0.1195 
0.0174 
0.0174 
0.0053 
 
0.617 
0.799 
0.254 
<0.001 
<0.001 
0.001 
0.013 
0.585 
0.249 
0.052 
Model 2 Group: 
Control vs. Cannabis 
Controls vs. Ketamine 
Gender 
Trial Number 
Probability  
Reward Value 
Expected Value 
Baseline Button Press 
 
-0.014 
0.035 
0.099 
-0.013 
0.339 
0.267 
0.292 
0.010 
 
0.1750 
0.1613 
0.0833 
0.0029 
0.1070 
0.0790 
0.1189 
0.0176 
 
0.935 
0.826 
0.236 
<0.001 
0.002 
0.001 
0.014 
0.589 
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BDI Total Score 
Cigarettes/day 
Group*Probability 
Control vs. Cannabis 
Control vs. 
Ketamine 
-0.007 
-0.010 
 
0.090 
-0.079 
0.0058 
0.0053 
 
0.1312 
0.1234 
0.265 
0.057 
 
1.095 
0.924 
Model 3 Group: 
Control vs. Cannabis 
Controls vs. Ketamine 
Gender 
Trial Number 
Probability  
Reward Value 
Expected Value 
Baseline Button Press 
BDI Total Score 
Cigarettes/day 
Group * Value 
Control vs. Cannabis 
Controls vs. Ketamine 
 
-0.019 
0.040 
0.095 
-0.013 
0.335 
0.263 
0.304 
0.009 
-0.007 
-0.010 
 
0.062 
-0.052 
 
0.1953 
0.1751 
0.0832 
0.0029 
0.0824 
0.0958 
0.1198 
0.0175 
0.0058 
0.0054 
 
0.1244 
0.1007 
 
0.923 
0.820 
0.255 
<0.001 
<0.001 
0.006 
0.011 
0.589 
0.248 
0.052 
 
0.620 
0.603 
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Model 4 Group: 
Control vs. Cannabis 
Controls vs. Ketamine 
Gender 
Trial Number 
Probability  
Reward Value 
Expected Value 
Baseline Button Press 
BDI Total Score 
Cigarettes/day 
Group * Expected Value 
Control vs. Cannabis 
Controls vs. Ketamine 
 
-0.061 
0.051 
0.099 
-0.013 
0.334 
0.266 
0.283 
0.009 
-0.007 
-0.010 
 
0.216 
-0.139 
 
0.1874 
0.1725 
0.0832 
0.0029 
0.0816 
0.0788 
0.1919 
0.0177 
0.0059 
0.0053 
 
0.2238 
0.2014 
 
0.744 
0.768 
0.233 
<0.001 
<0.001 
0.001 
0.141 
0.593 
0.257 
0.059 
 
0.334 
0.491 
Model 5 Group: 
Control vs. Cannabis 
Controls vs. Ketamine 
Gender 
Trial Number 
 
-0.028 
0.029 
 
-0.013 
 
0.1660 
0.1537 
 
0.0029 
 
0.868 
0.850 
 
<0.001 
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Probability  
Reward Value 
Expected Value 
Baseline Button Press 
BDI Total Score 
Cigarettes/day 
Group * Reward Value * 
Probability 
Control vs. Cannabis 
Controls vs. Ketamine 
0.335 
0.269 
0.280 
0.009 
-0.007 
-0.010 
 
 
0.083 
-0.054 
0.0817 
0.0814 
0.1960 
0.0177 
0.0059 
0.0053 
 
 
0.0882 
0.0804 
<0.001 
0.001 
0.153 
0.593 
0.258 
0.059 
 
 
0.344 
0.504 
Model 6 Group: 
Control vs. Cannabis 
Controls vs. Ketamine 
Gender 
Trial Number 
Probability  
Reward Value 
Expected Value 
Baseline Button Press 
BDI Total Score 
 
0.043 
-0.077 
0.073 
-0.012 
0.347 
0.258 
0.281 
0.012 
0.002 
 
0.1336 
0.1258 
0.0866 
0.0030 
0.0852 
0.0800 
0.1230 
0.0172 
0.0078 
 
0.749 
0.541 
0.397 
<0.001 
<0.001 
0.001 
0.022 
0.482 
0.781 
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Cigarettes/day 
BDI Anhedonia 
-0.010 
-0.049 
0.0055 
0.0365 
0.078 
0.178 
 
